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Prior to being a student at King’s College London, I worked as a clinical trials biostatistician within 
oncology.  In analysing and reviewing the results of the trials, I was forced to recognise that, every 
day, patients are exposed to medications that are of limited or even no benefit to them.  Classical 
clinical trials harvest a handful of measurements from thousands of people.  These trials typically are 
unable to distinguish patient characteristics that interact with response within a given treatment arm, 
resulting in treatment decisions that follow a ‘one size fits all’ approach.  My desire to explore the 
potential of genetics to explain variability in patient drug response provided the impetus for me to 
pursue the work presented in this thesis.   
While deciding which area to focus on for my PhD research, a clinical colleague approached me with 
an offer of collaboration and asked me to conduct a repeated measures analysis of clinical trial data.  
These data included a baseline measurement of outcome response prior to the initiation of treatment.  
While this was not the kind of analysis that I was used to from oncology trials, I recalled from lectures 
on the subject that I could include the baseline as a covariate (ANCOVA), calculate the change 
between baseline and each subsequent measurement (change score – CSA) or retain the baseline 
measurement as part of the outcome vector.  I searched the internet for guidance on which of the 
three analysis methods to use, and found only toy examples (in which all analysis methods yielded 
the same result), or complex discussions about bias with the ANCOVA, and numerous references to 
the choice of analysis method being akin to ‘Lord’s Paradox’ (with which I was previously unfamiliar).  
I realised that it would take some time to truly know the implications of each method, however, my 
clinical colleague was keen to move ahead, without waiting for me to explore the statistical subtleties 
of each method.  We therefore chose to use the analysis with the highest p-value for the primary 
endpoint.  I rationalised this choice as statistical-conservatism, secure in the knowledge that I could 
not be accused of ‘cherry-picking’ the most favourable p-value.  The paper was published in a 
reputable journal [1], but this was cold comfort since I was still no closer to understanding why each 
analysis method had yielded different results.  When my supervisor asked me for a justification of my 
analysis choice my ‘conservatism’ rationale sounded hollow.  With her encouragement, I set out to 
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understand exactly when and why different methods of handling the baseline measurement yield 
different results.  The work resulting from this exploration forms Part 2 of the thesis (Chapters 8-11).  
To quote my primary supervisor, “a PhD is a training degree and one of the few opportunities to 
pursue your learning interests without constraint”, and in this regard my work on repeated measures 
linear models was an unparalleled success.  From programming simulations of correlated and missing 
data to linear algebra, each step of this project challenged me to learn new things and expand my 
view of the tests that we so often use in statistics.  
For a data-driven component to the thesis, my supervisor used her collaboration with the Purine 
Research Laboratory to secure for me data from cancer patients treated within St. Thomas Trust.  
These data contained baseline, characteristics, germline genetics and patient response (efficacy and 
safety endpoints).  This data provided the platform from which I could pursue my original interest in 
understanding sources of variation in patient response – or as it is better known, personalised 
medicine. 
The result is a thesis with two distinct parts.  As my primary research interest is personalised 
medicine, the first half of my thesis (Chapters 2-6) uses patient data to identify genetic and baseline 
patient characteristics for their association with efficacy and safety responses.  My early work forms 
the second half of my thesis (Chapters 7-11) which explores repeated measures linear regression. 
It is my hope that this thesis has contributed to a refined understanding of repeated measures linear 
regression and the identification of prognostic factors associated with cancer therapy that can be 








Statistical analysis methods that analyse complex data appropriately are necessary for medical 
research to fulfil its aims of improving cancer treatment.  To move towards this goal, this thesis uses 
data from clinical studies and simulation to explore two different areas: (1) genetic associations with 
efficacy and safety of chemotherapy, and (2) repeated measures analysis of clinical trial data.   
Several studies have reported that safety events occurring during chemotherapy are predictors of 
significantly longer survival for cancer patients.  Recent research has identified germline genetic 
variants associated with either safety or efficacy drug response outcomes.  We sought to understand 
the similarities and differences in the genetic association signals between safety and efficacy 
endpoints.  Our work highlights the difficulties in combining cohorts of patients across cancer types, 
since differences between cohorts with respect to baseline characteristics and efficacy responses 
prohibit the use of meta-analysis for the discovery of response-associated factors.  Our work confirms 
that baseline patient characteristics can be important prognostic factors in drug response, however, 
we conclude that the addition of baseline factors as covariates does not assist in the identification of 
genetic variants associated with response.  Lastly, we develop a novel graphical method to describe 
the similarities in genetic association results between any two clinical endpoints measured in cancer 
studies. 
Baseline values are commonly measured in clinical trials to help assess drug response following 
randomisation.  Treatment effects on mean change from baseline can be analysed: 1) including the 
baseline value as part of the treatment response, 2) using only the post-randomisation values in the 
response analysis only the post-randomisation values and baseline as a covariate, or 3) using the 
calculated change from baseline value as the dependent variable.  We consider each of these 
analysis methods for their accuracy and precision in estimating the between-group difference in the 
mean change from baseline.  We conclude that the method by which the baseline responses are 
used in the analysis influences both the accuracy and the efficiency of identifying the response slope 
difference between treatment arms.  The difference in accuracy and precision between methods 
depends on the number of post-randomisation assessments, with-patient correlation strength and 
correlation structure of repeated measurements.  
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Chapter 1. Introduction 
It is far more important to know what person the disease has than what 
disease the person has.  
 – Hippocrates of Cos  
1.1 Introduction to personalised medicine in cancer 
Clinical outcomes in response to drugs exhibit large inter-patient variability in terms of treatment 
efficacy and drug toxicity.  Patient demographics, behaviours and genetics all are underlying factors 
hypothesised to contribute to this variation [2].  Personalised medicine is essentially the ability to tailor 
treatments, as well as prevention strategies, to the unique characteristics of each person.  One vision 
of personalised or stratified medicine is to use knowledge of these sources of variation in order to 
identify subgroups or strata of patients who are more (or less) likely to respond to a treatment [3]. 
 
Figure 1.1.1 Sources of variability in drug response. 
Variation in drug response is known to be influenced by an individual patient’s genetic and 
environmental factors as well as baseline characteristics. 
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1.2 Baseline characteristics and behaviours  
The concept of personalised medicine is not new.  Within oncology, the concept of matching 
treatments to patients to achieve remission and avoid re-occurrence is well established.  Clinicians 
have long observed that different patients respond differently to medical interventions, and it is 
standard clinical practice to optimise an individual's treatment based upon differences in patient 
characteristics or prognostic factors [4].  A prognostic factor provides information about patient 
outcomes irrespective of therapy; a predictive factor is one that modulates the effect of a therapeutic 
intervention [5].   
During recent decades, numerous studies have investigated prognostic and predictive factors for lung 
and ovarian cancer survival.  These studies have identified disease stage [6-9], performance status 
(PS) [7, 8, 10-13], gender [11, 14, 15] and weight loss [7, 14, 16, 17] as strong prognosticators of 
survival and risk of toxicity.  The role of other factors, including age [7, 8, 11, 18, 19], ethnicity [19-21] 
and smoking status [22, 23]  as significant prognostic factors in lung and ovarian cancer remains 
controversial.  Accurate characterisation of prognostic factors is essential for predicting patient 
outcomes, reporting the results of comparative studies in cancer therapy, and comparing new 
investigational results to previous studies.  
Translating the concepts of personalised medicine into direct benefit to patients requires identification 
of the many factors that influence patient variability in response.  This creates the need for extensive 
characterisation of the various baseline characteristics factors that influence patient response.   
1.3 Pharmacogenomics 
Pharmacogenomics is the part of personalised medicine that aims to identify inherited genetic 
variants that may in part explain inter-patient response variation based upon genetic differences 
between patients.  The terms pharmacogenomics and pharmacogenetics are often used 
interchangeably; within this thesis we use the term pharmacogenomics.  Within the field of oncology, 
applications of pharmacogenomics cover two main areas: avoidance of safety reactions - adverse 
events (AE), and prediction of treatment efficacy for a given patient [24].  Some pharmacogenomic 
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tests are now in standard clinical practice.  For example, patients are tested for presence of HLA-
B*57:01 before treatment with abacavir, as this variant increases risk of abacavir hypersensitivity.  
Low thiopurine methyltransferase (TPMT) enzyme activity can lead to toxic effect when azathioprine 
and similar drugs are taken.  Pharmacogenomic tests are used to identify people with no TPMT 
activity (for whom a different drug should be used) or low activity (who need a reduced dosage).    
To identify variants associated with a particular drug therapy, genome-wide-association-studies 
(GWASs) are often performed.  Such studies assess single-nucleotide-polymorphism (SNP) variation 
between individuals and determine how this genetic variation is associated patient response [25].  
Within oncology, genetic association studies have previously been used to successfully correlate 
particular genomic signatures with drug efficacy response and risk of toxicity development [26] in 
patients treated with irinotecan (colorectal cancer) [27], capecitabine (breast and colorectal cancer) 
[28, 29], cyclophosphamide (leukaemia) [30], and tamoxifen (breast cancer [31], metastatic colorectal 
cancer [32, 33], chronic myeloid leukaemia [34]). 
1.3.1 Germline vs. somatic variation 
In cancer pharmacogenomics, there are two genomes that may influence variation to drug response: 
the genome of the person with cancer (germline) and the genome of the malignant cells (somatic).  
Almost all cancers are associated with damaged DNA that allows cells to grow unchecked.  This 
means that tumour genomes are a mixture of cancer and normal cells and therefore each tumour 
contains inherited (germline) and tumour-specific (somatic) variants.   
These tumour-specific genetic changes provide potential targets for cancer treatment and have 
already started to transform treatment strategies in oncology.  Afatinib (lung), alectinib (lung), 
bevacizumab (lung and ovarian), ceritinib (lung), gefitinib (lung), necitumumab (lung), nivolumab 
(lung), ramucirumab (lung) are all examples of targeted therapies [35] that use somatic mutation 
induced cellular changes to target cancer cells with greater precision than traditional chemotherapy 
agents.  
Despite the success of targeted agents, the mechanism that provides their success is also their key 
limitation.  Within a tumour, the cancer cells may be heterogeneous; different sections of the tumour 
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may be derived from different clonal expansions.  Consequently, within the same patient, different 
tumours and even different cells within the same tumour will carry alternate somatic mutations.  This 
means that treatment strategies based upon somatic mutations will frequently not be able to target 
all tumours within a patient.  For this reason, targeted therapies rarely result in durable tumour 
regressions and most patients will ultimately experience disease progression despite an initial period 
of response [36].   
By contrast, germline mutations are present in every tumour and non-tumour cell, theoretically 
increasing the chance of response to a mutation-targeted agent.  Traditionally, germline mutations 
were used to identify cancer risk, however, there is growing evidence that germline variants are both 
prognostic and predictive of efficacy and safety treatment responses.  Previous studies have 
determined that the presence of a germline mutation may affect overall survival independent of 
therapy.  There is evidence of a prognostic effect for BRCA1 and BRCA2 mutations in ovarian cancer 
[37, 38] and for mismatch repair gene mutations in colorectal cancer [39-41].  In addition to their 
prognostic potential, germline mutations may also be predictive of response to therapy.  Several trials 
have confirmed an increased rate of tumour response (reduction in tumour size) in patients 
with BRCA mutations [42-44].  Conversely, a mutation may predict lack of response, such as the 
evidence suggesting that taxane therapy might be less effective in certain BRCA carriers [45-47].  
One major advantage of using germline variants to guide clinical care over somatic variation is that 
the actionable variants will remain fixed for a patient throughout their lifetime.  
Now that testing is becoming cheaper and faster, genotype data for a cancer patient may be already 
available or is easily attainable.  The challenge is to identify genetic variants that are relevant for 
cancer treatment, and then to integrate germline variation into routine cancer care across different 
oncology landscapes in order to maximise the therapeutic potential of this information [48]. 
1.4 Platinum therapy 
The ‘platinum’ chemotherapy drugs cisplatin, carboplatin and oxaliplatin are commonly used for the 
treatment of lung, colorectal, ovarian, breast, head/neck, bladder and testicular cancers [25].  The 
first platinum-based chemotherapy drug discovered by researchers was cisplatin, which was 
   
   
30 
 
approved for the treatment of both ovarian and testicular cancer in 1978 [49]. In 1989 a second 
platinum agent, carboplatin, was approved for treatment of ovarian cancer, and due to subsequent 
clinical trial results the U.S. Food and Drug Administration (FDA) approved carboplatin for use treating 
patients with non-small cell lung cancer [50].  Finally, in 2002, a third-generation platinum drug, 
oxaliplatin, was approved for treatment of metastatic colorectal cancer [51]. Due to the success of 
platinum agents in their approved indications they are frequently used by oncologists ‘off-label’ for 
the treatment of other cancers [52].  Consequently, cisplatin is the most commonly used 
chemotherapy drug in the USA [53]. Yet the use of platinum therapy is not without risk, the potential 
antineoplastic benefit of these frequently prescribed drugs is often compromised by severe side 
effects including gastrointestinal upset and neutropenia.  Cisplatin is regarded as the platinum drug 
with the most severe side effects, including nausea and vomiting, neurotoxicity, nephrotoxicity (kidney 
damage), and ototoxicity (hearing damage) [25, 54-56].  Beyond the immediate debilitation 
associated with an adverse event, patients experiencing severe symptoms often discontinue the 
original treatment regimen in an effort to resolve the adverse event.  This discontinuation may be a 
dose reduction, a dose delay or complete withdrawal from platinum therapy, all of which potentially 
compromises a patient’s benefit from the platinum compound.   
To minimise the risk of adverse events while taking advantage of the antitumor activities of the 
platinum agents, efforts to identify safety biomarkers are under way.  Two previous studies [57, 58] 
have identified variants within the GSTP1 gene associated with an increased risk of neurotoxicity in 
patients treated with platinum therapy.  In contrast, Nagashima et al. [59] identified a variant within 
the SCN1A gene that was associated with decreased risk of neurotoxicity.   
Despite these efforts, we have only begun to identify genetic markers which determine the association 
between platinum agents and toxic side effects.  In this thesis, we use data from a collection \ number 
of patients from Guy’s and St. Thomas’ NHS Foundation Trust treated with platinum therapy for lung 
and ovarian cancer.  The patients represent a cross section of the individuals treated within a 
metropolitan care centre and therefore provide data from real-life routine practice conditions.  This 
study aimed to identify association between exome-located SNPs and susceptibility to adverse drug 
reactions with the clinical goal of using genetic markers to guide the choice of platinum therapy [60, 
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61].  We obtained permission to use this data to explore the relationship between efficacy and safety 
by identifying the baseline characteristics and genetic factors that predict these factors.    
Intensive cancer chemotherapy dosing is a complex interplay between chemotherapy complications 
and death from progression.  For example, in acute myeloid leukaemia (AML) it is estimated that 10% 
of patients die from treatment related adverse events rather than progression of the underlying 
disease [62].  The dose intensity is recognised as a crucial factor in a patient's response to cytotoxic 
drugs [63].  In general, the higher the dose intensity, the greater the probability that an efficacious 
dose will be achieved [64].  Neutropenia is one of the most important dose-limiting toxicities of 
cytotoxic cancer therapy.  Patients experiencing neutropenia are often given a therapy dose below 
their initial dosage [65] until the neutropenia has resolved.  Therefore, many oncologists might 
consider that the absence of neutropenia a positive with respect to patient outcome as the probability 
of achieving an adequate tumour response will be enhanced in the absence of a dose reduction.  
However, since the 1990s, several studies have reported that neutropenia or leukopenia occurring 
during chemotherapy is positively associated with improved survival outcomes in women with breast 
cancer [66-69].  A meta-analysis of 1265 patients with advanced non-small-cell lung cancer (NSCLC) 
pooled from three randomised trials confirmed a positive association between chemotherapy-induced 
neutropenia and increased survival [70].  
The introduction of patient genetic information has led to a further paradigm shift within oncology as 
researchers seek genetic markers that could predict patient response.  Some researchers [19, 71] 
have focused on efficacy response, and propose that the risk of an adverse event is limited to only 
those patients who stand to derive meaningful benefit from therapy.  A similar but separate 
incorporation of patient genetics views a drug as equally beneficial to all patients; where the more 
drug that can be given, the better the patient outcome.  Such researchers [72, 73] have focused 
genetic markers of adverse events; and propose that dose be maximised in patients not predisposed 
to side effects thereby improving patient outcomes.  The analysis in this thesis tests for genetic 
association with both efficacy and adverse events, and assesses evidence for genetic correlation 
between these outcomes.   
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1.5 Repeated measures studies 
Repeated measures designs are a type of longitudinal trial design characterised by the collection of 
the trial endpoint or outcome for each patient repeatedly through time [74].  As with all longitudinal 
studies, the primary goal is usually to explore the change in response over time and the factors that 
influence change.  The analysis of longitudinal data has been, and remains, a major topic in the 
statistical literature.  The paired t-test and the analysis of variance (ANOVA) for repeated measures 
both represent early longitudinal analysis methods and highlight the reason for the popularity of 
longitudinal trial designs.  Rather than model the group means at the final time point, as would be 
done in a simple t-test or ANOVA, the paired/repeated methods exploit the ability to measure change 
in response at the individual level and thereby allows patients to act as their own control.  By modelling 
the change in response across time points, the variability in the response within groups is reduced, 
resulting in increased power to detect group differences in the pattern of change. 
However, the benefit of a repeated measures design is not without cost and there are several 
statistical challenges created when collecting and correctly analysing longitudinal data.  One aspect 
of longitudinal data that complicates the statistical analysis is that repeated measures on the same 
individual are usually positively correlated.  This correlation violates the assumption of independence 
of errors.  The recognition that failure to account for this correlation may result in biased results led 
to the formulation general linear models with correlated error structure [75] and also correlated 
random effects structure [75].  
Clinical trials are prospective studies which often employ longitudinal measurement designs to 
answer questions regarding patient interventions.  Within the many clinical trial designs, randomised 
controlled trials (RCTs) are generally considered the gold standard for evaluating the effects of new 
interventions or established interventions in novel disease settings.  RCTs are the most robust 
method for establishing whether a relationship exists between treatment and outcome and for 
assessing the relative effectiveness of alternate treatments [76]. 
The fact that participants are randomised to the treatment arms is meant to ensure that, at least in 
expectation, the treatment groups will be balanced with respect to baseline characteristics that 
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influence prognosis other than the treatment being considered.  Consequently, differences in 
outcomes between the two groups can be attributed to the effect of the differences in intervention 
rather than baseline characteristics. 
Statistically speaking, this means that the treatment effect estimate from trial is unbiased, even 
without adjusting for any baseline covariates.  Furthermore, it has been argued that this remains true 
even when there appears to be an imbalance between treatment arms with respect to the baseline 
response; and only the expectation of balance is required [77].  This is because even if imbalance is 
observed, it is impossible to disentangle whether there has been a failure of the randomisation 
process, or whether the imbalance at baseline is due to chance [78].   
In reality, the ‘expectation’ of no imbalance is very hard to achieve.  When planning a randomisation, 
statisticians attempt to identify the key prognostic factors related to outcome to achieve a balance 
between treatment arms with respect to these important factors [79, 80] through the use of a stratified 
randomisation.  Stratified randomisation differs from simple randomisation (randomisation based only 
on treatment arm allocation probability) in that patients who enter a clinical trial are first grouped into 
strata per clinical features that may influence outcome risk.  Within each stratum, patients are 
assigned to a treatment arm using simple randomisation schedules [81, 82].  Stratification factors are 
usually identified through a combination of clinical experience and prior data.  If the relevant 
prognostic factors are unknown or poorly identified, then it is reasonable to expect that there may 
exist a factor imbalance between treatment arms.  Even if all the relevant factors are well understood 
the randomisation may fail (creating treated groups that are unbalanced for prognostic features, 
including the baseline measurement of the outcome variable) as randomisation usually incorporates 
only a few of the key prognostic factors.  The reason for this is that the subsequent analysis should 
reflect the design of the study and consequently stratification variables should be adjusted for in the 
analysis in order to obtain the correct type I error rates [83, 84]; and yet guidance from the European 
Medicines Agency (EMA) states that: “No more than a few covariates should be included in the 
primary analysis.  Even though methods of adjustment, such as analysis of covariance, can 
theoretically adjust for a large number of covariates it is safer to pre-specify a simple model” [85].  
Consequently, even in well understood disease models where there is clear evidence of multiple 
prognostic factors, less than a handful are ever incorporated into the trial as randomisation factors.  
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Prognostic factors not incorporated into the randomisation have the potential to create baseline 
imbalance between treatment arms.  Other factors that may result in a failed randomisation include: 
1) small sample size [86], 2) the timing of analyses (interim analyses may not have recruited all 
patients and failed to achieve the treatment group balance that would be manifest at full sample size), 
and 3) prolonged recruitment periods, which may result in changes over time with respect to 
prognostic characteristics of enrolled patients [81]. 
No matter the reason, it is fair to conclude that randomisation does not guarantee a baseline balance 
between treatment arms with respect to the response variable or other prognostic factors; in any 
individual trial, there may be large imbalances in important prognostic covariates between treatment 
groups merely by chance.  While a pronounced baseline imbalance is not expected a priori in a 
randomised trial, when a baseline imbalance is observed post-hoc then researchers are faced with 
two options for how to proceed: 1) assume that the randomisation has worked correctly and assume 
that the imbalance in a random phenomenon that can be ignored, or 2) include the baseline measure 
as a covariate.  
It is well accepted [78] that imbalance can lead to spurious estimates of the treatment effect if not 
accounted for in the analysis.  Perhaps for this reason, EMA guidance suggests that “When the 
analysis is based on a continuous outcome…the baseline value should be included as a covariate in 
the primary analysis.” [85].  Despite this regulatory guidance, in repeated measures clinical trials the 
decision of whether to adjust for the baseline measurement remains controversial [77, 87].   
1.6 Chapter outline 
This thesis covers research in two distinct fields corresponding to the areas introduced above:  
personalised medicine in chemotherapy, using data from a cohort of patients from Guy’s and St. 
Thomas’ NHS Foundation Trust, and an assessment of the different statistical methods used to 
analyse repeated measures data, with simulated data (see Figure 1.6.1).  
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Figure 1.6.1 Schematic of thesis chapters. 
Illustration of the two research lines pursued in this thesis and their relation to the chapter structure. 
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Chapters 2 through 6 of the thesis summarise a series of studies examining the role of baseline 
(demographic and disease) and genetic factors on efficacy and safety responses of Guy’s and St. 
Thomas’ NHS Foundation Trust cancer patients treated with platinum therapy.  
Chapter 2 introduces the clinical data used in this section of the thesis.  We describe the similarities 
and differences between two cohorts of data collected from patients with lung and ovarian cancer, 
and discuss the potential to combine the data from both cohorts through meta-analysis in subsequent 
association analyses. 
Chapter 3 outlines our hypothesis for a link between efficacy and safety before exploring whether 
safety responses during treatment are predictive of landmark (2-year) overall survival and/or 
progression free survival.  This chapter draws attention to the alternate methods and limitations of 
efficacy prediction from safety events.   
Chapter 4 investigates the baseline factors which are predictive/prognostic of safety and efficacy 
responses.  In this study, we tested several patient characteristics for their prognostic value in relation 
to both safety and efficacy outcomes to identify subgroups of patients who may be at high risk for a 
safety event and/or those more likely to have a positive efficacy response.  We compare our results 
to previously identified prognostic factors and discuss the similarities and differences between our 
findings and previous studies in similar patient populations. 
Chapter 5 explores whether SNPs, either alone or combined with baseline covariates could be used 
to predict patient responses.  Several recent pharmacogenomic studies have identified SNPs 
associated with toxicity and overall survival in lung cancer patients.  However, these recent genetic 
association studies only used the genomic data without adjusting for established clinical covariates 
that are known to have predictive value.  We explore whether the inclusion of clinical covariates alters 
the top SNP-outcome associations as compared with analyses that exclude clinical covariates in 
searching for SNPs associated with the outcome.    
Chapter 6 introduces a novel framework for exploring the similarities and differences of genetic 
association results from individual phenotype analyses.  Each efficacy or safety response can be 
thought of as a phenotype.  The most common (and simplest) way to deal with multiple phenotypes 
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is to test each SNP against each phenotype one at a time, testing for association between SNP and 
efficacy or safety response.  We develop a graphical approach that captures both correlation and 
distributional differences between association results from analyses of individual phenotypes.     
In Part 2 of the thesis, Chapters 7-11 explore how correlated repeated measures response data 
generate special challenges and opportunities for researchers in terms of the methodologies for 
analysis and sample size calculation. 
Chapter 7 provides a review of sample size methods for repeated measures experiments.  Repeated 
measurements collected from the same subject tend to be correlated, and the correlations must be 
accounted for in calculating the sample size.  Failure to account for intra-patient correlation between 
the repeated measurement outcomes, or incorrect specification of the correlation, can result in 
erroneous sample size estimates.  In this chapter, we review methods for the estimation of sample 
size in repeated measurement designs where the baseline measurement is analysed as part of the 
response and when the baseline measurement is used to control for individual differences through 
the analysis of change scores or the analysis of covariance (ANCOVA).  Furthermore, we emphasise 
the distinction between repeated measures designs with two or with more than two time points.   
Chapter 8 builds upon the material introduced in the previous chapter to explore sample size 
calculations for repeated measures data.  Here we introduce the concept of correlation structure, a 
critical component of all repeated measures analysis.  This study examines the influence of the 
strength of the correlation structure and the number of repeated measures assessments upon the 
required sample size to achieve a given level of power for a fixed type-I error level. 
Chapter 9 reviews some of the major advances in the analysis of repeated measures data.  Both 
marginal and mixed-models for repeated measures data model the covariance structure of the 
repeated measurements and represent common analysis methods for repeated measures data.  In 
this review, we present a basic overview of each of these repeated measures analysis methods.  
Furthermore, we review literature which has compared alternate strategies for handling the baseline 
measurement within the analysis of repeated measures data. 
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Chapter 10 describes an extensive simulation study in repeated measures.  While general linear 
models have emerged as the standard for analysing repeated measures data, there are several 
commonly employed strategies for handling the baseline measurement: 1) retain it as part of the 
outcome vector (RMA); 2) use the baseline measurement as a covariate in the analysis of the post-
baseline measurements (ANC); 3) subtract the baseline measurement from all of the remaining post-
baseline measurements and then analyse the change scores (CSA).  Using simulation, we compare 
the model coefficients returned from each strategy to design parameters (i.e. treatment intercepts 
and slopes) in the simulated data. 
Chapter 11 continues the comparison between RMA, ANC and CSA analysis methods.  In this 
chapter, our focus switches to the variance of model parameter coefficients.  Using matrix algebra 
and simulation, we explore the similarities and differences between analysis methods as they pertain 
to variance of the coefficients and statistical power to detect significant model effects.    
Finally, Chapter 12 summarises the contribution of these studies with a discussion of the key 
limitations of the work and potential future research directions.  
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Chapter 2. A comparison of efficacy, safety and baseline 
characteristics between lung and ovarian cancer cohorts 
The combination of some data and an aching desire for an answer does not 
ensure that a reasonable answer can be extracted from a given body of 
data. 
– John W Tukey 
2.1 Abstract 
Background 
Platinum agents form the backbone of first-line chemotherapeutic treatment regimens for 
both lung and ovarian cancer patients.  Despite proven efficacy, platinum use carries a high 
risk of toxicity.  Baseline characteristics in patients with cancer may predict response to 
therapy, including the risk of experiencing an adverse event (safety outcome / toxicity).  We 
compared the baseline of two cohorts of cancer patients (lung and ovarian), both of which 
contained patients treated with platinum chemotherapy, for differences with respect to 
established prognostic factors for safety and efficacy outcomes. 
Methods 
Data from 566 patients were used to compare two cohorts of cancer patients – lung and 
ovarian – for similarity between baseline and demographic characteristics, safety profiles 
and survival characteristics.  The cohorts were compared using independent t-tests for 
continuous characteristics.  Ordinal logistic regression, generalised logit models, and chi-
square tests were used to compare categorical characteristics between cohorts, as 
appropriate for the specific baseline characteristic. 
Results 
Differences between cohorts were observed for the proportion of patients in each 
performance scale category and with respect to the relative proportion of patients within 
each cohort treated with cisplatin and carboplatin containing regimens.  The frequency of 
severe infection (p=0.0331) and fatigue (p=0.0156) was higher in the in the lung cohort as 
compared with the ovarian cohort.  Lastly the ovarian cohort had significantly longer overall 
survival (p<0.0001) and progression free survival (p<0.0001) as compared with the lung 
cohort.   
Conclusion 
Despite the similarity of treatment regimens, patients from the ovarian and lung cohorts 
differed significantly with respect to response profiles.  Future work exploring genetic 
associations with safety or survival outcomes cannot combine the data from both cohorts as 
the clinical heterogeneity between cohorts would potentially introduce confounding. 
 
 
   




Prognostic factors are variables that associate with subsequent clinical outcome in people with a 
given disease [88, 89].  Such factors include baseline patient characteristics (i.e. age, gender, 
ethnicity), patient behaviours (smoking status) and genetic factors.  Robust identification of prognostic 
factors is a crucial component of personalised medicine as they are the building blocks of risk 
prediction models [90] and can be used to predict treatment response [89, 91].  As noted in section 
1.2, there is a distinction between ‘prognostic’ and ‘predictive’ factors.  Within this thesis, since all 
patients received similar therapy (platinum agents), we are not able to differentiate between 
prognostic and predictive factors, and as such the terms are used interchangeably. 
Within the context of clinical trials, the similarity of comparison groups is often assessed through the 
baseline and demographic characteristics of comparison groups [79].  This comparison allows 
reviewers to make up their own mind as to whether the comparison groups were similar with respect 
to important prognostic factors (variables that may influence the outcome) at the start of the study.  If 
patients are similar with respect to prognostic characteristics, then any difference in the response can 
be attributed to the treatment differences between comparator groups.  Similarly, if patients are 
receiving the same chemotherapeutic agent then differences in the response can be potentially be 
attributed to differences in the baseline, demographic and genetic characteristics between 
comparator groups.  In this regard, safety and efficacy outcomes are an opportunity to assess the 
similarity of two or more sample populations. 
 When a treatment is described as safe it does not mean there are no potential risks associated with 
its use, only that the benefits to the patient of taking the treatment are deemed to outweigh the 
potential risks.  An adverse event (AE) is any unfavourable, unintended symptom, sign (for example 
an abnormal laboratory finding) or disease associated with the use of treatment.  Pharmacovigilance 
(PV), also known as drug safety, is the pharmacological discipline related to the collection, detection, 
assessment, monitoring, and prevention of adverse effects with pharmaceutical products [92].  The 
weight of evidence regarding the risk of particular adverse events for a given therapeutic agent is 
known as the ‘safety profile’. 
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The safety profile of a drug is thought to relate to both the physical and chemical properties if the drug 
in question as well as the process of by which the human body responds to the administration of the 
drug – adsorption, metabolism and excretion (ADME).  This implies that the same drug will have a 
similar safety profile in patients with similar ADME properties.  However, it has been established that 
demographic characteristics influence an individual’s ADME.  A number of age related changes in 
drug ADME contribute to differences in treatment response between younger and older patients.  As 
a person ages, changes in body composition are associated with a rise in the volume of distribution 
for lipid soluble drugs and a reduction in the volume of distribution for hydrophilic drugs [93].  
Furthermore, age related changes in renal mass might result in reduced ability to metabolise drugs 
and clear metabolites [94]. Beyond age, it is conceivable that alternate forms of cancer as well as 
cancer stage (tumour burden) might result in response differences to the same therapeutic agent.      
Platinum-based agents are chemotherapeutic agents used as therapy across a range of cancers.  
These platinum complexes react in the body, causing DNA strands to crosslink and ultimately trigger 
cell apoptosis.  The various platinum-based chemotherapy drugs are used against advanced, 
metastatic forms of colon cancer, small cell and non-small cell lung cancer, breast cancer, 
adrenocortical cancer, anal cancer, endometrial cancer, non-Hodgkin lymphoma, ovarian cancer, 
testicular cancer, melanoma as well as head and neck cancers. 
Platinum based chemotherapy drugs are known to elicit strong side effects including neurotoxicity, 
nephrotoxicity (kidney damage), ototoxicity (hearing damage), nausea, fatigue and vomiting.  Several 
studies have highlighted differences in the safety profile of separate platinum agents.  Two large 
phase III trials have compared carboplatin plus paclitaxel with cisplatin-based combinations in 
patients with non-small cell lung cancer.  Both trials demonstrated similar efficacy between 
carboplatin and cisplatin, but lower rates of nausea, leukopenia, and nephrotoxicity with the use of 
carboplatin as compared with cisplatin [95, 96].  Similarly, three trials have investigated the 
equivalence of carboplatin and cisplatin in combination with paclitaxel for first-line treatment of 
patients with ovarian cancer.  All three trials concluded that carboplatin is associated with significantly 
lower neurotoxicity and renal toxicity [97-99].  
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Below we characterise the similarities and differences in baseline characteristics, safety and efficacy 
responses between two cohorts (lung and ovarian) of cancer patients treated with platinum containing 
regimens.  Participants in both cohorts were recruited from the same treatment centre (oncology 
outpatient clinics at Guy’s and St. Thomas’ NHS Hospitals Foundation Trust); under the same 
research protocol and all patients received a platinum agent to treat their cancer (similar 
chemotherapy regimens).  Ultimately, we wish to use the data from both cohorts to search for genetic 
variants associated with either safety or efficacy responses.  From an analysis perspective, we would 
like to be able to combine the data from both cohorts thereby maximising our statistical power to 
detect SNP-response associations.  Towards this end we need to explore the feasibility of combining 
the data from both cohorts.  Specifically, we wish to compare cohorts for prognostic baseline 
characteristics, the frequency and severity of adverse events and similarity of efficacy profiles.  
2.3 Materials and methods 
2.3.1 Data collection 
2.3.1.1 Patients and recruitment 
The data sets described in this and subsequent chapters were collected as part of a study performed 
at Guy’s and St. Thomas’ NHS Foundation Trust (Principal Investigators Jeremy Sanderson, Anthony 
Marinaki, James Spicer) to identify genetic variants associated with platinum toxicity [100].  The study 
was funded by Guy’s and St. Thomas’ Charity and the Purine Metabolic Patient Association.  The 
study was approved by the Regional Ethics Committee (10/H1109/47) and all participants provided 
written informed consent [100].  Two independent cohorts of platinum treated patients with lung and 
ovarian cancer were recruited.  Both these cancer types receives platinum agents as first-line therapy 
and it was hypothesised that germline genetic variants associated with platinum toxicity would exert 
their influence largely irrespective of the specific cancer type [61].  
Patients were recruited from oncology outpatient clinics at Guy’s and St. Thomas’ NHS Foundation 
Trust by Dr Adele Corrigan, Dr Sasala Wickramasinghe and Teagan Hoskin.  Eligible patients were 
identified based upon planned or current treatment with a platinum containing chemotherapy regimen.  
Additionally, all participants considered for inclusion were ≥18 years old, exhibited adequate 
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haematological status to receive therapy and had histologically confirmed carcinoma.  All patients 
were platinum-naïve prior to this study and up to four cycles of platinum-based chemotherapy were 
recorded.  Patients within the lung cancer cohort were treated with either cisplatin (75-80 mg/m2) or 
carboplatin (area under the curve (AUC) 5/6) in combination with a concomitant agent.  Patients in 
the ovarian cohort were treated with carboplatin alone at AUC 5/6, or in combination with paclitaxel.  
2.3.1.2 Clinical variables 
Per institutional treatment practice, prior to each cycle of therapy, patients were evaluated for 
treatment tolerance.  Patient outcomes and characteristics were then collected through manual 
review of the patient electronic records.  Review of patient records is believed to be the most useful 
method for estimating the rate of adverse events among patients [101, 102].  Although this method is 
labour-intensive and cannot offer real-time monitoring of safety events, it is an appropriate method 
for retrospective analysis as employed in both the original work with this data and the analyses 
conducted in this thesis. 
All adverse events were graded in accordance with the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) Version 4.7.   
2.3.1.3 Genotyping platform  
At treatment initiation, consenting patients provided a blood sample from which they were genotyped.  
The choice of genotyping platform has been described previously [60, 100] . In brief, the choice was 
a function of the hypothesis that coding region variants are likely to have high pharmacogenomic 
relevance.  The Illumina® Human Exome v1.1 DNA Analysis BeadChip Kit (Illumina UK Ltd., Saffron 
Walden, UK) contains ˃240,000 exon located and near gene polymorphisms.  Content for this chip 
was derived from the results of 12,000 whole genome or whole exome sequences gathered from an 
international consortium whose research interests included depression, obesity and cancer.  This 
chip was chosen as the platform on which to genotype all patients from the separate cancer cohorts.  
Genotypes were called using GenCall Data Analysis Software v1.0 clustering algorithm in Genome 
Studio v2011.1 (Illumina).  Genotyping was conducted at the King’s Genomics Centre.  Both 
genotyping and calling was performed on this study prior to my involvement. 
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Several quality-control filters were applied to samples and variants prior to analysis.  
Individuals were excluded for the following reasons: sex mismatch, individual call rate of >97%, SNP 
call rate of >99%, Hardy–Weinberg Equilibrium p-value <10-6, cryptic relatedness and minor allele 
frequency >0.05.  Population stratification was assessed using principal components (PCs).  Principal 
components analysis was carried out using EIGENSOFT v3.0 on all common SNPs (minor allele 
frequency 0.05).  EIGENSOFT performs principal component analysis on the 𝑔𝑒𝑛𝑜𝑡𝑦𝑝𝑒 ×  𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 
matrix.  The observed structure within the matrix usually reflects slight differences in genetic ancestry 
between study participants, which is captured by the eigenvector loadings for individuals.  Genetic 
association studies standardly use the principal components (eigenvector loadings) as covariates 
within a regression model.  These covariates model any correlation between outcome variable and 
ancestry, and reduces the risk of false positive results arising from this population stratification.  All 
quality control and principal components analysis was completed by Dr Jemma Walker (Statistical 
Genetics Unit, King's College London). 
2.3.2 Data available for analysis 
The primary analysis of this data set was performed by Drs Adele Corrigan and Jemma Walker [60].  
The principal investigators generously allowed me access to the data set to perform secondary 
analysis and for methods development.  The data collection process outlined above provided me with 
4 distinct datasets: 
1) Lung clinical characteristics 
2) Ovarian clinical characteristics 
3) Lung SNP data 
4) Ovarian SNP data 
Below we describe the scope and format of the data within each of these 4 datasets. 
2.3.2.1 Clinical data 
The general structure of both clinical datasets was a ‘wide’ format (i.e. 1 row per patient).  The lung 
cohort dataset contained 396 unique records while the ovarian cohort dataset contained 230 records.  
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The columns of these datasets contained baseline, efficacy and safety variables.  Owing to minor 
differences in the safety variables collected for each cohort (see section 2.3.2.1.3), the exact number 
of columns differed between each dataset.  We discuss each category (baseline, efficacy and safety) 
of variable below, and unless otherwise stated the variables mentioned are present in both lung and 
ovarian clinical datasets. 
2.3.2.1.1 Baseline characteristics 
The baseline characteristics collected were: age, gender, renal impairment graded using CTCAE, 
ECOG performance status, ethnicity and smoking status.  Below we explain some of the baseline 
characteristics and methods of adverse event coding for readers less familiar with oncology data. 
Performance status (PS) is an assessment of a patient’s level of physical function and ability to take 
care of themselves [103].  The ECOG Scale of Performance status is one such measurement [104]. 
The ECOG performance status is an ordinal measure between 0 and 5, with 0 representing no 
restriction as compared with prior to the disease, and 5 representing death (see Table 2.3.1). 
Table 2.3.1 ECOG performance status† 
GRADE Grade Description 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g. light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities; up 
and about more than 50% of waking hours 
3 Capable of only limited self-care; confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled; cannot carry on any self-care; totally confined to bed or chair 
5 Dead 
† Developed by the Eastern Cooperative Oncology Group, Robert L. Comis, MD, Group Chair. 
The National Cancer Institute (NCI) of the National Institutes of Health (NIH) has published 
standardised definitions for adverse events (AEs), known as the Common Terminology Criteria for 
Adverse Events (CTCAE, also called "common toxicity criteria") [105], to describe the severity of 
toxicity for patients receiving cancer therapy (see Table 2.3.2).  These criteria are used for the 
management of chemotherapy administration and dosing, and in clinical trials to provide 
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standardisation and consistency in the definition of treatment-related toxicity.  In addition to providing 
consistent interpretation of severity between clinicians within a particular adverse event, the common 
criteria also allow for severity comparisons between adverse events.  By convention, and used here, 
any adverse event (AA) of CTCAE grade 3 or greater is considered ‘severe’. 
   Table 2.3.2 Grades of CTCAE 
Grade 0 Asymptomatic 
Grade 1 Mild symptoms, no course of action is required to 
treat the symptoms of the AE 
Grade 2 Moderate; for this grade of AE minimal, intervention 
may be indicated, for example, this might involve 
treating the symptom (e.g. nausea and vomiting 
caused by a cancer treatment managed/prevented 
by giving the patient drugs to stop sickness, rather 
than stopping the anticancer drug) 
Grade 3 Severe but not immediately life-threatening; for such 
AEs hospitalization and investigation/management 
are often indicated 
Grade 4 Usually life-threatening consequences; for these 
AEs urgent intervention is indicated 
Grade 5 Death related to AE 
 
2.3.2.1.2 Efficacy 
The efficacy variables collected were: date of treatment initiation, death date/date of last patient 
contact, progression date / date of last scan with no disease progression.  Additionally, the data 
contained censoring markers for each of these date variables to differentiate between censors and 
events.  Progression free survival (PFS) was calculated as the interval from the date of first dose until 
the date of documented disease progression or death (whichever occurred first).  Patients without 
documented progression or death were censored at the time of the last disease evaluation.  Similarly, 
the overall survival (OS) was calculated as the interval from the date of first dose until the date of 
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death from any cause.  If a patient was lost to follow-up, the patient was censored on the date of last 
contact. 
2.3.2.1.3 Safety 
In contrast to the majority of clinical trials which collect all adverse events during the treatment period, 
the data collection process employed for these data targeted specific adverse events hypothesised 
to be associated with treatment.  Across both data cohorts, severity information was collected for 19 
specific adverse event terms (see Table 2.3.3) over 4 cycles of treatment.  Consistent with the wide 
data format, within each dataset, specific adverse event status was represented by a column for each 
cycle (i.e. C1_Alopecia, C2_Alopecia for cycle 1-Alopecia and cycle-2 alopecia assessments 
respectively).  Neither the specific date nor the treatment compliance of dosing was available.  The 
severity of each AE at each cycle for each patient was recording using the CTCAE.  
In contrast to the baseline characteristics and efficacy variables, the safety information captured from 
each cohort differed.  Specifically, information on arthralgia, lymphocytes, myalgia and chronic kidney 
disease was collected from the ovarian cohort but not from the lung cohort.  Similarly, information 
regarding dysgeusia and tinnitus was collected from the lung cohort but not from the ovarian cohort.  
Lastly, information regarding patient alopecia was collected across all 4 cycles in the ovarian cohort 
but only for the first 2 cycles in the lung cohort (Table 2.3.3). 
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Table 2.3.3: Adverse events collected by cycle and cohort 
Adverse Event Term Overall Ovarian Cohort Lung Cohort 
 Ovarian Lung Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 1 Cycle 2 Cycle 3 Cycle 4 
Alopecia X X x x x x x x   
Anaemia X X x x x x x x x x 
Arthralgia X  x x x x     
Constipation X X x x x x x x x x 
Diarrhoea X X x x x x x x x x 
Dysgeusia  X     x x x x 
Fatigue X X x x x x x x x x 
Infection X X x x x x x x x x 
Lymphocytes X  x x x x     
Mucositis X X x x x x x x x x 
Myalgia X  x x x x     
Nausea X X x x x x x x x x 
Neutropenia X X x x x x x x x x 
Peripheral Neuropathy X X x x x x x x x x 
Thrombocytopenia X X x x x x x x x x 
Tinnitus  X     x x x x 
Vomiting X X x x x x x x x x 
WBC X X x x x x x x x x 
Chronic kidney disease X  x x x x     
 
X Information for this adverse event was collected for this cohort x Information for this adverse event was collected for this cycle 
 Information for this adverse event was not collected for this cohort  Information for this adverse event was not collected for this cycle 
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2.3.2.2 Genotype data 
The genotype data for each cohort was provided in a wide format with participants as rows and 
each SNP-ID forming a new column.  A total of 29328 variants in 343 individuals were available 
for analysis from the lung cancer cohort and a total of 29028 variants and 223 individuals were 
available for analysis from the ovarian cancer cohort. 
The number of shared variants across both cohorts was 26962. 
 
Figure 2.3.1 CONSORT diagram of patient numbers. 
Schematic diagram showing clinical and genotype patient numbers by cohort.  After merging the 
genotype and clinical data there were a total of 566 patients and 26962 SNPs available for 
analysis across both cancer cohorts. 
 
2.3.3 Cohort comparison objectives  
The primary objective of our study was to compare the lung and ovarian cohorts with respect to 
baseline patient characteristics and severe adverse events occurring at any time during the 
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treatment period.  A severe adverse event was defined as any adverse event greater than or 
equal to CTCAE grade 3 that occurred following the first dose exposure and up to 30 days after 
the last dose of study treatment.  Secondary objectives included a cohort comparison of overall 
survival (OS) and progression free survival (PFS).  
Baseline differences in group characteristics between lung and ovarian cancer cohorts are 
compared using the following methods:  
 An independent sample t-test was used to compare age between cohorts.  
 The chi-square test was used to compare gender, ethnicity and smoking status.   
 Ordinal logistic regression was used to analyse renal function 
 A generalised logit model was used to analyse performance status.  This analysis 
method was chosen as we rejected the null hypothesis of proportional odds when 
performance status was analysed as an ordinal variable. 
 
Continuous data are described as the mean (standard deviation), median and range while the 
counts and percentages are presented for categorical data.  Descriptive statistics were used to 
summarise the adverse events for each cohort and across both cohorts.  Formal comparisons 
were made between cohorts only for adverse events occurring in greater than 5% of patients in 
both cohorts.  These cohort comparison analyses were conducted using a chi-square statistic.  
Overall survival and progression free survival differences between cohorts were compared using 
two-sided log-rank tests.  Hazard ratios were obtained from a Cox model.  A 2-sided p-value less 
than 0.05 was considered significant, with no correction performed for multiple testing.  All 
analyses were performed using SAS version 9.4. 
2.4 Results 
2.4.1 Baseline and demographics 
Table 2.4.1 presents demographic and baseline characteristics by cohort and overall for the study 
population.  Statistically significant differences between cohort groups were noted for age 
(p=0.015), performance status (p<0.0001), smoking status (p<0.0001) and renal function (p= 
0.020).  Additionally, there were stark differences between cohorts with respect to the gender 
composition and platinum subclass, as expected.
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Table 2.4.1 Demographic and baseline characteristics of the subjects according to cohort and 
overall 
   Cohort  







Age(years)       0.015 
   N 223 343 566  
   Mean(SD) 61.2 (12.9) 63.6 (10.2) 62.7 (11.4)  
   Median 63.0 64.0 64.0  
   Min, Max 19,88 28,88 19,88  
Gender, n(%)    N/A 
   Male     0 196 (57.1) 196 (34.6)  
   Female 223 (100.0) 147 (42.9) 370 (65.4)  
Ethnic Origin, n(%)       0.458 
   Caucasian 189 (87.1) 298 (87.4) 487 (87.3)  
   Asian     3 (  1.4)     6 (  1.8)     9 (  1.6)  
   Black   18 (  8.3)   25 (  7.3)   43 (  7.7)  
   Other     5 (  2.3)     8 (  2.3)   13 (  2.3)  
   Mixed     2 (  0.9)     4 (  1.2)     6 (  1.1)  
   Missing     6     2      8   
Performance status, n(%)    <.0001 
     0 66 (33.7)   82 (24.8) 148 (28.1)  
     1 92 (46.9) 217 (65.6) 309 (58.6)  
     2 29 (14.8)   30 (9.1)   59 (11.2)  
     3   9 (4.6)     2 (0.6)   11 (2.1)  
     4   0     0     0  
     5   0     0     0  
Missing 27    12    39   
Smoking Status, n(%)    <.0001 
  Never   64 (57.7)   41 (12.6) 105 (24.0)  
  Ex-smoker   14 (12.6)   97 (29.8) 111 (25.4)  
  Current   33 (29.7) 188 (57.7) 221 (50.6)  
  Missing 112    17 129   
Renal Function     
    0 169 (78.6) 229 (68.4) 398 (72.4) 0.020 
    1   18 (  8.4)   58 (17.3)   76 (13.8)  
    2   26 (12.1)   46 (13.7)   72 (13.1)  
    3     2 (  0.9)     2 (  0.6)     4 (  0.7)  
    Missing     8      8    16   
Treatment, n(%)    N/A 
    Cisplatin     0  206 (60.1) 206 (36.6)  
    Carboplatin 220 (100) 137 (39.9) 357 (63.4)  
    Missing     3      0      3   
Note: Percentages are based on total number of non-missing patients within each variable for 
each treatment group or overall as appropriate. 
(a) P Value is based on Chi-Square test for the categorical variables, on 2-sample t test for 
the continuous variables, and using ordinal logistic regression for renal function and 
generalised logit model for performance status (owing to rejection of the proportional 
odds model when analysed as an ordinal variable). 
(b) Missing values are not included in the analyses comparing cohorts for categorical 
variables 
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2.4.1.1 Age and gender  
Overall mean age was 62.7 years, with the range of 19 to 88 years.  In both cohorts, the majority 
of patients were over 60 years of age however the median and mean age were higher in the lung 
cohort as compared with the ovarian cohort. 
2.4.1.2 Gender 
In the lung cohort, most patients were male (57.1%); as expected, 100% of patients in the ovarian 
cohort were female.  
2.4.1.3 Ethnic origin 
The majority of patients in both cohorts were Caucasian (87.3% Overall – 87.1% and 87.4% for 
the ovarian and lung cohorts respectively).  Black persons were the second largest ethnic group 
- 43 (7.7%).  Other ethnic groups made up a very small percentage of the studied patient 
population.   
2.4.1.4 Performance status 
In general, the lung cohort had higher ECOG performance status values as compared with the 
ovarian cohort.  The proportion of ovarian cancer cohort and lung cancer cohort patients with 
grade 0 ECOG performance status was 33.7% and 24.8% respectively.  The number of patients 
with an EGOC score of 1 was 65.6% in the lung cohort and 46.9% in the ovarian cohort.  The 
ovarian cohort had a higher proportion of patients with both PS grades 2 and 3 (14.8% and 4.6% 
respectively) compared with the lung cohort (9.1% and 0.6% respectively).  No patients in either 
cohort was recorded as 4 or 5 on the ECOG scale.  The cohorts differed in the number of missing 
performance status patients – 27 patients had missing values in the ovarian cohort as opposed 
to 12 patients in the lung cohort. 
2.4.1.5 Smoking status 
The proportion of current (57.7%) and ex-smokers (29.8%) is much higher in the lung cohort as 
compared with the ovarian cohort (29.7% and 12.6% respectively).  The ovarian cohort had a 
large proportion of participants with 'Unknown' smoking status (112 - 48.1% of the cohort), which 
hints that the current and ex-smoker percentages may represent underestimates; however, the 
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ovarian cohort still has a larger proportion of never-smokers (57.7%) as compared with the lung 
cohort (12.6%) indicating that the proportion of current and ex-smokers is still likely to be higher 
in the lung cancer cohort. 
2.4.1.6 Renal function 
In general, the lung cohort patients had higher renal function scores (impairment) as compared 
with the ovarian cohort patients.  The percentage of patients with a renal function score of 0 was 
78.6% for the ovarian cohort and 68.4% for the lung cohort.  The lung cohort had a higher 
proportion of patients with both renal function scores 1 and 2 (17.3% and 13.7% respectively) 
compared with the ovarian cohort (8.4% and 12.1% respectively).  Both cohorts had 2 patients 
with a renal function score of 3 and again both cohorts had 8 patients missing renal function 
results in their records. 
2.4.1.7 Treatment  
In the ovarian cohort, all patients with recorded treatment received carboplatin (100%) as the 
platinum agent.  By contrast, in the lung cohort, 60.1% of patients with recorded treatment were 
treated with cisplatin and 39.9% were treated with carboplatin.  In both the lung and ovarian 
cohorts, 3 patients had missing values for their platinum chemotherapy agent. 
2.4.2 Adverse events (AEs) 
2.4.2.1 Brief summary of adverse events  
A summary of severe adverse events by CTCAE grade is provided in Table 2.4.2.  Across both 
cohorts, approximately half of all patients experienced at least one severe adverse event (grade 
≥3): 302 (53%).  The proportion of patients experiencing severe adverse events was higher in the 
lung cohort (196 patients - 57%) as compared with the ovarian cohort (106 patients - 48%).  The 
proportion of patients experiencing grade 4 events in the lung cohort (16%) was approximately 
twice the proportion of patients experiencing grade 4 events in the ovarian cohort (8%) 
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Table 2.4.2 Severe adverse events by CTCAE grade  
 Lung Ovarian Overall 
 n (%) 
Any Severe AE 196 (57)  106 (48) 302 (53) 
AEs of CTCAE Grade 3 183 (53) 104 (47) 287 (51) 
AEs of CTCAE Grade 4 54 (16) 17 (8) 71 (13) 
AEs of CTCAE Grade 5 1 (<1) 2 (<1) 3 (<1) 
 
2.4.3 Frequency of severe adverse events 
Table 2.4.3 lists the incidence of all adverse reactions of grade 3 or greater by the Medical 
Dictionary for Regulatory Activities (MedDRA) system order class and preferred term in each 
cohort and overall.  Of the 566 study patients examined, 302 (53%) had at least one severe 
(CTCAE grade 3 or greater) adverse event during the treatment period.  This group of patients 
had a total of 749 events indicating that some patients experienced multiple severe events, 
detailed further in Chapter 3. No patients experienced severe dysgeusia or alopecia. 
2.4.4 Adverse events leading to death 
Three patients (1 in the lung cohort and 2 in the ovarian cohort) experienced fatal adverse events 
(CTCAE grade 5) (see Table 2.4.2). All three fatal adverse events were recorded using the 
preferred term ‘infection’. The patient in the lung cohort experienced the fatal infection at cycle 2. 
For the two patients in the ovarian cohort the fatal infections were recorded at cycle 2 and cycle 
3.  These deaths contribute to the counts presented in Table 2.4.3. 
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Table 2.4.3 Severe adverse events by body system, preferred term, and cohort 
System Organ Class / 
Preferred Term 














OVERALL 490 196 (57) 259 106 (48) 749 302 (53) 
Blood and lymphatic system 
disorders 
80 56 (16) 23 19 (9) 103 75 (13) 
     Thrombocytopenia 32 26 (8) 13 11 (5) 45 37 (7) 
     Anaemia 48 40 (12) 10 10 (4) 58 50 (9) 
Ear and labyrinth disorders 16 9 (3) . . . 16 9 (2) 
     Tinnitus 16 9 (3) . . . 16 9 (2) 
Gastrointestinal disorders 74 45 (13) 34 20 (9) 108 65 (11) 
     Mucositis 6 5 (1) . . . 6 5 (1) 
     Constipation 5 5 (1) 5 5 (2) 10 10 (2) 
     Diarrhoea 9 9 (3) 10 7 (3) 19 16 (3) 
     Vomiting 25 21 (6) 11 10 (4) 36 31 (5) 
     Nausea 29 24 (7) 8 8 (4) 37 32 (6) 
General disorders and 
administration site conditions 
44 40 (12) 15 14 (6) 59 54 (10) 
     Fatigue 44 40 (12) 15 14 (6) 59 54 (10) 
Infections and infestations 43 38 (11) 14 13 (6) 57 51 (9) 
     Infection 43 38 (11) 14 13 (6) 57 51 (9) 
Investigations 232 126 (37) 152 72 (32) 384 198 (35) 
     Lymphocytes . . . 34 14 (6) 34 14 (2) 
     WBC 45 36 (10) 15 11 (5) 60 47 (8) 
     Neutropenia 187 120 (35) 103 61 (27) 290 181 (32) 
Musculoskeletal and 
connective tissue disorders 
. . . 9 8 (4) 9 8 (1) 
     Arthralgia . . . 2 2 (1) 2 2 (0) 
     Myalgia . . . 7 7 (3) 7 7 (1) 
Nervous system disorders 1 1 (0) 11 9 (4) 12 10 (2) 
     Peripheral sensory 
neuropathy 
1 1 (0) 11 9 (4) 12 10 (2) 
Renal and urinary disorders . . . 1 1 (0) 1 1 (0) 
     Chronic kidney disease . . . 1 1 (0) 1 1 (0) 
 
Across both cohorts, most patients experienced at least 1 severe adverse event: 196/343 patients 
(57%) in the lung cohort and 106/223 patients (48%) in the ovarian cohort.  The severe adverse 
events with the highest incidence in the two cohorts included neutropenia (Lung: 120/343 patients, 
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35 %; Ovarian: 61/223 patients, 27 %), fatigue (Lung: 40/343 patients, 12%; Ovarian: 14/223 
patients, 6 %), and infection (Lung: 38/343 patients, 11 %; Ovarian: 13/223 patients, 6 %).   
Table 2.4.4 presents the cohort comparison of severe adverse reactions reported for more than 
5% of patients in both cohorts.  This comparison revealed significant differences between the lung 
and ovarian cohorts for the incidence of fatigue (p=0.0156) and infection (p=0.0331). 






 n (%)  
Fatigue 14 (6.3) 43 (12.5) 0.0156 
Infection 13 (5.8) 38 (11.1) 0.0331 
Neutropenia 62 (27.8) 120 (35.0) 0.0738 
†Chi-square test comparing the number of patients experiencing each adverse event type 
between cohorts 
2.4.5 Efficacy 
There were clinically meaningful differences in efficacy between the lung and ovarian cohort (see 
Table 2.4.5).  Both the median OS and median PFS are significantly longer in the ovarian cohort 
as compared with the lung cohort.  The OS difference between cohorts (HR=0.337) is greater 
than the PFS difference (HR=0.527) indicating that ovarian and lung cohorts differ not only in time 
to progression but also in their post-progression survival. 
Table 2.4.5 Summary of efficacy outcomes 
Outcome 
Cohort 
HR† (95% CI; p-value) Ovarian 
(N = 223) 
Lung 
(N = 343) 
OS (days), median (95% CI) 2625 (1811-NE) 788 (685-934) 0.337 (0.257, 0.442; 
p<0.0001) 
PFS (days), median (95% CI) 578 (498-709) 299 (267-338) 0.527 (0.430,0.645; 
p<0.0001) 
† - HR calculated using a Cox model with the ovarian cohort as the numerator and the lung 
cohort as the denominator; p-value calculated using the log-rank tests stratified by cohort. 
NE = Not able to estimate due to the low fraction of patients who had experienced death 
within the ovarian cohort 
   




Our results showed clinically meaningful differences between lung and ovarian cohorts with 
respect to prognostic baseline characteristics, the frequency of severe adverse events and the 
efficacy responses.  The baseline data indicates two distinct differences between the cohorts 1) 
the proportion of patients in each performance status category and 2) the proportion of patients 
treated with cisplatin and carboplatin containing regimens. 
Within cancer research, PS is considered a major prognostic factor [103], predicting both efficacy 
responses [106] as well as toxicity response to treatment [107].  Owing to this prognostic status, 
PS scales are commonly used within cancer research clinical trials to stratify patients at 
randomisation [103, 108].  Within non-small-cell lung cancer (NSCLC), the benefit derived from 
platinum therapy over best supportive care or single agent chemotherapy is more pronounced in 
'fit' patients (PS 0 or 1) [109-111].  Consequently, differences between each cohort with respect 
to PS would be might result in differential survival endpoint distributions between each cohort 
independent of the survival prognosis associated with each disease type. 
Several meta-analyses have confirmed that in the treatment of NSCLC, cisplatin and carboplatin 
based regimens are similarly effective [112-114].  Ardizzoni et al. [113] analysed data from 2968 
NSCLC patients from nine trials conducted between 1990 and 2004.  The authors observed that 
cisplatin-based chemotherapy was associated with more severe nausea and vomiting, and 
nephrotoxicity; severe thrombocytopenia was more frequent during carboplatin-based 
chemotherapy.  Du Bois et al. [98] compared the efficacy and safety of cisplatin/paclitaxel vs. 
carboplatin/paclitaxel regimens in the first-line treatment of ovarian cancer patients.  Similar to 
the NSCLC studies, the authors concluded similar efficacy between treatment arms but noted that 
the carboplatin containing regimen was associated with a higher frequency of hematologic 
toxicity, but a lower frequency of gastrointestinal and neurologic toxicity, than the cisplatin 
containing regimen.  Within our own data, carboplatin and cisplatin use was 98.7% and 1.3% 
respectively for the ovarian cohort and 39.9% and 60.1% respectively for the lung cohort.  This 
difference in the relative proportion of cisplatin use between cohorts might explain the observed 
cohort differences in the frequency of fatigue and nausea adverse events.  
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From an analysis perspective, we would like to be able to combine the data from both cohorts 
thereby maximising our statistical power.  This benefit of pooling each cohort's individual patient 
data requires that cohorts: 1) contain sufficient common information for analyses, and 2) that their 
populations are reasonably comparable [115].  As both cohorts followed the same protocol for 
data collection, the first methodological concern is addressed.  However, the comparability of 
populations is less obvious to assess.  Superficially, both cohorts are comprised of patients 
experiencing solid tumour cancers, all of which are treated with platinum containing regimens.  
Additionally, the ethnic composition of each cohort is similar.  However, owing to differences 
between cohorts in both ECOG performance status and platinum therapy subtypes, it is logical to 
conclude that we cannot combine cohorts in a meta-analysis of response to platinum therapy  
As both cisplatin and carboplatin are thought to be equally efficacious, a meta-analysis of survival 
may be possible, however here the differences in the cancer types must be considered.  Recent 
research has found that the 1-year survival rate for women with ovarian cancer following diagnosis 
is greater than 70%.  Moreover, almost 50% of women will survive their cancer for 5 years or 
more [116].  By contrast for women with lung cancer, the one year survival rate is only 35.1% and 
the 5-year survival rate is 11.6% [116].  For men, the survival prognosis is even lower as the 1 
year and 5 year survival rates are 30.4% and 8.4% respectively [116].   
Recruitment to research trials is challenging, particularly for life threatening diseases.  It has been 
estimated that fewer than 5% of cancer patients participate in clinical trials.  While these data are 
not obtained from a prospective clinical trial each patient was required to complete a consent form 
and provide blood for genetic analyses and it is likely reasonable to assume that a number of 
patients were approached for every consent obtained.  Institutional hurdles and privacy issues 
contribute to the labour-intensive process of gathering patient information.  The data examined 
were part of an ambitious project to detect genetic variants associated with toxicity during 
chemotherapy with a platinum agent.  At the time of experimental design, it was envisioned that 
one cohort could serve as the primary analysis and the second cohort could act as the replication 
cohort.  Despite the similarity between cohorts with respect to the use of platinum agents as the 
backbone of chemotherapy treatment, we contend that differences between the cohorts with 
respect to the baseline characteristics, proportion of patients treated with cisplatin (rather than 
carboplatin) and rate of health decline (as evidenced from median PFS and OS), imposed by the 
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alternate cancer types, render the two cohorts’ poor replication for one another.  Moreover, the 
clinical heterogeneity of the two cohorts prohibits our ability to combine the data for meta-analysis.  
Consequently, in all subsequent sections of this thesis we will conduct our analyses separately in 
the ovarian and lung cohorts.  A further limitation of the data collection protocol is the lack of cycle 
date for administration and/or recorded assessment of adverse event status at each cycle.  This 
lack of date shaped the analysis that was possible.  Without the specific date of each adverse 
event onset it was not possible to explore the time-to-onset of specific adverse event categories.  
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Chapter 3. Early adverse events as predictors of mortality 
during platinum therapy 
Chemotherapy isn't good for you.  So when you feel bad, as I am feeling 
now, you think, 'Well that is a good thing because it's supposed to be 
poison.  If it's making the tumor feel this queasy, then I'm OK with it. 
– Christopher Hitchens 
3.1 Abstract 
Background  
Platinum chemotherapeutic agents provide effective treatment for a variety of cancers, 
however most patients experience at least one adverse event (AE) during therapy.  
Chemotherapy induced adverse events have previously been reported to be prognostic 
of efficacy for some cancers although the exact relationship between non-fatal AEs and 
survival is not well understood.  We sought to determine the impact of AEs occurring 
during the first 4 cycles of therapy and one-year mortality.  
Methods  
We examined two different adverse event types for their potential prognosis in efficacy 
outcomes: 1) neutropenia (NEU) and 2) gastrointestinal disorders (GID).  For each 
adverse event patients were stratified into two groups, those experiencing grades 0-2 
neutropenia and those experiencing grades 3-4 neutropenia.  The efficacy outcomes 
studied were 2-year overall survival (OS) and 2-year progression free survival (PFS).  
We employed three models to explore the potential of adverse events to predict survival 
outcomes: 1) treating adverse event status as time-invariant; 2) treating adverse event 
status as time-varying and 3) the total adverse event frequency across the treatment 
period was used to explore if patients experiencing multiple categories of adverse 
events associate with poorer outcomes. 
Results  
No associations were found between adverse events and efficacy outcomes across any 
of the three analysis strategies.  
Conclusions 
We were unable to confirm the prognostic implications of chemotherapy induced 
toxicity.  As the frequency and severity of adverse events are often managed 
prophylactically through concomitant medications, it is possible that their use in our 
study population confound our ability to detect an association between toxicity and 
efficacy.  Studies assessing the prognostic potential of toxicity should consider detailed 




   




Large randomised studies have demonstrated the therapeutic benefit conferred by treatment with 
regimens containing either cisplatin or carboplatin for the treatment of ovarian and lung cancer 
[117-122].  Such studies describe benefit at the population level, however, the reality is that 
survival varies significantly between individual patients with some patients surviving years while 
others survive no more than a few days or months.  In order to maximise the probability of positive 
patient outcomes, it is critical to have an understanding of the variety of factors which adversely 
affect survival, particularly beyond the first several months after termination of therapy.  
Previous reports have documented the influence of baseline patient characteristics on patient 
mortality.  Amongst the various factors identified as influencing survival in lung and ovarian cancer 
are: performance status [123-126], sex (lung) [123, 124], age [125, 127, 128] and lower body 
mass index BMI [124].  More recently there has been is shift in focus from baseline characteristics 
to early safety responses in the prediction of patient survival following chemotherapy [129-131].  
Neutropenia is a condition characterised by abnormally low blood levels of infection-fighting 
neutrophils, a specific kind of white blood cell [132]. Neutropenia is a common side effect of 
chemotherapy [65, 133].  Most chemotherapeutic agents work by disrupting cell division [134]. 
While rapid cell division is a defining characteristic of cancer cells it is also a characteristic of 
several ‘normal’ cell types, including the blood cells in the bone marrow, cells in the hair follicles, 
and cells in the mouth and intestines [135]. Consequently, patients undergoing chemotherapy 
often experience chemotherapy-induced neutropenia, alopecia and gastrointestinal disorders. 
Neutropenia during chemotherapy has been reported to be a predictor of better survival in patients 
with several types of cancers including metastatic colorectal cancer [136], adjuvant breast cancer 
[67], testicular cancer [137], ovarian cancer [138], non-Hodgkin’s lymphomas [139], non-small-
cell lung cancer [70, 140], and gastric cancer [141].  However, the relationship between 
neutropenia and survival is not straightforward.  Neutropenia often results in a lower neutrophil-
to-lymphocyte ratio, a condition that has been associated with poorer patient outcomes [142-144].  
These opposing perspectives on the relationship between neutropenia and survival can best be 
understood by examining the dose response curve. 
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The dose intensity is recognised as a key aspect in a patient’s response to cytotoxic 
chemotherapy drugs [63].  This means that both the probability of achieving an efficacy response 
and the probability of experiencing an adverse event both increase with dose.  As safety events 
will limit or delay further treatment administrations (thereby depriving the patient of the therapeutic 
benefit conferred by the treatment), this creates a ‘bell curve’ relationship between dose and 
favourable patient response in which initial increases in dose result in improved probability of 
favourable patient response up to an ‘optimal’ dose, at which the probability of favourable patient 
response is maximised.  Further increases in dose beyond the optimum reduce the probability of 
a favourable patient response (see Figure 3.2.1). 
Most chemotherapy agent doses are calculated using body surface area (BSA).  As volume 
increases as a cubic function and BSA varies with patient size as a squared function, BSA 
standard dosages may be too small for optimal efficacy in larger patients, or too large to avoid 
unnecessary adverse effects in smaller patients. 
 
Figure 3.2.1 Dose response curve. 
In section A, increasing the dose improves the probability of a favourable patient response.  The 
point B on the dose scale represents the ‘optimal’ dose at which the probability of a favourable 
patient response is maximised.  Further increases in dose (region C) decrease the probability of 
a favourable patient response due to AEs. 
 
 
   
   
63 
 
This dose-response relationship can best be understood by partitioning the efficacy and safety 
dose response relationships (see Figure 3.2.2). 
At low dose, the probability of either an efficacy or adverse response is low.  The probability of 
achieving an efficacy response increases with dose until sufficiency is reached, at which point 
further increases in dose will not improve the chances of an efficacy response.  The probability of 
a dose-limiting adverse response also increases with dose, but at a slower rate than the efficacy 
curve.  The difference in the slope of probability between efficacy and safety responses creates 
a dose window in which the probability of achieving a positive efficacy response is greater than 
the probability of an unwanted safety response.  The difference between the dose that is 
efficacious and the dose that causes adverse effects is known as the ‘therapeutic window’.  
Subtraction of the safety response curve from the efficacy response curve creates a distribution 
that we can recognise as the ‘favourable patient response’ curve. 
 
Figure 3.2.2 Dose response curves for efficacy, safety and favourable patient response. 
The favourable patient response curve is derived from the subtraction of the safety response 
curve from the efficacy response curve.  The shape of the favourable response curve is a product 
of the difference in slopes between the efficacy and safety dose-response curves. 
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These curves show that the proportion of patients who are receiving less than the optimal dose, 
and the proportion of patients who are receiving beyond the optimal dose, will influence whether 
a study finds a positive or negative association between an adverse event and survival.  
Irrespective of the direction of association, this framework establishes that a link between efficacy 
and safety endpoints is a logical assertion.  
We hypothesised that clinically significant, but nonfatal, AEs that occur during the first four 
treatment cycles would be predictive of later-term survival. 
Therefore, utilising standardised CTCAE definitions, we conducted a retrospective analysis of 
patients receiving platinum therapy for the treatment of solid tumour cancers to determine the 
separate and combined effects of early adverse events on two-year overall survival and 
progression free survival. 
3.3 Methods 
3.3.1 Adverse events  
Neutropenia (NEU) and gastrointestinal disorder (GID) adverse events reported during the first 
four cycles of platinum therapy were included in the analyses.  Adverse event information was 
obtained from patient responses and laboratory assessments during clinic visits.  The severity of 
each adverse event was assessed using the CTCAE.  The system organ class (SOC) was 
determined using MedDRA.  The specific terms included in gastrointestinal disorder (GID) were: 
mucositis, constipation, diarrhoea, vomiting, and nausea. 
3.3.2 Endpoints 
Although adverse events during the treatment period may influence OS/PFS at any time beyond 
the treatment phase, second and third line therapy has the potential to introduce time-dependent 
confounding as patient OS may well be influenced by the use of post-progression therapy [145, 
146]. We chose to assess the impact of toxicity responses upon efficacy at a given time point: 2 
years [145]. This time-point captured the majority of OS events in both cohorts while reducing the 
risk for subsequent therapy to influence patient OS as compared with analysis of the raw survival 
times.  
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In this method, patients who had not experienced the survival event by the landmark time were 
censored in the analysis. 
PFS was therefore defined as the time from treatment initiation to the earliest documentation of 
disease relapse or death (all causes) or end of 2-year follow-up, whichever came first.  Similarly, 
OS was defined as the time on treatment to the date of death or end of 2-year follow-up, whichever 
came first.  
The relationship between the occurrence of specific adverse events (NEU and GID) and efficacy 
outcomes (OS and PFS) was assessed.  Furthermore, we evaluated the relationship between 
outcome measures and the number of different kinds of specific adverse events reported per 
patient. 
3.3.3 Survival analysis 
In oncology studies, the primary efficacy outcome under assessment is the time to an event of 
interest, such as the time from cancer diagnosis or treatment initiation to cancer recurrence or 
death.  The event of interest may not have occurred for every patient at the time of the statistical 
analysis, and similarly, a subject may be lost to follow-up before the event is observed.  In such 
cases, the data are censored at the time of the analysis or at the time the patient was lost to 
follow-up.  Censored data still contribute information to the analysis; whilst we do not know the 
exact date of the event, we know that it had not occurred up until the censoring time. 
The Kaplan-Meier method is a common statistical method used to analyse survival data [147, 
148], and to estimate the survival probability - S(t), the probability that a subject survives beyond 
some time t.  
The survival probability is estimated by the survival function S(t) = P (T > t), where T is the survival 
time.  The Kaplan-Meier method assumes no specific underlying function and therefore estimates 
the survival probability non-parametrically [148].  
The survival curves can be compared statistically using either the log-rank test or a Cox 
proportional hazard model.  While simpler to calculate, the log-rank test does not allow for the 
inclusion of covariates (or continuous predictors) [149].  By contrast the Cox proportional hazard 
(PH) model accounts for multiple categorical or continuous risk factors simultaneously [150] .  
   
   
66 
 
3.3.3.1 Static/constant predictors 
A static predictor is any factor that does not change across time (i.e. biological sex).  A Cox model 
incorporating only static explanatory variables can be expressed in the following way: 




Where baseline hazard rate 𝜆0(𝑡) is an unspecified non-negative function of time that corresponds 
to the hazard rate when all covariate values are equal to zero (i.e. 𝑋𝑖1 = 0, 𝑋𝑖2 = 0,…𝑋𝑖𝑘 = 0); and 
𝛽1, 𝛽2, . . . , 𝛽𝑘 are the coefficients of the regression function. 
If we are interested in a single categorical covariate with two levels (𝑋1
∗and 𝑋1 where 𝑋1
∗ = 𝑋1 + 1) 
then the hazard is: 




The hazards for patients with covariate values 𝑋1 and 𝑋1
∗ are given respectively by  
ℎ(𝑡, 𝑋1) = 𝜆0(𝑡)𝑒




, and the hazard ratio (HR) is calculated by: 








An important feature of equation (3.3.3) is that 𝜆0(𝑡) cancels out of the numerator and 
denominator and therefore the HR corresponds to the change in hazard associated with one-unit 
increase in the explanatory variable 𝑋 on the risk of event. If the HR is greater than one (β > 1), 
the event risk is increased for subjects with covariate value 𝑋1
∗ as compared to subjects with 
covariate value 𝑋1, while a HR lower than one (β < 1) indicates a decreased risk.  Although the 
hazard rate ℎ(𝑡, 𝑋) will vary over time, the HR is constant; this is the assumption of proportional 
hazards [150].  
3.3.3.2 Time-varying predictors 
The model for the hazard, given in (3.3.1), involves the proportional-hazards assumption of 
constant/static covariate status across the observation period.  This means that for each patient, 
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their specific covariate value will not change from baseline.  While many patient characteristics 
should remain constant throughout the observational period of a study, others could vary across 
time: time-dependent (or time varying) variables.  Performance status, smoking status and 
adverse event status are all examples of variables that could vary over time.  While typically 
researchers hold the values of such variables fixed at a certain point in time (traditionally 
baseline), it has been demonstrated that allowing the predictor values to vary with time can yield 
a more accurate estimate of the predictor effect [151]. 
To extend (3.3.2) to allow the predictor 𝑋 to change over time we need to create an interaction 
term between X and a function of time 𝑡 for example (𝑓(𝑡) = 𝑡, 𝑡2, 𝑙𝑜𝑔(𝑡)).  For simplicity, we will 
assume that 𝑓(𝑡) = 𝑡:  




And the HR is given by:  







In contrast to (3.3.3), in models with time-varying covariates the HR corresponds a unit increase 
in the variable 𝑋 but the HR is now time-dependent through the function 𝑓(𝑡).  Even though the 
HR varies with time in (3.3.5), the coefficient (𝛽) of the difference in values of the time dependent 
variable 𝑋1 is itself not time dependent.  The coefficient therefore represents an aggregate effect 
of the time-varying variable across the observation period [152]. 
3.3.4 Statistical analysis 
The primary objective of this study was to evaluate the association between severe (CTCAE 
grade   ≥3) gastrointestinal / neutropenic adverse events during four cycles of platinum therapy 
and the efficacy endpoints overall survival (OS), and progression free survival (PFS). 
In order to evaluate the prognostic implications of each adverse event we first identified the worst 
grade of each adverse event during treatment for each patient.  Owing to the size of the study 
population, we pooled each adverse event into two categories: unaffected (grades 0-2) and 
affected (grades 3-4).  Overall survival was defined as the interval between the date of treatment 
initiation and the date of death or last follow-up.  Similarly, progression free survival was defined 
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as the interval between the date of treatment initiation and the date first documented progression 
or death or last follow-up, whichever occurred first. 
To evaluate the impact of each AE on efficacy we used 3 analyses strategies: 
(1) Univariate regression analyses without time-varying covariate (TVC) - i.e. time-invariant 
analyses, examined the 2-year OS and PFS of patients in each cohort against adverse 
event status (affected / unaffected) by specific adverse event, cycle and cohort.   
 
(2) Number of specific adverse events reported - to explore if total adverse event count 
during treatment period influenced efficacy, we examined the 2-year OS and PFS of 
patients in each cohort against total sum of neutropenic and gastrointestinal adverse 
events during the treatment period.  Univariate analysis explored the association 
between efficacy endpoints and the frequency of adverse events in the absence of 
covariates.  Multivariable analyses repeated the univariate analysis including six 
baseline characteristics as covariates to the adverse event count: gender, age, 
performance status, renal function, race and smoking status. 
 
(3) Univariate and multivariable regression analyses with TVC – As adverse event status 
can vary by cycle, our first analysis could be biased by early event lead time, therefore 
we analysed each adverse event as a TVC where the length of each cycle was 
assumed to be 28 days.  As with the fixed effect analyses the covariates in the multiple 
variable regression were: gender, age, performance status, renal function, race and 
smoking status. 
 
All analysis strategies utilised the Cox proportional hazards model and therefore the measure of 
association in this study was the HR along with the 95% confidence interval (95%CI).  In the 
multivariable analyses, only the main effects were entered into the model; we did not explore 
interaction terms between covariates (possible synergistic effects).  Within the context of the 
software employed for the analysis (SAS v.9.4), Type III tests refer to a test of hypothesis that all 
coefficients in the model are 0, that is, an overall test of whether there are any differences in event 
rate across any of the levels of the covariate [153, 154]. 
As described in the previous chapter, all analyses were performed separately in the ovarian and 
the lung cohorts.  All tests we performed with an alpha of 0.05, with no correction for multiple 
testing, the limitations of which are highlighted in the discussion.  
3.4 Results 
3.4.1 Patient characteristics - NEU, GID  
Baseline characteristics of the unaffected and affected patients for each adverse event are 
presented in Table 3.4.1.  In both cohorts (ovarian and lung) more patients experience severe 
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neutropenia (NEU) as compared with severe gastrointestinal adverse events (GID).  Affected 
patients in both adverse event types had marginally higher mean age, performance status and 
renal function scores as compared with unaffected patients. 
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Table 3.4.1 Baseline characteristics for unaffected and affected patients by adverse event type and cohort 
 Ovarian Lung 



















Male 0 0 0 0 179 (60.1) 17 (37.8) 129 (57.8) 67 (55.8) 
Female 203 (100.0) 20 (100.0) 162 (100.0) 61 (100.0) 119 (39.9) 28 (62.2) 94 (42.2) 53 (44.2) 
Age 
N 203 20 162 61 298 45 223 120 
Mean 61.0 64.0 60.7 62.6 63.6 63.8 62.6 65.4 
SD 13.18 9.56 13.26 11.91 10.08 11.23 10.64 9.15 
Max 88 78 88 86 88 79 88 84 
Min 19 46 19 42 28 36 28 39 
Ethnicity, n(%) 
Caucasian 172 (84.7) 17 (85.0) 139 (85.8) 50 (82.0) 258 (86.6) 40 (88.9) 191 (85.7) 107 (89.2) 
Asian 2 (1.0) 1 (5.0) 2 (1.2) 1 (1.6) 6 (2.0) 0 2 (0.9) 4 (3.3) 
Black 17 (8.4) 1 (5.0) 12 (7.4) 6 (9.8) 21 (7.0) 4 (8.9) 20 (9.0) 5 (4.2) 
Other 4 (2.0) 1 (5.0) 4 (2.5) 1 (1.6) 8 (2.7) 0 6 (2.7) 2 (1.7) 
Mixed 2 (1.0) 0 1 (0.6) 1 (1.6) 3 (1.0) 1 (2.2) 2 (0.9) 2 (1.7) 
Missing 6 (3.0) 0 4 (2.5) 2 (3.3) 2 (0.7) 0 2 (0.9) 0 
Performance status, n(%) 
0 63 (31.0) 3 (15.0) 49 (30.2) 17 (27.9) 73 (24.5) 9 (20.0) 50 (22.4) 32 (26.7) 
1 84 (41.4) 8 (40.0) 61 (37.7) 31 (50.8) 185 (62.1) 32 (71.1) 150 (67.3) 67 (55.8) 
2 23 (11.3) 6 (30.0) 22 (13.6) 7 (11.5) 26 (8.7) 4 (8.9) 18 (8.1) 12 (10.0) 
3 8 (3.9) 1 (5.0) 8 (4.9) 1 (1.6) 2 (0.7) 0 0 2 (1.7) 
4 0 0 0 0 0 0 0 0 
Missing 25 (12.3) 2 (10.0) 22 (13.6) 5 (8.2) 12 (4.0) 0 5 (2.2) 7 (5.8) 
Smoking status, n(%) 
Never 58 (28.6) 6 (30.0) 45 (27.8) 19 (31.1) 32 (10.7) 9 (20.0) 25 (11.2) 16 (13.3) 
Ex-smoker 12 (5.9) 2 (10.0) 11 (6.8) 3 (4.9) 86 (28.9) 11 (24.4) 67 (30.0) 30 (25.0) 
Current 31 (15.3) 2 (10.0) 25 (15.4) 8 (13.1) 166 (55.7) 22 (48.9) 120 (53.8) 68 (56.7) 
Unknown 102 (50.2) 10 (50.0) 81 (50.0) 31 (50.8) 14 (4.7) 3 (6.7) 11 (4.9) 6 (5.0) 
Renal Function, n(%) 
0 156 (79.6) 13 (68.4) 124 (79.5) 45 (76.3) 198 (68.0) 31 (70.5) 157 (72.4) 72 (61.0) 
1 18 (9.2) 0 15 (9.6) 3 (5.1) 54 (18.6) 4 (9.1) 34 (15.7) 24 (20.3) 
2 21 (10.7) 5 (26.3) 16 (10.3) 10 (16.9) 37 (12.7) 9 (20.5) 25 (11.5) 21 (17.8) 
3 1 (0.5) 1 (5.3) 1 (0.6) 1 (1.7) 2 (0.7) 0 1 (0.5) 1 (0.8) 
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3.4.2 Association of NEU and GID with OS and PFS, by cohort and cycle 
Table 3.4.2 shows the results of univariate analyses of 2-year OS and PFS against severe 
adverse event, by adverse event type, cycle and cohort.  Each HR measures the hazard of 
affected over unaffected patients.  Univariate Cox analyses suggested that patients experiencing 
severe gastrointestinal events during cycle 1 of therapy were associated with higher risk of death 
(p=0.0234; Table 3.4.2) in the lung cohort only.  The HR for affected-GID patients relative to 
unaffected-GID patients was 1.908 (95% CI: 1.081-3.368).  We did not observe any associations 
between specific adverse events and overall survival in the ovarian cohort.  In both cohorts, cycle 
1 severe gastrointestinal adverse events were associated with a shorter progression free survival 
time (p=0.0183 and p=0.0286 for the ovarian and lung cohorts respectively).  The HR for affected-
GID patients relative to unaffected-GID patients was similar between cohorts:  2.087 (95% CI: 
1.117-3.898) in the ovarian cohort and 1.723 (95% CI: 1.052-2.821) in the lung cohort. 
3.4.3 Number of specific adverse event association with OS and PFS 
A patient could have a maximum of two types of specific AEs, which was the sum of neutropenic 
and gastrointestinal events (affected/unaffected) across 4 cycles.  This gives a total range of 
between 0 and 8.  The observed range was between 0 and 5.  As only one patient experienced 5 
specific AEs during the treatment period, this patient was counted as having 4 specific AEs in the 
analyses.  Figure 3.4.1 shows a distribution of patient scores within each category.  Table 3.4.3 
presents the results of both univariate and multivariable regression analyses.  The highlighted 
cells provide the Type III test of association results and the non-highlighted cells provide 
association values for each event count level of affected status patients relative to unaffected 
patients (event count=0).  We found no evidence of association between the sum of specific AEs 
and efficacy outcomes in either cohort (See Table 3.4.3). 
   




Figure 3.4.1 Frequency of patients in each sum of specific AEs category (i.e. sum of all 
neutropenic and gastrointestinal adverse events across all cycles) – pooled across both cohorts. 
 
3.4.4 TVC adverse event association with OS and PFS 
Table 3.4.4 presents the results of the univariate and multiple regression analyses when 
considering each severe adverse event as a TVC.  In these analyses, severe adverse events 
were not identified as being prognostic factors for OS or PFS.  
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Table 3.4.2 Landmark analysis of two-year survival outcomes predicted by neutropenic and gastrointestinal adverse events  
 Ovarian Lung 
 Neutropenia Gastrointestinal Disorder Neutropenia Gastrointestinal Disorder 
Cycle HR† 95% CI p-value HR† 95% CI p-value HR 95% CI p-value HR† 95% CI p-value 
Overall Survival 
1 1.275 0.392-4.149 0.68596 1.907 0.677-5.375 0.21420 1.130 0.732-1.746 0.58070 1.908 1.081-3.368 0.02340 
2 1.576 0.659-3.770 0.30273 N/A N/A 0.48230 0.657 0.411-1.050 0.07701 0.868 0.384-1.964 0.73403 
3 1.703 0.806-3.599 0.15795 3.059 0.417-22.43 0.24676 0.794 0.510-1.236 0.30574 0.613 0.227-1.655 0.32908 
4 1.263 0.528-3.021 0.59968 3.462 0.832-14.40 0.06890 0.986 0.569-1.707 0.95943 2.478 0.789-7.785 0.10774 
Any 1.785 0.931-3.422 0.07697 1.635 0.638-4.188 0.30089 0.926 0.667-1.285 0.64347 1.209 0.770-1.897 0.40922 
Progression Free Survival 
1 1.561 0.815-2.989 0.17503 2.087 1.117-3.898 0.01829 0.923 0.645-1.319 0.65840 1.723 1.052-2.821 0.02864 
2 1.479 0.883-2.476 0.13409 0.539 0.075-3.860 0.53170 0.800 0.568-1.126 0.19849 0.980 0.535-1.796 0.94852 
3 1.566 0.998-2.457 0.04901 0.814 0.114-5.834 0.83724 0.702 0.489-1.009 0.05400 0.809 0.400-1.636 0.55319 
4 1.121 0.669-1.876 0.66444 0.843 0.208-3.411 0.80979 0.943 0.614-1.448 0.78744 1.107 0.354-3.458 0.86122 
Any 1.431 0.970-2.111 0.06956 1.409 0.790-2.512 0.24278 0.820 0.631-1.067 0.13817 1.167 0.809-1.683 0.40912 
†HR calculated using analysis strategy (1) – Cox regression without time-varying covariate 
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Table 3.4.3 Two-year survival outcomes predicted by the number of specific adverse events reported 
























0 ref - 0.348 ref - 0.293 ref - 0.998 ref - 0.859 
1 2.115 1.006-4.445 0.048 1.548 0.732-3.275 0.253 0.996 0.676-1.467 0.985 1.043 0.699-1.556 0.838 
2 1.681 0.671-4.211 0.267 2.123 0.827-5.449 0.117 0.920 0.572-1.480 0.731 0.781 0.481-1.267 0.316 
3 2.256 0.302-16.870 0.427 5.534 0.704-43.520 0.103 1.004 0.506-1.993 0.990 0.864 0.412-1.812 0.699 
4 1.437 0.192-10.740 0.724 1.709 0.226-12.930 0.603 0.000 0.000-NE 0.972 0.000 0.000-NE 0.973 
Progression Free Survival 
0 ref - 0.148 ref - 0.106 ref - 0.749 ref - 0.374 
1 1.590 0.985-2.567 0.057 1.289 0.793-2.095 0.305 0.958 0.705-1.302 0.782 0.905 0.656-1.249 0.544 
2 1.776 1.049-3.008 0.032 1.988 1.159-3.411 0.012 0.764 0.515-1.134 0.181 0.673 0.450-1.007 0.054 
3 1.479 0.361-6.056 0.586 2.401 0.576-10.010 0.229 0.936 0.530-1.653 0.818 0.836 0.457-1.528 0.559 
4 1.511 0.549-4.160 0.424 1.624 0.587-4.495 0.350 0.738 0.183-2.984 0.670 0.590 0.143-2.425 0.464 
‡ p-values calculated using analysis strategy (2) – Cox regression without time-varying covariate.  When the event count=0, the p-value is derived from the Type III 
test of association results; when event count > 0 the p-value represents association values for each event count level of affected status patients relative to 
unaffected patients (event count=0). 
NE = Not able to estimate due to the low fraction of patients who experienced 4 severe events within the lung cohort. 
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Table 3.4.4 Univariate and multivariable analyses with each adverse event modelled as a TVC 
 Ovarian Lung 
 Neutropenia Gastrointestinal Disorder Neutropenia Gastrointestinal Disorder 
Cycle HRτ 95% CI p-value HRτ 95% CI p-value HRτ 95% CI p-value HRτ 95% CI p-value 
Overall Survival 
Univariate 1.366 0.568-3.287 0.4856 NA NA 0.9895 0.829 0.512-1.343 0.4465 1.087 0.480-2.463 0.8419 
Multivariable 1.940 0.774-4.865 0.1576 NA NA 0.9895 0.643 0.389-1.060 0.0836 1.183 0.518 - 2.701 0.6894 
Progression Free Survival 
Univariate 1.131 0.754-1.696 0.5529 0.528 0.074-3.786 0.5255 1.067 0.791-1.440 0.6721 1.645 0.896-3.022 0.1085 
Multivariable 1.289 0.823 2.018 0.2674 0.518 0.071 3.797 0.5172 1.012 0.737 1.388 0.9427 1.392 0.734-2.640 0.3107 
τ HR calculated using analysis strategy (3) – Cox regression with time-varying covariate 
 
 
   




The objective of this study was to investigate whether chemotherapy-induced severe neutropenia 
or gastrointestinal disorders were related to efficacy endpoints and could therefore be used as a 
predictor of patient prognosis.  This analysis approach has been used to identify associations 
prognostic between safety endpoints in many studies [67, 69, 155] and is considered to be an 
appropriate analysis method in treatment scenarios where the number of deaths during the 
treatment period is low.  
The underlying mechanism of severe adverse events acting as prognostic factors could be 
explained by adverse events acting as a measure of the plasma drug concentration, i.e. the lack 
of adverse events might indicate that the chemotherapy dosage is too low to produce a toxicity 
response.  
The present analyses showed no evidence that patients who reported one or more adverse 
events during the first 4 cycles of therapy had alternate subsequent efficacy outcomes in terms 
of 2-year landmark analysis of PFS and OS patients as compared with patients who do not report 
these adverse event symptoms.  Only the non-time varying analysis of severe adverse events 
during therapy found evidence of association with efficacy at the pre-specified alpha level.  The 
strongest observed association was between cycle 1 GID and 2-year PFS.  A modest association 
was also observed between cycle 1 GID and worse survival outcomes in the lung cohort.  There 
was no evidence of associations between adverse events and OS in the ovarian cohort.  However, 
it must be pointed out that given the number of tests performed, these observed associations are 
likely spurious.  Based upon the number of hypothesis tests performed in exploring the 
association between two-year survival outcomes predicted by adverse events, a Bonferroni 
adjusted p-value threshold for the of 0.05/40 = 0.00125 is a more reasonable benchmark of 
association.  Using this critical threshold, none of the observed associations would pass correction 
for multiple testing (can be considered significant).   
A recognised limitation of using adverse events as a prognostic measure of efficacy is that 
patients who survive longer tend to receive more chemotherapy, and thus have a greater chance 
of developing adverse events.  Consequently, considering severe adverse events as a baseline 
factor can produce false-positive associations between safety and efficacy endpoints.  Our 
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specific data presented us with data only on the first four cycles of chemotherapy, and while we 
are not specifically aware of extended treatment, some patients may have continued to receive 
chemotherapy beyond four cycles.  In an effort to avoid spurious associations between safety and 
efficacy, we analysed each adverse event as a TVC [70, 136, 156].  In the analyses that 
considered severe adverse events as TVCs, neither neutropenia nor gastrointestinal disorders 
predicted overall survival or progression free survival.  These findings differ from previous studies 
which have identified chemotherapy induced neutropenia as a being associated with improved 
survival in metastatic colorectal cancer [157], breast cancer [158], non-small-cell lung cancer [70, 
159], gastric cancer [160], and ovarian cancer [159].   
This study has several important limitations that potentially hamper our ability to detect survival 
and toxicity links.  This investigation included patient data from medical records completed from 
within the same Guy’s and St. Thomas’ NHS Foundation Trust clinic but by alternate physicians.  
Heterogeneity in the reporting of adverse events is a potential source of confounding.  Historically, 
ovarian cancer patient survival is longer than that expected for patients with lung cancer.  
Consequently, it is possible that clinicians pay greater attention to the reporting and management 
of AEs within ovarian cancer as compared with lung cancer.  Because of the post-hoc nature of 
these analyses, concomitant medications and dose intensity were not recorded.  Granulocyte 
colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-
CSF) are glycosylated polypeptides that induce an increase in the proliferation and maturation of 
white blood cells including neutrophils and monocytes-macrophages.  Colony-stimulating factors 
have been shown to reduce the duration and severity of neutropenia and the risk of febrile 
neutropenia [161] and enable delivery of more intensive or dose-dense chemotherapy when 
indicated [162]. The American Society of Clinical Oncology (ASCO) release guidelines that detail 
how to use chemotherapy, and also concomitant medications to improve patient outcomes and 
quality of life through the management of adverse events.  The current guidelines call for 
prophylactic use of CSFs to reduce the risk of neutropenia when the risk of neutropenia is 
approximately 20% or higher [162]. Specifically, primary prophylaxis with a CSF should start with 
the first cycle and continue throughout subsequent cycles of chemotherapy.  Secondary 
prophylaxis with a CSF is recommended when a patient experiences a neutropenic event related 
to a prior dose of chemotherapy, in which primary prophylaxis was not given, in which the adverse 
event may result in a reduced dose or delay of treatment dose which may compromise disease-
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free or overall survival outcomes [162]. In addition to chemotherapy regimen and type of 
malignancy, advanced age, poor performance status and poor renal function are all risk factors 
for neutropenia indicated by ASCO [163-165].  While there are practical differences between 
America and Britain in the care of cancer patients, it is probable the NHS recognise similar risk 
factors for prophylaxes.  Consequently, despite the high rate of neutropenia observed in the two 
cohorts, CSF use might be confounding an association between severe neutropenia and efficacy 
outcomes. 
In addition to CSF use, the frequency of adverse events is related to treatment compliance.  
Patients who did not experience specific adverse events may not have been receiving the full 
dose of the prescribed regimen owing to other medical complications. 
No association was found between the cumulative incidence of gastrointestinal and neutropenic 
AEs upon survival.  Although it is conceivable that older patients may be less likely than younger 
patients to report AEs, that the platinum subtype may alter the risk of AE, or even that there may 
be gender differences in probability and/or reporting of adverse events, after adjusting for these 
possible confounders, no association between specific AEs and survival outcomes was observed.   
Although our results failed to show an association between specific adverse effects and efficacy 
outcomes, we believe that the approach has the potential to unlock meaningful associations and 
thus provide a valuable predictor and biomarker of treatment efficacy.  Future prospective studies 
might seek to use a different landmark analysis time point (i.e. 3 or 5-year survival) and also use 
different AE categories when examining the potential for association.  
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Chapter 4. Prognostic factors in patients treated with platinum 
containing regimens for cancer 
You can believe the diagnosis, not the prognosis 
– Deepak Chopra 
4.1 Abstract 
Background 
Cancer patient prognosis has two aspects: safety and efficacy.  Safety prognosis 
describes the risk that a patient will experience an adverse event in response to 
treatment and efficacy prognosis describes the probability of achieving favourable 
survival characteristics in response to treatment.   
Chemotherapy-related hospitalizations in patients with advanced cancer are both 
common and costly.  Methods to identify patients at high risk of chemotherapy toxic 
effects have the potential to aid in the development of targeted treatment strategies to 
prevent chemotherapy-related hospitalizations and allow for forecasting of 
hospitalisation rates.   
Patients with cancer commonly want to know the survival statistics for people in similar 
situations in an attempt to know what to expect.  The survival estimate is based upon 
person’s characteristics as they pertain to factors known to affect survival rates. 
The current study was undertaken to explore whether baseline characteristics predicts 
either adverse event rates or survival in cancer patients treated with platinum containing 
regimens. 
Methods 
Data were analysed from 566 patients, 223 with ovarian cancer and 343 lung cancer, 
who were treated with platinum chemotherapy.  Primary endpoints were progression 
free survival (PFS) overall survival (OS) and any severe adverse event (AA).  Potential 
prognostic variables were included in Cox proportional hazard regression models.  
Multivariable analysis was conducted to identify independent prognostic factors. 
Results 
Baseline performance status (PS) was a significant independent predictor for both PFS 
and OS in both lung and ovarian cohorts.  Baseline PS was also predictive of AA in the 
ovarian cohort while age and sex were predictive of AA in the lung cohort.  Sex was 
also an additional independent predictor for OS in the lung cohort and renal function 
was an additional predictor of OS in the ovarian cohort.  Smoking status at baseline 
predicted PFS in the lung cohort only. 
Conclusion 
Performance status at baseline isprognostic in both ovarian and lung cancer for efficacy 
endpoints PFS and OS.  Predictive factors for AA and additional factors predictive of 
OS and PFS were not shared between cohorts.  We hope that our findings will help in 
the development of prognosis scoring systems to help reduce-treatment related 
toxicities and accurately predict individual patient survival and progression times.  
 
   




For both patients and physicians, accurately predicting the prognosis once a malignancy has 
been diagnosed remains central to defining a treatment regimen that will increase the likelihood 
of achieving a positive tumour response while minimizing the risk of treatment related toxicities.  
Patients and their families are typically focused on the efficacy prognosis as they try to understand 
the seriousness of their illness and chances of medium to long-term survival.  By contrast, many 
clinicians are interested in prognosis of treatment-related toxicity as it worsens patient quality of 
life and is often the cause of dose reduction or treatment discontinuation.  In patients with 
advanced cancer, adverse events leading to hospitalisation are common and consequently 
represent a costly phenomenon associated with cancer care [158, 166-169].  Even in the absence 
of hospitalisation, if adverse events appear, healthcare providers typically offer a dose reduction 
or temporary treatment interruption in the hope that the adverse event may resolve and thereby 
allow continuation of treatment.  In the event of severe or persistent adverse events, treatment 
discontinuation may be necessary.  Any treatment interruption, whether temporary or permanent, 
has the potential to jeopardise the benefit from therapy.  Chemotherapy induced adverse effects 
are therefore undesirable outcomes.    
When making chemotherapy treatment plans, oncologists use many indicators to identify patients 
at risk for adverse effects.  Performance status, a clinical estimate of functional status, is the most 
important of these indicators, and patients with poor performance status (e.g. an Eastern 
Cooperative Oncology Group (ECOG) [104] performance status >2) are generally considered to 
face more risks than benefits from chemotherapy.  Beyond performance status, additional factors 
(including age and renal function) are also known to influence the risk of chemotherapy toxic 
effects [170, 171].  A number of previous studies have sought to develop discriminative 
approaches for assessing the risk of chemotherapy induced toxic responses [165, 171-173].  
While these studies explored alternate patient populations, predictors, and toxic effect outcomes, 
they were all able to demonstrate that model-based approaches can identify toxicity risk factors 
and have the potential to improve risk stratification for chemotherapy toxic effects [168].  
We set out to investigate and improve our understanding of the impact of baseline clinical and 
demographic patient characteristics on both efficacy and safety endpoints separately for patients 
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with lung cancer and patients with ovarian cancer.  Specifically, we investigated the impact of 
several pre-treatment factors including age, sex, performance status (PS), renal function (RF), 
smoking status and ethnicity. 
The ability to better identify patients at elevated risk for chemotherapy toxic effects has potential 
to improve patient outcomes at many levels.  Specifically, better risk assessment for 
chemotherapy toxic effects would improve the chemotherapy informed-consent process, allow for 
modification of treatment regimens to reduce the risk of toxic effects, and identify patients who 
may benefit from aggressive therapy regimens around the time of chemotherapy initiation. 
4.3 Methods 
4.3.1 Patients 
The current study was a retrospective review of data collected from patients with lung and ovarian 
cancers treated with platinum chemotherapy at Guy’s and St. Thomas’ NHS Foundation Trust.  
Baseline patient and demographic variables were extracted from standardised oncology outcome 
records completed at each clinic visit.  A more complete description of these data is provided in 
Chapter 2. 
4.4 Statistical analysis 
Three endpoints (one safety and two efficacy) were examined for prediction by baseline variables: 
any-AE (AA), overall survival (OS) and progression free survival (PFS).  Six baseline variables 
were included in the analyses: age, sex, performance status, renal function, ethnicity and smoking 
status.  For the safety endpoint AA, the univariate prognostic potential of baseline variables was 
assessed using a binary logistic regression model in which each patient was classified as being 
either ‘affected’ if they experienced any severe adverse event (grade 3 or greater) at any cycle 
during the treatment phase, or ‘unaffected’ if they did not experience a severe adverse event 
during treatment. 
For the survival endpoints (OS and PFS), the univariate prognostic potential of baseline variables 
was assessed using Cox regression models.  Multivariable stepwise regression analysis with both 
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entry and removal levels as 0.05 was used to identify independent predictors for PFS, OS or AA 
from the covariates studied in the univariate analyses.  
OS was defined as the time from first dose to death from any cause.  PFS was defined as the 
time interval from first-dose to first disease progression or death from any cause if disease 
progression did not occur.  
The baseline variables included in the models were: age, sex, performance status, renal function, 
ethnicity and smoking status.  Prior to the analyses, we created clinically meaningful grouping of 
both renal function and performance status owing to the small number of patients which were 
category 3 for each variable.  The grouping for both these variables therefore became “0-1” and 
“2-3”. 
All analyses were performed separately in patients with lung cancer and patients with ovarian 
cancer.  Statistical analyses were completed using SAS v.9.4 software. 
4.5 Results 
4.5.1 Patient characteristics 
Data from 566 patients (223 ovarian patients and 343 lung patients) were included in this study.  
Table 2.4.1 summarises the demographic and clinical characteristics.  In brief, the median age 
was 64 years.  Excluding missing values, the overwhelming majority of patients were Caucasian 
(87.3%).  Most patients had performance status in the 0-1 range (86.7%) and renal function 
scores in the 0-1 range (87%).  The ovarian cohort had a higher proportion of patients with 
performance status 2-3 (19.4%) as compared with the lung cohort (9.7%).  The proportion of 
patients in each renal function category was similar between cohorts.  
4.5.2 Adverse events 
The frequency of severe adverse events (CTCAE≥3) across all 4 cycles of therapy is presented 
by cohort and overall in Table 2.4.3 
Across both cohorts, the number of severe events is greater than the number of patients indicating 
that some patients experienced multiple severe events.  Figure 4.5.1 presents the patient 
frequency against number of severe adverse events by cohort.  264 patients (47%) had 0 (no) 
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severe adverse events; 157 (28%) had one severe adverse events; 83 (15%) had two severe 
adverse events; 34 (6%) had 3 severe adverse events, 14 (2.5%) had 4 severe adverse events, 
9 (1.6%) had 5 severe adverse events, 4 (0.7%) patients had 6 severe adverse events, and 1 
(0.17%) patient had 7 severe adverse events.   
The proportion of patients experiencing a singular or multiple severe adverse events is similar 
between cohorts (Figure 4.5.1).   
 
Figure 4.5.1 Proportion of patients against number of severe adverse events by cohort and overall 
 
4.5.3 Prognostic value of patient characteristics – safety endpoint 
Among baseline patient characteristics, univariate analysis showed that in the ovarian cohort, 
performance status (p=0.0276) and renal function (p=0.0272) were associated with patient risk of 
experiencing a severe adverse event.  In the lung cohort, age (p=0.0045), sex (p=0.0076) and 
renal function (p=0.0281) were all associated with patient risk of experiencing a severe adverse 
event (Table 4.5.1.) 
When fitted together in a multivariable analysis the only baseline characteristic that remained 
significantly associated with risk of severe adverse event in the ovarian cohort was performance 
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status (p=0.0438:  p-value from Type III analysis of effects1); where patients with PS 2-3 were 
more likely to experience a toxic event compared with patients who were PS 0-1 (OR=2.297 
95%CI=1.096-4.813, p=0.0125, AUC=0.563).  In the lung cohort only age (p=0.0042) and sex 
(p=0.0070) remained significant in the multivariable analysis with a combined AUC of 0.62 (Figure 
4.5.2).  Specifically, patients who were older were more likely to experience a severe adverse 
event (OR=1.032, 95%CI=1.010-1.055 p=0.0042) and men were less likely to experience a 
severe adverse event as compared with women (OR=0.540 95%CI=0.345-0.845, p=0.0070) 
4.5.4 Prognostic value of patient characteristics – efficacy endpoints2 
In the ovarian cohort, of the examined baseline characteristics, performance status, renal 
function, age and smoking status were predictive of both OS (p<.0001, p=0.0006, p=0.0008, and 
p=0.0418 for performance status, renal function, age and smoking status respectively) (see Table 
4.5.2) and PFS (p<.0001, p=0.0063, p=0.0335, p=0.025 and p=0.1544 for performance status, 
renal function, age and smoking status respectively) (see Table 4.5.3). When all factors were 
entered into a multivariable analysis, both performance status (p<.0001) and renal function 
(p=0.0145) were identified as independent predictive factors for overall survival.  Following 
multivariable analysis, performance status was the only independent factor of progression free 
survival (p<.0001).  Across both variables (OS and PFS), patients who were category 0-1 had 
improved median survival compared with patients of category 2-3 (Figure 4.5.3). 
In the lung cohort, univariate analysis identified sex (p=0.0308) and performance status (p= 
0.0016) as predictive of OS (see Table 4.5.2) and performance status (p= 0.0012) and smoking 
status (p=0.0191) as predictors of PFS (see Table 4.5.3.).  Multivariable analysis, confirmed both 
sex (p=0.0448) and performance status as independent prognostic factors of overall survival 
(Table 4.5.4).  Similarly, results from the multivariable analysis of PFS identified smoking status 
                                                     
1 Type III analysis of effects -   test for the significance of each explanatory variable, under the 
assumption that all other variables entered in the model equation are present. A significant p-
value indicates that at least one of the subcategories of the predictor variable is associated with 
the outcome.  In the univariate analyses we excluded ‘missing’ status from the predictor variable 
but left it in for the multivariable analyses as exclusion would have resulted in decreased sample 
size across predictors. 
2 The text presents the Type III test of overall effect for each prognostic variable.  Tables 4.5.4-
4.5.6 present the OR/HR and corresponding p-value for each predictor level relative to the 
reference level. 
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(p=0.0171) and performance status (p= 0.0009) as independent predictive factors for progression 
free survival (see Table 4.5.4). 
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Table 4.5.1 Univariate analysis of potential prognostic factors for any-AE (AA) 
Characteristic Ovarian Lung 
 Affected† Unaffected OR (95% CI) p-value Affected Unaffected OR (95% CI) p-value 
Age . . 1.016 (0.995-1.037) 0.1332 . . 1.032 (1.010-1.054) 0.0045 
Sex 116 107   . 145 198   . 
     Female 116 107   . 50 97 reference . 
     Male . . NE‡ . 95 101 0.548 (0.352-0.852) 0.0076 
ECOG Performance status 116 107   . 145 198   . 
     0-1 86 72 reference . 131 168 reference . 
     2-3 13 25 2.297 (1.096-4.813) 0.0276 9 23 1.992 (0.892-4.449) 0.0929 
Renal Function 116 107   . 145 198   . 
     0-1 103 84 reference . 127 160 reference . 
     2-3 9 19 2.588 (1.113-6.018) 0.0272 13 35 2.137 (1.085-4.209) 0.0281 
Ethnicity 116 107   . 145 198   . 
    Caucasian 101 88 reference . 122 176 reference . 
    Asian 1 2 2.295 (0.205-25.748) 0.9756 2 4 1.386 (0.250-7.688) 0.5090 
    Black 10 8 0.918 (0.347-2.428) 0.9645 13 12 0.640 (0.282-1.450) 0.5500 
    Other . 5 NE τ - 6 2 0.231 (0.046-1.164) 0.0718 
    Mixed 1 1 1.148 (0.071-18.621) 0.9673 1 3 2.080 (0.214-20.228) 0.3458 
Smoking 116 107   . 145 198   . 
    Never 33 31 reference . 17 24 reference . 
    Ex-smoker 6 8 1.419 (0.442-4.557) 0.2547 44 53 0.853 (0.408-1.786) 0.5290 
    Current 22 11 0.532 (0.222-1.276) 0.0894 77 111 1.021 (0.514-2.028) 0.6759 
† Affected patients are those that experienced a severe (Grade 3 or greater) adverse event 
‡NE – not able to estimate as the ovarian cohort contained no males 
τ NE – Not able to estimate due to there being no controls within this category of ethnicity 
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Table 4.5.2 Univariate analysis of potential prognostic factors for overall survival 
Characteristic† Ovarian Lung 
 Events Censors HR (95% CI) p-value Events Censors HR (95% CI) p-value 
Age 70 153 1.039 (1.016-1.063) 0.0008 221 122 1.011 (0.997-1.025) 0.1274 
Sex 70 153   . 221 122   . 
     Female 70 153   . 84 63 reference . 
     Male . . NE‡ . 137 59 1.350 (1.028-1.772) 0.0308 
ECOG Performance status 70 153   . 221 122   . 
     0-1 42 116 reference . 188 111 reference . 
     2-3 22 16 4.050 (2.388-6.869) <.0001 25 7 1.823 (1.199-2.772) 0.0050 
Renal Function 70 153   . 221 122   . 
     0-1 54 133 reference . 181 106 reference . 
     2-3 14 14 2.855 (1.560-5.226) 0.0007 35 13 1.236 (0.860-1.776) 0.2515 
Ethnicity 70 153   . 221 122   . 
    Caucasian 55 134 reference . 196 102 reference . 
    Asian 1 2 1.443 (0.199-10.469) 0.7171 4 2 1.114 (0.414-3.002) 0.8305 
    Black 8 10 1.525 (0.723-3.218) 0.2681 17 8 1.051 (0.640-1.726) 0.8437 
    Other 3 2 2.416 (0.751-7.777) 0.1391 2 6 0.343 (0.085-1.382) 0.1324 
    Mixed 1 1 1.019 (0.139-7.460) 0.9854 1 3 0.416 (0.058-2.972) 0.3823 
Smoking 70 153   . 221 122   . 
    Never 25 39 reference . 27 14 reference . 
    Ex-smoker 4 10 0.690 (0.240-1.986) 0.4917 65 32 0.982 (0.627-1.538) 0.9360 
    Current 10 23 0.863 (0.413-1.801) 0.6940 118 70 0.946 (0.622-1.437) 0.7932 
† ‘Missing’ status within each characteristic excluded from the analysis 
‡NE – not able to estimate as the ovarian cohort contained no males 
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Table 4.5.3 Univariate analysis of potential prognostic factors for progression free survival 
Characteristic† Ovarian Lung 
 Events Censors HR (95% CI) p-value Events Censors HR (95% CI) p-value 
Age 148 65 1.017 (1.001-1.032) 0.0335 275 62 1.000 (0.988-1.012) 0.9664 
Sex 148 65   . 275 62   . 
     Female 148 65   . 114 30 reference . 
     Male . . NE‡ . 161 32 1.092 (0.858-1.388) 0.4754 
ECOG Performance status 148 65   . 275 62   . 
     0-1 93 60 reference . 234 59 reference . 
     2-3 32 3 3.305 (2.184-5.001) <.0001 30 2 1.946 (1.325-2.857) 0.0007 
Renal Function 148 65   . 275 62   . 
     0-1 118 60 reference . 229 52 reference . 
     2-3 24 4 1.996 (1.282-3.110) 0.0022 39 9 0.975 (0.693-1.371) 0.8823 
Ethnicity 148 65   . 275 62   . 
    Caucasian 128 55 reference . 241 52 reference . 
    Asian 2 1 0.982 (0.242-3.981) 0.9801 5 1 1.564 (0.644-3.798) 0.3236 
    Black 12 4 0.994 (0.548-1.802) 0.9845 20 5 0.989 (0.627-1.561) 0.9620 
    Other 3 2 0.882 (0.278-2.795) 0.8312 6 2 0.784 (0.349-1.763) 0.5564 
    Mixed 1 1 0.306 (0.042-2.212) 0.2404 2 1 0.613 (0.152-2.467) 0.4905 
Smoking 148 65   . 275 62   . 
    Never 46 15 reference . 37 4 reference . 
    Ex-smoker 10 4 0.807 (0.407-1.600) 0.5382 76 19 0.555 (0.372-0.827) 0.0038 
    Current 21 11 0.873 (0.521-1.464) 0.6067 150 36 0.614 (0.427-0.884) 0.0087 
† ‘Missing’ status excluded from the analysis 
‡NE – not able to estimate as the ovarian cohort contained no males 
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Table 4.5.4 Results of multivariable analysis - independent prognostic factors for OS and PFS identified by Cox multivariable proportional hazard model with stepwise 
selection; independent prognostic factors for AA identified by multivariable logistic regression model with stepwise selection. 















Any AE (AA) 
Age  
NA† 
1.032 1.010- 1.055 0.0042 
Sex Male vs. Female 0.540 0.345- 0.845 0.0070 
Performance status 2-3 vs. 0-1 2.297 1.096 - 4.813 0.0125 NA† 
Overall Survival (OS) 
Sex Male vs. Female    1.322 1.006-1.736 0.0448 
Performance status 2-3 vs. 0-1 3.830 2.243- 6.540 <.0001 1.770 1.163-2.694 0.0077 
        
Renal Function 2-3 vs. 0-1 2.144 1.164- 3.950 0.0145 NA† 
Progression Free Survival (PFS) 
Smoking Status Current vs. Never NA† 0.598 0.415 - 0.861 0.0057 
 Ex-Smoker vs. Never  0.568 0.381 - 0.847 0.0056 
Performance status 2-3 vs. 0-1 3.305 2.184 - 5.001 <.0001 2.063 1.389 - 3.064 0.0003 




   




Figure 4.5.2 Results of multivariable analysis by cohort. 
In the ovarian cohort, only performance status was a significant predictor of AA.  In the lung cohort, age and sex were both predictors of AA.  The lung plot shows the AUC 
associated with each prognostic variable from the univariate analysis and the combined AUC from the multivariable analysis.
   







Figure 4.5.3 Multivariable analysis - independent prognostic factors for OS. 
(A) Ovarian Cohort – performance status (PS); (B) Ovarian Cohort – renal function (RF); (C) Lung 
cohort – performance status (PS); and (D) Lung cohort – sex.  The grey shaded table in each plot 






   







Figure 4.5.4 Multivariable analysis - independent prognostic factors for PFS. 
(A) Ovarian Cohort – performance status (PS); (B) Ovarian Cohort – renal function (RF); (C) Lung 
cohort – performance status (PS); and (D) Lung cohort – sex.  The grey shaded table in each plot 
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4.6  Discussion 
In this study, we have tested patient characteristics for their prognostic value in relation to both 
safety and efficacy outcomes in response to platinum chemotherapy.  This study identified that a 
low performance status predicted improved overall survival and progression free survival in both 
lung and ovarian cancer patients.  In addition, low performance status was associated with 
reduced risk of experiencing a severe adverse event in the ovarian cohort.  These results support 
previous studies which identified performance status as a significant prognostic factor in small 
cell lung cancer [174, 175], non-small cell lung cancer [176] and ovarian cancer [177].  In the 
ovarian cohort, renal function was also identified as an independent prognostic factor for OS.  This 
result was unexpected as clinicians typically use renal function when generating a performance 
status [178], resulting in a strong correlation between the two measures.  Impaired renal function 
is known to be associated with decreased physical function and physical activity [179-181] and 
several previous studies have identified an association between renal function and physical 
performance [182-184].  Our results suggest that renal function scores offer additional information 
that helps predict overall survival beyond the impact upon physical activity. 
In the lung cohort, age and sex were identified as prognostic of safety but were not associated 
with either survival endpoint.  This contrasts with previous studies which have identified old age 
at diagnosis as an important determinant of survival prognosis [7, 185-187].  In general, patients 
are more likely to exhibit co-morbidities with increasing age in patients with lung cancer [188, 
189].  Consequently, the use of aggressive chemotherapy in elderly patients is controversial 
because of the increased possibility of adverse event side effects compared with younger patients 
[190]. Our finding that increased age was associated with an increase in the incidence of adverse 
events in the lung cohort supports the perspective that older age increases the risk of potentially 
harmful adverse events and therefore patient age needs to be accounted for when deciding upon 
a treatment regime. 
Smoking is a recognised risk factor for lung cancer [191-193], and we had hypothesised that 
current and ex-smokers would have reduced PFS and OS as compared with never-smokers.  It 
was surprising that current, ex-smokers and unknown smoking status patients all had a longer 
progression free survival as compared with never-smokers.  Ignoring patient error in reporting 
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accurate smoking status, it could be that never-smokers who develop lung cancer have been 
exposed to cancer risk agents that result in a more aggressive disease state.  As the current study 
did not collect disease staging, it is impossible to test this hypothesis but we believe this feature 
warrants further research.  We did not detect an association between smoking status and survival.  
This may be due to a lack of power in the OS analysis (PFS has more events) but it might also 
imply that there are post-progression survival differences between patients of alternate smoking 
status classes. 
We observed that male patients in the lung cohort were less likely to experience an adverse event 
as compared with females, however, male patients had reduced survival as compared with female 
patients.  This is consistent with previous reports that have documented an OS [194, 195] and 
PFS [196] advantage in women treated for lung cancer; and also greater toxicity for females as 
compared with males in response to chemotherapy [197-200].  Whether the survival difference 
results from improved treatment response or different tumour biology (including stage and 
subtype) is not well understood [195]. 
The strength of the present study is that it represents essentially unselected patients at a cancer 
treatment centre within a major metropolitan area.  Unlike clinical trials, there were no 
demographic or baseline variable exclusions (i.e. age, PS, renal function) in the sample 
population.  These data are therefore representative of the patient heterogeneity that clinicians 
are presented with in regular oncology patient care. 
Several of the baseline characteristics we tested did not show a significant prognostic value in 
the multivariable models assessing PFS and OS.  These markers have been explored in the 
previous clinical studies with varying results.  The discrepancy between their results and our   may 
be explained by differences in the disease stage of the patient population, lack of power due to 
small numbers of patients, or the use of different treatment schedules.  Additional variables of 
dose-intensity, concomitant medications and disease staging would be valuable to test for any 
confounding.  For consistency with the other sections of this work, we tested for an association 
between baseline characteristics and neutropenia and gastrointestinal disorders (see 0: Table 
12.2.1 and Table 12.2.2).  These analyses of adverse event subgroups failed to replicate all of 
the baseline characteristic-adverse event associations observed in the Any-AE analysis.  This is 
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most likely a power issue as the number of Grade 3 or greater events is much smaller when we 
slice the severe adverse event pool by different subtypes.  
Lastly, we observed differences in the prognostic characteristics between cohorts but cannot 
explain the discrepancy.  Both cohorts had a similar proportion of patients experiencing a severe 
event and a similar distribution of patients with no adverse event, a single event and multiple 
events.  The key difference between cohorts is the survival distribution.  If we assume that both 
cohorts have the same underlying prognostic factors, then it could be argued that the aggressive 
nature of lung cancer (shorter survival) reduces our ability to detect factors that will ameliorate or 
accelerate hazard, and therefore the ovarian data findings are more relevant.  Alternatively, the 
longer survival time associated with ovarian cancer as compared with lung cancer means that the 
survival curves are subject to bias because of confounding associated with competing risks, 
concomitant therapy and subsequent therapy.  This suggests that the results from the 
associations with the lung cohort could be viewed as unbiased and therefore more clinically 
relevant.  It is also possible that ovarian and lung cancer do not share the same underlying 
prognostic factors.  The cancer characteristics could be disparate enough to render the factors 
prognostic for safety and efficacy different between each cancer type.  
Our study emphasises the importance of performance status assessment in patients with ovarian 
and lung cancers as the score provides useful prognostic information.  In advanced ovarian 
cancer, renal function should be assessed in addition to performance status, as this information 
is of importance in influencing treatment outcomes.  In lung cancer patients receiving platinum 
chemotherapy, we confirm the importance of gender in both the risk of developing a toxic 
response and in its prognosis of survival.  
The divergent results of our current and previous studies highlight the complexity of patient 
prognosis and represent a barrier to the use of these factors in daily practice.  Establishing clear 
prognostic variables for efficacy and safety may help clinicians to decide on a patient specific 
treatment regime that effectively balances benefit and risk.  
Our work considered each outcome (OS, PFS and AA) separately, a common way of analysing 
several outcomes from the same trial [201]. An alternative analysis strategy could have been to 
analyse each predictor against the set of outcomes through one of several statistical methods 
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designated as multivariate methods [202]. In the case where we considered a multivariate model 
for the survival endpoints only (OS and PFS) there are 3 alternate multivariate strategies: the joint 
survival function [203], the marginal survival function [204] and the conditional survival function 
[205]. Alternatively, if we were to ignore the survival times and categorise each according to their 
status at the end of the observation period as either having experienced the survival event or not 
(binary) then a multivariate logistic model could be used to explore both survival outcomes and 
the safety outcome simultaneously.  Multivariate analysis is frequently used to control type-I error 
probability, the logic being that if the multivariate analysis yields significance then it may be 
appropriate to carry out multiple univariate tests to identify the specific outcome variable that 
associates with a given predictor or set of predictors [206].  
Huberty and Morris [206] outline four instances (within the context of ANOVA) in which multiple 
univariate analyses may be favourable to a multivariate analysis: 1) when the outcome variables 
are conceptually independent, that is the question of interest is how the predictor variable(s) affect 
each of the outcome variables without interest in the relationship between outcome variables; 2) 
when the research being conducted is exploratory in nature, i.e. a new predictor and/or outcome 
are being studied and the effects of the predictor upon the outcome are being investigated to 
reach “tentative conclusions”; 3) when the outcome variables in the current study have previously 
been studied within univariate context; 4) and lastly when the research question is needed to 
show that two or outcomes are equivalent with respect to a set of predictors. For our study, the 
endpoints were not conceptually independent; OS is frequently considered conditional upon PFS, 
as patients do not tend to die of non-progressing tumours.  In support of the multiple analyses, 
our work was both exploratory and followed numerous previous studies which have explored 
survival and safety outcomes independently.  Additionally, analysing the outcomes separately, as 
we did, does not require that the outcomes are measured on the same scale, and the difference 
in the recording of date between survival and safety events within this data lends itself towards 
separating survival and safety outcomes.  However, through analysing both safety and binary 
survival outcomes together, correlation between the outcomes can be used to increase power to 
detect predictor effects.  However, the gain in power from the multivariate model must be 
considered against the added number of predictor terms.  As discussed further in Chapter 5, 
within the logistic regression framework, increasing the number of covariates inflates both the 
parameter estimate and the variance of the estimate for the variable of interest [207, 208], so 
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while multivariate models are generally considered more powerful, this may be offset through the 
additional predictor term(s) required in the model.  
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Chapter 5. Genetic variation as predictor of efficacy and toxicity 
in platinating agent treated patients 
If it were not for the great variability among individuals, medicine might 
as well be a science and not an art. 
– Sir William Osler 
5.1 Abstract 
Background 
Lung and ovarian carcinomas are common malignancies and each is a leading 
contributor to cancer deaths worldwide each year.  Both forms of cancer are treated 
with chemotherapy regimens involving a ‘platinum’ compound.  
Previous studies have identified that clinical factors (including age, sex, performance 
status and disease stage), and the genetic profile of an individual are each independent 
predictors of efficacy response and toxicity in platinum treated patients. 
Most genetic association studies only used the genomic data without adjusting for 
established clinical covariates that are known to have predictive value. 
The aims of the present study were thus:  
1) To explore how combining prognostic baseline factors (age and sex) with GWAS 
analysis would alter the pattern and strength of observed SNP-phenotype 
association results. 
2) To identify novel candidate single nucleotide polymorphisms (SNP) associated with 
overall survival (OS), progression free survival (PFS), neutropenia (NEU), or 
gastrointestinal disorder (GID) in lung and ovarian cancer patients. 
Methods 
An exome array of approximately 30,000 SNPs was tested for association against each 
of the safety and efficacy phenotypes in both a lung (N=343) and ovarian cancer cohort 
(N=223). 
Association of the SNPs with OS and PFS was determined by using the Cox regression 
model.  Association of the SNPs with NEU and GID was determined by using the 
logistic regression model.  We analysed the association of each SNP with and without 
the inclusion of the clinical variables age and sex. 
Results 
Of the ~30000 successfully genotyped SNPs, 2 SNPs passed multiple correction for 
association with overall survival in the lung cohort (rs17117678 with in the OMA1 gene 
and rs35075952 within the TACSTD2 gene) with and without the addition of clinical 
covariates.  No other multiple testing corrected associations were significant.  Both 
SNPs had reduced association signals once modelled with baseline covariates.  Across 
all the examined outcomes (OS, PFS, NEU and GID), the addition of baseline 
covariates either reduced the strength of association or had a negligible effect.   
Conclusions 
Our results indicate that further work needs to be done to explore how best to model the 
effect of clinical and genetic sources of variation.  Our study identified SNPs in key 
candidate genes associated with overall survival in lung cancer.  If validated in a 
replication cohort, these findings might provide opportunities to personalise therapeutic 
strategies. 
   




Platinum-based doublet therapy including cisplatin or carboplatin combined with taxanes, 
gemcitabine, vinorelbine, and etoposide are standard first-line treatments for advanced non-small 
cell lung cancer (NSCLC), small cell lung cancer [209-211] and ovarian cancer [212, 213]. 
The use of platinum therapy is not without risk, the potential antineoplastic benefit of these 
frequently prescribed drugs is often compromised by severe side effects including gastrointestinal 
upset and neutropenia.  Cisplatin is frequently regarded as the platinum drug with the most severe 
side effects, including nausea and vomiting, neurotoxicity, nephrotoxicity (kidney damage), 
ototoxicity (hearing damage) [25, 54-56].  In response to the unwanted side effects, known as 
adverse events (AEs), therapy may be either continued at a reduced dose or discontinued 
completely [214, 215].  Both courses of action potentially compromise patient benefit as patients 
are denied the full therapeutic benefit of the platinum agent. 
There is considerable inter-individual variation in the efficacy and safety responses to platinum 
therapy [215]. The inter-individual variation can likely be explained, in part, by genetic variation 
[216, 217] as well as baseline and clinical prognostic factors [218]. Response prediction from 
genetic data is an active field in today’s medical research.  Most often association analyses utilise 
only the genomic data without including established clinical covariates that often are known to 
have predictive value with respect to the phenotype.  Correspondingly, it might be beneficial to 
also integrate complementary information from patients when building multivariable risk prediction 
models for a clinical endpoint, such as treatment response or survival [219]. Age adjustment is 
widely used in studies comparing survival of different cancer patient populations [220].  This is 
because patient age is both important risk factor but also prognostic of survival for many kinds of 
cancer [221]  (including lung cancer [222] and ovarian cancer [223, 224]).  Patient sex has also 
been identified as a predictor for lung cancer survival [225]; with women having better survival 
than men across all cancer stages and independent form the therapeutic approach [226]. 
Several recent papers have included both clinical and genetic covariates when seeking genetic 
associations with cardiomyopathy [227], multiple sclerosis [228],and cancer [229].  The 
integration of clinical and genetic has the potential to improve our understanding, and our ability 
to predict disease risk and prognosis [229, 230].  Beyond accuracy of the predicted outcome, 
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conditioning on covariates associated with phenotype can increase study power by reducing 
phenotypic variance [231]. However it is well known that the addition of covariates can result in a 
dramatic loss in power depending on the type of model used to ascertain the SNP-outcome 
association [207, 208]. With respect to survival outcomes analysed with a Cox regression model, 
it is not obvious how to the addition of clinical covariates may impact our ability to ascertain SNP-
outcome associations [232]. The inclusion of covariates within a Cox model can both improve the 
accuracy of the predictor of interest and/or help with achieving proportional hazards in which case 
their inclusion is necessary to meet the model assumptions.  Our analyses focus on the former 
however situation we accept that the inclusion of covariates in alternate studies may be for a 
different reason.  
Consequently, we sought to examine if combining clinical and genomic information influenced the 
strength of SNP-phenotype association signals. 
The objectives of this paper are thus: 
1) To explore how combining prognostic clinical factors with GWAS analysis would alter 
the pattern and strength of observed association results. 
2) To identify novel candidate single nucleotide polymorphisms (SNPs) associated with 
overall survival (OS), progression free survival (PFS), neutropenia (NEU), or 
gastrointestinal disorder (GID) in lung and ovarian cancer patients 
5.3 Methods 
5.3.1 Study population 
A more detailed description of the population has been published elsewhere [60] and is provided 
in the preceding chapters.  In brief, all patients were recruited from within Guy’s and St. Thomas’ 
Hospitals NHS Foundation Trust.  Patients who began treatment for either lung or ovarian cancer 
between 02/17/2000 and 05/17/2013 were identified by the institutional treatment registry.  Of 
these, 589 patients were treated with first-line platinating-agent based chemotherapy.  Patients 
eligible for possible inclusion into the study were approached in order to obtain consent for a 
laboratory blood draw to be used in genotyping.  Information regarding patient demographics, 
baseline characteristics, and outcomes was collected through manual review of the patient 
electronic records.  The institutional ethics committee approved the study.  
   




DNA was extracted from ethylenediaminetetraacetic acid (EDTA) whole blood using the QIAamp 
DNA Blood Mini Kit (Qiagen, Crawley, West Sussex, UK).  All patients were genotyped with the 
Illumina Infinium HumanExome BeadChip v1.1 (Illumina, San Diego, CA, USA), which provides 
coverage of over 240,000 SNPs, including functional exonic variants (>90%), disease-associated 
tag markers from recently published GWAS, ancestry-informative markers, and other markers.  
Genotypes were called using GenCall Data Analysis Software v1.0 clustering algorithm in 
Genome Studio v2011.1 (Illumina).  Genotyping was conducted at the King’s Genomic Centre.  
Genotyping and calling was performed on this study prior to my involvement, and I obtained 
genotype and phenotype data from Dr. Adele Corrigan on 13th October 2015. 
Several quality-control filters were applied to samples and variants prior to analysis.  Individuals 
were excluded for the following reasons: sex mismatch, individual call rate of <97%, SNP call rate 
of <99%, Hardy–Weinberg Equilibrium p-value <10-6, cryptic relatedness and minor allele 
frequency <0.05.  Population stratification was assessed using principal components.  Principal 
components analysis was carried out using EIGENSOFT on all common SNPs (minor allele 
frequency 0.01).  All quality control and principal components analysis was completed by Dr 
Jemma Walker (Statistical Genetics - King's College London).  
After exclusions, a total of 29328 variants and 343 individuals were available for analysis from the 
lung cancer cohort and a total of 29028 variants and 223 individuals were available for analysis 
from the ovarian cancer cohort. 
5.3.3 Statistical methods 
5.3.3.1 Sample size 
The data for this study were originally collected for an examination of compound safety events.  
Consequently, the study was not designed for the analyses we present in this paper.  We 
computed post hoc power analysis using two approaches depending upon the endpoint: 1) for 
survival endpoints we use a modification of the sample size estimation methods for non-binary 
covariates [233] which is itself an extension of an earlier formula for the case of a single, binary 
covariate derived by Schoenfeld [234]; 2) for safety endpoints we computed the effective sample 
size and statistical power using the case-control for discrete traits option in the web browser 
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program, Genetic Power Calculator developed by Purcell et al., 
(http://pngu.mgh.harvard.edu/~purcell/gpc/). 
Both types of power calculations were conducted under the assumption of an additive genetic 
model with a minor/risk allele frequency (MAF) of 0.1 and 0.2.  These thresholds were chosen as 
representative of common variant frequencies within complex disease, to place in context the 
power of our datasets. 
The Genetic Power Calculator (GPC) [235] calculates the power for a genetic association study.  
It requires input parameters of the minor allele frequency and the odds ratio (OR) for risk conferred 
by the allele, in addition to sample size and significance level.  GPC uses the OR and population 
allele frequency to calculate the allele frequency in patients with and without adverse events, and 
then calculates the power to detect this difference in allele frequencies between the two groups.  
5.3.3.2 Significance threshold 
Our study analysed ~30,000 SNPs across 4 phenotypes (2 efficacy endpoints and 2 safety 
endpoints).  To maintain an overall error rate of 5%, applying the principles of Bonferroni 
correction, we define our significance threshold for evidence of association as: 
 
𝛼




≅ 2.1e − 7 
(5.3.1) 
 
5.3.3.3 Safety endpoints 
 Based upon the observed number of patients experiencing neutropenic or gastrointestinal 
adverse events in each cohort we calculated that the prevalence for neutropenia was 0.27 in the 
ovarian cohort and 0.35 in the lung cohort.  For gastrointestinal events, the prevalence was 0.09 
for the ovarian cohort and 0.13 for the lung cohort.  Using the calculated prevalences and 
assuming a risk allele frequency of 0.2, Table 5.3.1 presents the odd ratio (OR) that we had 80% 
power to detect in each cohort for each safety endpoint: 
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Table 5.3.1 Minimum OR (conferred by each copy of the risk allele) needed to provide 80% 
power to detect an association between a SNP the safety phenotype based upon the observed 
prevalence of cases assuming a frequency of 0.1 or 0.2 for the risk allele (MAF) in the 
population (𝛼 = 2.1𝑒 − 7) 
 MAF Ovarian Lung 
Neutropenia 0.1 7.4 5.0 
 0.2 4.8 3.4 
Gastrointestinal Disorder 0.1 9.9 5.6 
 0.2 8.7 4.3 
 
5.3.3.4 Efficacy endpoints 
For survival analyses, the power is a function of the number of events rather than the sample 
size.  With two equally sized comparator groups, for a two-sided test of α, the number of events 
required to achieve power of 1-β for a specific hazard ratio (Δ) is given by [234]: 
 𝐷 =





Where 𝑍𝛼 2⁄  and  𝑍𝛽 are standard normal percentiles. 
If, however the fraction of patients is not equal between comparator groups then (5.3.2)) will 
underestimate power.  A modified equation taking into account the relative proportion of each 
comparator arm is [236]:  
 𝐷 =








Where 𝜋1and 𝜋2 are the proportions to be allocated to each of the two comparator groups. 
When the group allocation is equal (i.e. 𝜋1 = 𝜋2 = 0.5) then (5.3.2) and (5.3.3) will yield the same 
result. 
 It is interesting to note that in both (5.3.2) and (5.3.3) the number of censored observations does 
not enter in to the power calculations.  To obtain a formula for the sample size, N, we need to 
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inflate D by dividing by 𝑃𝐸, the proportion of subjects expected to fail during the observation period 
of the study.  
Thus, the formula for 𝑁 is [236]: 
 𝑁 =








All of the above equations assume that there are only two groups undergoing comparison (a 
binary covariate).  For a large proportion of the examined SNPs, patients will fall into one of three 
categories (homozygous major allele, heterozygous, and homozygous minor/risk allele). 
Hsieh and Lavori [233] provides a method for calculating the required number of events when the 
covariate 𝑋1 has more than 2 levels (i.e. is non-binary).  The authors demonstrate that in a 
univariate model, without making assumptions about the distributions of covariate 𝑋1, the total 
number of deaths required is given by the following formula: 
 𝐷 =





Where σ2 is the variance of 𝑋1.  Equation (5.3.5) is similar to equation (5.3.3) except that the 
variance of 𝑋1, 𝜋1𝜋2 has been replaced by a more general term, σ
2.   
If 𝑋1 is binary (𝑋1 = 0 or 𝑋1 = 1) the variance (σ
2) of  𝑋1 (using the sample variance calculation 
rather than a population variance calculation) will be equal to 0.5 and equation (5.3.5) will yield 
an identical result to equation (5.3.2). 
While the authors do not explicitly state in their article, implicit in equation (5.3.5) is that the group 
sizes for each level of 𝑋1 are equal. 
If 𝑋1 is made up of 3 levels (AA, Aa, aa) then the variance of 𝑋1 will be 1.  Using similar logic for 
the link between equations (5.3.2) and (5.3.3), we surmise that: 
 𝐷 =
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Which means that equations (5.3.6) and (5.3.5) will produce identical results when there are an 
equal number of patients in each of the genotype groups. 
Again using similar logic to the link between equations (5.3.3) and (5.3.4) we can modify equation 
(5.3.6) to calculate the required sample size rather than the number of events: 
 𝑁 =











Equation (5.3.7) can be rearranged to isolate for power: 










5.3.3.5 Expected proportions 
Under the assumption of Hardy ‐ Weinberg equilibrium, the alleles that comprise a genotype can 
be thought of as having been chosen at random from the alleles in a population and the 
relationship between genotype frequencies and allele frequencies are given by: 
 
𝑃(𝐴𝐴) = 𝑃(𝐴)𝑃(𝐴) 
𝑃(𝐴𝑎) = 2𝑃(𝐴)𝑃(𝑎) 
𝑃(𝑎𝑎) = 𝑃(𝑎)𝑃(𝑎) 
(5.3.9) 
 
Based upon the observed number of patients experiencing survival event during the study for 
each cohort we calculated that the failure proportion (𝑃𝐸) for overall survival was 0.31 in the 
ovarian cohort and 0.64 in the lung cohort.  For progression free survival, the failure proportion 
was 0.70 in the ovarian cohort and 0.82 in the lung cohort. 
Assuming a risk allele frequency of 0.2, the expected proportions of each genotype are 0.04, 0.32, 
0.64 for the aa, Aa and AA genotypes respectively (with a being the risk allele).  Similarly, a risk 
allele frequency of 0.1 would produce expected genotype proportions of 0.01, 0.18, and 0.81 for 
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the aa, Aa and AA genotypes respectively.  Table 5.3.2 presents the hazard ratios that we had 
80% power to detect in each cohort for each efficacy endpoint (calculated using equation (5.3.8)): 
Table 5.3.2 Minimum HR (conferred by each copy of the risk allele) needed to provide 80% 
power to detect an association between a SNP the safety phenotype based upon the observed 
prevalence of cases assuming a frequency of 0.1 or 0.2 for the risk allele (MAF) in the 
population (𝛼 = 2.1𝑒 − 7) 
 MAF  Ovarian Lung 
Overall Survival 0.1  38.70 7.78 
 0.2  4.67 2.37 
Progression Free Survival 0.1  11.40 6.13 
 0.2  2.79 2.15 
 
5.3.4 Efficacy 
The most widely used statistical method in the analysis of survival endpoints is the Cox 
proportional hazards model, which describes the instantaneous risk of failure at time t by the 
hazard rate (see section 3.3.3.1) 
 The median survival is a commonly used metric to summarise the survival function of a group of 
patients.  A unique feature of survival data is the presence of censored observations due to either 
the withdrawal of patients or to the termination of the study observation period prior to all patients 
experiencing the survival event in question (endpoint).  The median of such data cannot be 
analysed by ignoring the censored observations because, amongst other considerations, longer-
lived patients are more likely to be censored.  Hence ignoring the censored observation would 
likely result in an underestimate of the true median survival.  The Kaplan-Meier method (also 
called the product-limit method) is used to calculate the survivor function (and confidence 
intervals) from which the median survival of a group of patients can be estimated.  This analysis 
methodology correctly uses the censored observations in addition to the uncensored 
observations.  The Kaplan-Meier estimate [148] of the survivor function is given by Kalbfleisch 
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Where 𝑡1 < 𝑡2 < ⋯ < 𝑡𝐷 represent the distinct ordered event times.  For each 𝑖 = 1,… , 𝐷, 𝑛𝑖 is 
the number of patients remaining in the risk set prior to 𝑡𝑖, and 𝑑𝑖 is the number of patients that 
have experienced the event at 𝑡𝑖.    
If we let 𝑠𝑖 = 𝑛𝑖 − 𝑑𝑖, the population of patients for which the event did not occur then the estimate 
of the standard error corresponding to the survival function is given by: 







The second quartile (median – 50th percentile) of the survival function is the time beyond which 
50% of the patients in the population are expected to survive and can be estimated by: 
 𝑞.50 = min{𝑡𝑗|?̂?(𝑡𝑗) < 0.50} (5.3.12) 
 
The Kaplan-Meier method was also used to calculate the median follow-up time.  By reversing 
the censored status indicator, i.e. death censors the true, but, unknown, observation time of an 
individual, and censoring is the endpoint of interest, the product limit estimate now computes the 
follow-up time [238].  
5.3.5 Safety 
As described in Chapter 2, all safety endpoints were collected using the Common Terminology 
Criteria for Adverse Events (CTCAE).  CTCAE is a list of terms (adverse events) commonly 
encountered in oncology interventions.  Each AE term is defined and associated with a rating 
scale of severity that indicates the severity of the AE.  While the definition of a dose-limiting toxicity 
(DLT) is determined by the individual treatment circumstances and not the CTCAE it is typical 
that Grade 3/4 adverse events based CTCAE represent DLTs even when the specific symptoms 
can be controlled or ameliorated with appropriate supportive care measures.  For this reason, we 
consider Grade 3 or greater to be ‘medically relevant’.  Consequently, we recoded each safety 
endpoint response 𝑦𝑖 as binary, assuming only two values that for convenience we code as one 
or zero. 
𝑌𝑖 = {
1  𝑖𝑓 𝑡ℎ𝑒 𝑖𝑡ℎ 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑒𝑥𝑝𝑒𝑟𝑖𝑒𝑛𝑐𝑒𝑑 𝑎 𝑔𝑟𝑎𝑑𝑒 3 𝑜𝑟 𝑔𝑟𝑒𝑎𝑡𝑒𝑟 𝑒𝑣𝑒𝑛𝑡 𝑎𝑡 𝑎𝑛𝑦 𝑐𝑦𝑐𝑙𝑒
0 𝑖𝑓 𝑡ℎ𝑒 𝑖𝑡ℎ 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑒𝑥𝑝𝑒𝑟𝑖𝑒𝑛𝑐𝑒𝑑 𝑎 𝑔𝑟𝑎𝑑𝑒 2 𝑜𝑟 𝑙𝑒𝑠𝑠𝑒𝑟 𝑒𝑣𝑒𝑛𝑡 𝑎𝑡 𝑎𝑛𝑦 𝑐𝑦𝑐𝑙𝑒
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𝜋𝑖 = 𝑃(𝑌𝑖 = 1|𝑋𝑖 = 𝑥𝑖) : the probability that the dependent variable equals a 
case given the value of a predictor. 
(5.3.13) 
 
5.3.6 Two different models 
 For each SNP, we test that hypothesis that SNP alleles have an effect upon efficacy and/or safety 
response (but with unknown effect size).  Cox proportional hazards models and logistic regression 
models were fitted to the efficacy and safety endpoints respectively.  The term ‘effect estimate’ 
therefore refers to hazard ratios in the Cox proportional hazards models and odds ratios in the 
logistic regression models.  
We start out with univariate SNP analyses, i.e. a Cox or logistic regression model including only 
the individual SNP and top 5 principal components (PCs) as covariates.  The inclusion of the 
principal components will adjust for ethnic differences [239] and allow for the inclusion of all 
ethnicities without the need to analyse only the Caucasian subset.  Hereafter we refer to this 
analysis as ‘SNP Only’, despite the inclusion of the PCs in every model: 
𝐗 = (𝑆𝑁𝑃𝑖 , 𝑃𝐶1, 𝑃𝐶2, 𝑃𝐶3, 𝑃𝐶4, 𝑃𝐶5)
𝑇 
Next, we performed a set of analyses that were adjusted for age (as a continuous term) and sex 
in addition to each SNP together with the top 5 PCs – hereafter referred to as ‘SNP Age Sex or 
Full Model’: 
𝐗 = (𝑆𝑁𝑃𝑖 , 𝑃𝐶1, 𝑃𝐶2, 𝑃𝐶3, 𝑃𝐶4, 𝑃𝐶5, 𝐴𝑔𝑒, 𝑆e𝑥)
𝑇 
 For both the efficacy and safety endpoints, the reported p-value is from the Wald test [240]. 
The association results between each SNP and safety / efficacy endpoints are summarised using 
Manhattan plots.  Quantile-quantile (Q-Q) plots were used to examine the observed association 
against expected association for each analysis.   
   




5.4.1 Treatment, response and outcomes  
Overall, 566 patients (223 ovarian and 343 lung) who received platinum chemotherapy as a first-
line therapy were included in the analysis.  The demographic and clinical characteristics of 
patients are described in section 2.4.1.  All participants were followed until 05/09/2014.  The 
median follow-up duration (Kaplan-Meier estimates) was 36.76 months (assuming 30.436875 
days to a Gregorian month), and 291 patients (51.4%) were deceased by the end of the study.  
The median OS time was 37.7 months (95% confidence interval (CI), 32.6–43.7 months).  In the 
lung cohort, 221 patients (64.4%) had died by the end of the observation period.  In the ovarian 
cohort, 70 patients (31.4%) had died by the end of the observation period.  As patients tend to 
exhibit cancer progression prior to death, in both cohorts the number of PFS events was greater 
than the number of OS events (Lung: 275 patients – 81.6%, Ovarian: 148 patients – 69.5%).  The 
number of events and censors by cohort are presented in Table 5.4.1.  Table 5.4.2 summarises 
the survival functions for OS and PFS by cohort.   
Figure 5.4.1 shows that the OS for the ovarian patients was significantly longer compared with 
lung patients.  Similarly, Figure 5.4.2 shows that the PFS for the ovarian patients was significantly 
longer compared with lung patients. 
Table 5.4.1 Number and proportion of censors and events by endpoint and cohort 
 Overall Survival Progression Free Survival 
 Ovarian Lung Ovarian Lung 
Number Events 70 (31.4%) 221 (64.4%) 148 (69.5%) 275 (81.6%) 
Number Censored 153 (68.6%) 122 (35.6%) 65 (30.5%) 62 (18.4%) 
   








 Ovarian Lung 
Overall Survival, days 
Median (95% 
CI) 
2625 (1811-NE) 788 (685-934) 
3rd Quartile 
(95% CI) 










95% CI 0.76-0.86 0.47-0.58 
Progression Free Survival, days 
Median (95% 
CI) 
578 (498-709) 299 (267-338) 
3rd Quartile 
(95% CI) 
1649 (1063-2172) 641 (530-800) 
NE = upper confidence interval of the median survival in the ovarian cohort was not 
estimable due to the low number of events. 
 
   








Figure 5.4.2 Kaplan-Meier progression free survival curves for the lung and ovarian cohorts 
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Table 5.4.3 shows the frequency of neutropenia and gastrointestinal disorder by grade category 
(0-2, 3-4) by cohort and platinum therapy within cohort.  In both lung and ovarian cohorts, grade 
3-4 neutropenia (i.e. severe neutropenia) was more common than grade 3-4 gastrointestinal 
disorder.  
Table 5.4.3 Number of patients in each safety endpoint category by cohort 
Toxicity and Grade Ovarian Lung 
 Carboplatin Carboplatin Cisplatin All 
Neutropenia     
0-2 162 72 151 223 
3-4 61 65 55 120 
Gastrointestinal Disorder     
0-2 203 121 177 298 
3-4 20 16 29 45 
 
5.4.2 GWAS discovery and identification of SNPs associated with survival (efficacy) 
endpoints 
The results of the association between the SNPs and overall survival in the lung cohort are 
presented in Figure 5.4.3.  Panel A presents the ‘SNP Only’ results, panel B presents the ‘full 
model’ results and panel C is an overlay between both plots.  Appendix B presents the 
corresponding figures for OS in the ovarian cohort and PFS, GID and NEU Manhattan plots for 
both the lung and ovarian cohorts (see Table 5.4.4).  Appendix C presents the results for the Q-
Q plots matching the data presented in the Manhattan plots.  As the points on the lower end of 
the distribution fall on the reference line, we conclude that the p-values follow a normal 
distribution.  This indicates that there was no inflation of test statistics, and that any population 
stratification was well controlled for using PCs in the analyses.  
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Table 5.4.4 Manhattan plots contained within Appendix B 
Cohort Endpoint Figure Number 
Ovarian Overall Survival Figure 12.2.1 
Ovarian Progression Free Survival Figure 12.2.2 
Lung Progression Free Survival Figure 12.2.3 
Ovarian Neutropenia Figure 12.2.4 
Lung Neutropenia Figure 12.2.5 
Ovarian Gastrointestinal Disorder Figure 12.2.6 
Lung Gastrointestinal Disorder Figure 12.2.7 
 
Typically, within GWAS studies, only SNPs that are significantly associated (pass multiple testing 
correction) with the phenotype are presented in the results.  As we had so few significant results, 
and our goal was to compare models that include clinical covariates from those that do not, we 
present the top 5 most associated results from each phenotype, irrespective of their significance. 
The 5 SNPs that were most significantly associated with each outcome from each analysis are 
summarised in Table 5.4.5-Table 5.4.8.  Below we detail the results presented in the Figures and 
Tables. 
5.4.2.1 Overall survival 
The SNPs that were most significantly associated with OS are summarised in Table 5.4.5.  In the 
ovarian cohort, of the top 5 SNPs from the SNP Only results, 2 SNPs (rs186885699 and 
rs34422484) remained in the top 5 most associated once age and gender were added as 
covariates.  Two of the top 5 SNPs from each analysis are contained within annotated genes with 
3 of the top 5 SNPs from each analysis being intergenic.  
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Table 5.4.5 Top 5 SNPs from each cohort: Outcome OS 




𝐒𝐍𝐏 𝐎𝐧𝐥𝐲† 𝐅𝐮𝐥𝐥 𝐌𝐨𝐝𝐞𝐥† 
Hazard‡ 
Ratio 








rs140634372 PRDM5 4:121719544 T\A 7.331 3.148-17.07 3.86E-06 .   . 
rs186885699 MROH5 8:142480801 G\A 6.652 2.941-15.05 5.34E-06 6.166 2.773-13.71 8.13E-06 
rs34422484   22:50696678 G\A 4.901 2.441-9.840 7.85E-06 5.321 2.641-10.72 2.91E-06 
rs2234455   11:5529152 A\G 2.465 1.613-3.767 3.07E-05 .   . 
rs73974725   17:10409241 A\G 5.706 2.508-12.98 3.30E-05 .   . 
exm2271283*    10:47646751 G\A .   . 2.256 1.508-3.376 7.59E-05 
rs140112498   22:38026059 G\A .   . 6.511 2.656-15.96 4.21E-05 






rs17117678 OMA1 1:58999651 A\C 2.431 1.789-3.304 1.36E-08 2.338 1.714-3.188 8.11E-08 
rs35075952 TACSTD2 1:59042311 A\C 2.402 1.764-3.269 2.57E-08 2.304 1.686-3.148 1.63E-07 
rs2001030   26:1438 G\A 2.496 1.691-3.687 4.23E-06 2.395 1.617-3.547 1.32E-05 
rs5741809   20:36956026 A\G 3.613 1.950-6.695 4.46E-05 3.565 1.974-6.439 2.51E-05 
rs2076212   22:44322970 C\A 1.674 1.294-2.167 8.92E-05 .   . 
rs17130717 GBP1 1:89524657 G\C .   . 2.560 1.589-4.125 1.13E-04 
Τ: Chr indicates the chromosome number and BP indicates position in base pairs 
†: All analyses included the top five principal components as covariates 
‡: The coding of the Cox analysis was such that the hazard ratio represents the increase in hazard for each copy of the minor allele  
*: I used the Illumina RSID mapping spreadsheet to convert each Illimuna exm-ID back to an RSID.  Not all tags had an equivalent RSID, exm2271283 was one 
such SNP 
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The results of the association between the SNPs and OS for the lung cohort are presented in 
Figure 5.4.3.  In the lung cohort, of the top 5 SNPs from the SNP Only results, 4 SNPs 
(rs17117678, rs2001030, rs35075952 and rs5741809) remained in the top 5 most associated 
once age and sex were added as covariates.  Similar to the ovarian cohort, 2 of the top 5 SNPs 
from each analysis are located within annotated genes while the remainder are intergenic.
   




Figure 5.4.3 Exome array analysis results of overall survival in the lung cohort. 
The association of SNP genotype and overall survival was evaluated using a Cox regression 
models for 29328 SNPs across 343 patients with lung cancer treated with platinum-therapy 
containing regimens.  regression included p-values (−log10 p-values; y axis) are plotted against 
the respective chromosomal position of each SNP (x axis). (A) SNP Only results; (B) SNP Age 
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Figure 5.4.4 presents the results for the top 5 SNPs from each analysis.  In the majority of SNPs 
that overlap between analyses, the addition of covariates does not improve the association signal 
strength.  
 
Figure 5.4.4 Five most OS associated SNPs by cohort. 
SNP Only: SNP + top 5 principal components; SNP Age Sex: SNP + top 5 principal components 
+ Age + Sex. 
 
Two SNPs reached genome wide significance in the lung cohort SNP Only analysis (rs1711767, 
p=1.36E-08; and rs35075952; p=2.57E-08).  Both SNPs remained significant at the predefined 
alpha threshold (2.1e-7) with the addition of clinical covariates (rs1711767, p=8.11E-08; and 
rs35075952; p=1.63E-07).  We tested each SNP for proportional hazard by including a minor 
allele count × time interaction [241], neither SNP failed the proportional hazard assumption in the 
SNP only model (p=0.0844 and 0.0807 for the rs35075952 and rs1711767 SNPs respectively) or 
with the addition of age and sex covariates (p=0.3647 and 0.3551 for the rs35075952 and 
rs1711767 SNPs respectively). The Kaplan–Meier plots of these two SNPs stratified by minor 
allele count (MAC) are presented in Figure 5.4.5.  The most significant association was with 
rs1711767, located in the OMA1 gene.  A regional plot of rs1711767 reveals that it is in strong 
linkage disequilibrium (LD) with rs35075952 (r2=0.97), so these are not independent signals of 
association (Figure 5.4.6).   
 
   




Figure 5.4.5 Kaplan-Meier plots of overall survival in the lung cohort for top two associated SNPs 
stratified by minor allele count. 
Plots and summary tables show the relationship between genotype at (A) TACSTD2 rs35075952; 
(B) OMA1 rs17117678 and overall survival in the lung cohort. MAC refers to the number of copies 
of the risk/minor allele.  For both SNPs, variant carriers had reduced survival. 
 
 
Figure 5.4.6 SNP-OS association results in the lung cohort. 
The plot shows association results for SNPs (–log10 p-value) as a function of genomic distance.  
The purple diamonds indicates the SNP with the strongest association evidence (rs17117678).  
Each circle represents a SNP, with the colour of the circle indicating the correlation between that 
SNP and the index SNP (purple diamond).    These results suggest rs35075952 is in strong LD 
with the index SNP (rs17117678) and therefore the association that each SNP has with overall 
survival is likely not independent. 
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5.4.2.2 Progression free survival 
In the ovarian cohort, of the top 5 SNPs from the SNP Only analysis, 3 SNPs (rs3751057; 
rs62007840 and rs7212197) remained in the top 5 most associated once age and gender were 
added as covariates.  None of the most associated SNPs from either analysis was contained 
within annotated genes (see Table 5.4.6) and none reached our Bonferroni-corrected threshold 
of significance. 
In the lung cohort, of the top 5 SNPs from the SNP Only analysis, 2 SNPs (rs1478091 and 
rs34379253) remained in the top 5 most associated once age and sex were added as covariates.  
Similar to the ovarian cohort, 1 SNP from each analysis are located within annotated genes while 
the remainder are intergenic. 
Figure 5.4.7 presents the results for the top 5 SNPs from each analysis.  As with OS, where the 
SNPs are within the top 5 associated for both SNP Only and SNP Age Sex analyses, the addition 
of clinical covariates does not improve the association strength signal. 
 
Figure 5.4.7 Five most PFS associated SNPs by cohort. 
SNP Only: SNP + top 5 principal components; SNP Age Sex: SNP + top 5 principal components 
+ Age + Sex. 
 
   




In the ovarian cohort, all the top 5 SNPs from the SNP Only analysis remained in the top 5 most 
associated once age and gender were added as covariates.  Three of these SNPs were contained 
within annotated genes (see Table 5.4.7). 
In the lung cohort, of the top 5 SNPs from the SNP Only analysis, 4 SNPs remained in the top 5 
most associated once age and sex were added as covariates.  Only 1 SNP from the SNP Only 
analysis is located within an annotated gene. 
Figure 5.4.7 presents the results for the top 5 SNPs from each analysis.  The addition of clinical 
covariates does not alter the association strength of the SNPs with neutropenia. 
 
Figure 5.4.8 Five most neutropenia associated SNPs by cohort. 
SNP Only: SNP + top 5 principal components; SNP Age Sex: SNP + top 5 principal components 
+ Age + Sex. 
 
5.4.2.4 Gastrointestinal disorders 
In the both the ovarian cohort and lung cohort, all of the top 5 SNPs from the SNP Only analysis 
remained in the top 5 most associated once age and gender were added as covariates.  Three of 
these SNPs were contained within annotated genes (see Table 5.4.7). 
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Figure 5.4.7 presents the results for the top 5 SNPs from each analysis.  The addition of clinical 
covariates does not alter the association strength of the SNPs with neutropenia. 
 
Figure 5.4.9 Five most gastrointestinal disorder associated SNPs by cohort. 
SNP Only: SNP + top 5 principal components; SNP Age Sex: SNP + top 5 principal components 
+ Age + Sex. 
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Table 5.4.6 Top 5 SNPs from each cohort: outcome PFS 




𝐒𝐍𝐏 𝐎𝐧𝐥𝐲† 𝐅𝐮𝐥𝐥 𝐌𝐨𝐝𝐞𝐥† 
Hazard‡ 
Ratio 








rs7212197   17:48335925 A\G 0.534 0.325-0.723 1.65E-05 0.507 0.316-0.686 3.69E-06 
rs62007840   15:78570918 A\G 0.593 0.471-0.924 3.66E-05 0.613 0.496-0.974 1.32E-04 
rs2491014   23:138897130 C\A 4.246 0.719-5.794 5.40E-05 .   . 
rs13057352   22:47095235 C\A 3.863 0.689-4.600 5.57E-05 .   . 
rs3751057   11:9051475 C\G 2.615 0.715-2.738 7.41E-05 2.761 0.797-3.082 3.64E-05 
exm2268202*   19:48800338 G\A .   . 1.842 1.443-3.209 2.23E-05 






rs1478091   4:131790501 A\G 2.117 1.205-2.369 4.64E-06 2.135 1.173-2.306 3.89E-06 
rs34379253   16:57449687 G\A 2.508 1.003-2.565 2.02E-05 2.471 0.941-2.421 2.91E-05 
rs35075952 TACSTD2 1:59042311 A\C 1.810 1.764-3.269 4.77E-05 .   . 
rs74991234   18:52604083 A\G 2.166 1.315-2.880 5.69E-05 .   . 
rs9546785   13:36801415 G\A 0.693 0.622-0.923 6.51E-05 .   . 
rs2076212   22:44322970 C\A .   . 1.688 1.276-2.144 6.23E-05 
rs2286455 PROM1 4:16020162 G\A .   . 1.853 0.984-1.855 3.88E-05 
rs5741809   20:36956026 A\G .   . 2.916 1.974-6.439 5.26E-05 
Τ: Chr indicates the chromosome number and BP indicates position in base pairs 
†: All analyses included the top five principal components as covariates 
‡: the coding of the Cox analysis was such that the hazard ratio represents the increase in hazard for each copy of the minor allele  
*: I used the Illumina RSID mapping spreadsheet to convert each Illimuna exm-ID back to an RSID.  Not all tags had an equivalent RSID, exm2271283 was one 
such SNP 
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 Table 5.4.7 Top 5 SNPs from each cohort: outcome neutropenia 
Cohort RSID GENE Chr:BPτ 
Major/ minor 
allele 
𝐒𝐍𝐏 𝐎𝐧𝐥𝐲† 𝐅𝐮𝐥𝐥 𝐌𝐨𝐝𝐞𝐥† 
Odds 
Ratio 
95% CI p-value 
Odds 
Ratio 








exm1633987 *  23:36371719 A\T 5.246 2.430-11.32 2.42E-05 5.123 2.374-11.06 3.15E-05 
rs4858817 
FBXW12 
3:48416756 G\A 2.692 1.647-4.399 7.78E-05 2.719 1.660-4.454 7.07E-05 
rs3206852 
FOCAD 
9:20953049 A\G 2.650 1.622-4.331 1.00E-04 2.767 1.678-4.564 6.67E-05 
rs9876781  3:48487338 G\A 2.567 1.588-4.150 1.19E-04 2.594 1.600-4.205 1.10E-04 
rs1891460 
PM20D1 






rs389389  17:56676368 A\G 2.451 1.611-3.730 2.84E-05 2.445 1.600-3.736 3.57E-05 
rs8071623  17:56621286 A\C 2.294 1.524-3.452 6.87E-05 2.284 1.511-3.451 8.85E-05 
rs2680701  17:56438301 G\A 2.410 1.549-3.750 9.64E-05 2.362 1.513-3.687 1.55E-04 
rs1037926 
CCSER1 
4:91227681 G\A 0.515 0.365-0.726 1.55E-04 .  . 
rs9621049  22:31013419 G\A 2.508 1.557-4.040 1.58E-04 2.680 1.649-4.358 7.02E-05 
rs636252  6:117157774 G\A .  . 1.862 1.336-2.595 2.45E-04 
Τ: Chr indicates the chromosome number and BP indicates position in base pairs 
†: All analyses included the top five principal components as covariates 
*: I used the Illumina RSID mapping spreadsheet to convert each Illimuna exm-ID back to an RSID.  Not all tags had an equivalent RSID, exm2271283 was 
one such SNP 
 
   




Table 5.4.8 Top 5 SNPs from each cohort: outcome gastrointestinal disorder 
Cohort RSID GENE Chr:BPτ Major/ minor allele 
𝐒𝐍𝐏 𝐎𝐧𝐥𝐲† 𝐅𝐮𝐥𝐥 𝐌𝐨𝐝𝐞𝐥† 








rs78367010   10:135195148 G\A 21.026 5.002-88.39 3.22E-05 20.499 4.816-87.25 4.36E-05 
rs10889205 RLF 1:40705726 A\T 5.204 2.369-11.43 4.01E-05 6.193 2.708-14.16 1.56E-05 
rs35032920 OSBPL6 2:179188959 G\A 10.125 3.291-31.16 5.42E-05 11.066 3.521-34.78 3.88E-05 
rs2781806   10:116060427 C\G 16.455 3.763-71.96 1.99E-04 19.436 4.226-89.39 1.38E-04 






rs3815045   11:61669946 G\A 11.858 3.540-39.72 6.08E-05 13.620 3.911-47.43 4.09E-05 
rs900399   3:156798732 A\G 2.685 1.641-4.393 8.49E-05 2.739 1.667-4.499 6.97E-05 
rs900400   3:156798775 A\G 2.685 1.641-4.393 8.49E-05 2.739 1.667-4.499 6.97E-05 
rs1539172 CCDC171 9:15784631 G\A 2.619 1.603-4.280 1.22E-04 2.875 1.710-4.834 6.82E-05 
rs11806429 PLEKHG5 1:6550505 G\A 3.448 1.752-6.789 3.41E-04 3.765 1.875-7.561 1.94E-04 
Τ: Chr indicates the chromosome number and BP indicates position in base pairs 




   




The motivation behind this study was to examine if the addition of baseline covariates could 
improve our ability to detect SNP associations with efficacy and/or safety outcomes.  The 
approaches and scenarios examined represent standard analysis techniques and typical data for 
which the decisions of covariate inclusion are made on a regular basis.  Our analyses indicate 
that the introduction of covariates to the variable of interest (SNP) does not improve the power to 
detect SNP-phenotype interactions.  
The purpose of adjustment for covariates in genome-wide association studies (GWAS) is to 
account for potential confounding factors that can bias SNP effect estimates, and/or to improve 
statistical power by reducing residual variance [208, 242].  Within genetic association studies, it 
is standard to adjust for ancestry-informative principal components calculated from individual 
genotypes in order to account for potential confounding from population structure [208, 242].  
Failure to adjust for confounding factors can result in spurious associations [208].  Besides 
confounding factors, it is common practice in medical research to adjust for demographic factors 
such as sex and age in an effort to increase statistical power [243, 244].  We contend that the 
rationale for the inclusion of these demographic factors is the commonly held belief that if they 
truly are predictive of the outcome then they should decrease the residual variance of the outcome 
variable and therefore increase the magnitude of the SNP effect size relative to the phenotypic 
variance which will lead to an increase in power [231]. 
In a linear regression model (as would be appropriate for a continuous phenotype), inclusion of 
an independent (of genotype) predictive covariate would not change the magnitude of the 
estimated SNP effect.  It would however improve the precision of the estimator thereby increasing 
statistical power [233].  In contrast, the effect of covariates is not so straightforward in the context 
of non-linear models like logistic and Cox regression methods. 
Logistic regression differs from linear regression in that inclusion of an independent predictive 
covariate both increases the magnitude of the estimated effect and simultaneously reduces the 
precision of the effect estimator [207, 245].  The consequence for power depends on the relative 
increase in the estimated effect (which would increase power) against the inflation of the estimator 
variance (decrease in precision - which would reduce power) [246]. Similarly, for Cox proportional 
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hazards models, the inclusion of a predictive covariate will not always increase power [247]. This 
loss of power is attributed to either non-independence between the SNP effect and the other 
covariates in the model [247]; or the fact the covariate itself might not have a consistent 
multiplicative effect upon hazard across the range of the covariate.  Hsieh et al. [233, 246, 247] 
noted that as the use of covariates increases, the variance of the estimated effect size for the 
parameter of interest also increased, and thus proposed increasing the sample size for a PH 
model by a variance inflation factor when covariates are included in the model, even when the 
covariates are necessary for the model assumptions to hold. 
In summary, use of covariates in the analyses resulted in smaller SNP-phenotype association 
signals in both of the non-linear analytic approaches used, although the impact of their use was 
generally modest.  The use of covariates in the analysis of medical studies often is guided by our 
understanding of linear models where the inclusion of prognostic factors increases power to 
detect an association between the response and the primary independent variable.  In studies 
employing non-linear methods, the inclusion of covariates can reduce power to detect an 
association between the response and the primary independent variable.  Consequently, only 
confounding factors needed to produce an unbiased estimate of effect should be included in the 
model as covariates.  For models employing Cox regression, prognostic factors may help with 
achieving proportional hazards in which case their inclusion is necessary to meet the model 
assumptions however researchers should be aware of the implications on power that are created 
in these circumstances. 
We identified two SNPs within the OMA1 and TACSTD2 genes that were significantly associated 
with overall survival in lung cancer patients receiving platinum-based chemotherapy.  
The gene OMA1 encodes a metalloprotease, an enzyme which plays a role in regulation of the 
inner membrane of mitochondria.  Several authors had already identified OMA1 as a colorectal 
cancer driver gene – a gene in which genetic changes increase the mutation rate in the cell 
leading to more rapid tumour evolution and metastases [248]. However, these studies relied upon 
tumour tissue where our genotyping methods would only capture germline variation.  Kong et al. 
[249] examined cisplatin sensitive and cisplatin resistance ovarian and cervical cell lines. The 
authors found that cisplatin exposure induces L-Opa1 processing and mitochondrial 
fragmentation in chemo-sensitive but not in chemo-resistant cells.  As Metallopeptidase OMA1 is 
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involved in L-Opa1 processing, the authors implicate OMA1 as playing a role in cisplatin 
resistance.  Within our data, none of the ovarian cancer patients was receiving cisplatin and the 
majority of patients in the lung cohort were receiving cisplatin.  If the effect of OMA1 were limited 
to cisplatin and not the other platinum agents, then this might explain the discrepancy between 
the lung and ovarian association results.  Alternatively, the median survival time is much greater 
for ovarian cancer as compared with lung cancer.  This results in fewer survival events for ovarian 
cancer and therefore lower power to detect SNP-OS associations.  The effect sizes for these two 
SNPs were in the opposing directions for each cohort.  As presented in Table 5.4.5, for SNP 
rs17117678, in the lung cohort the hazard ratio was 2.431 and 2.338 for the SNP Only and full 
models respectively.  In the ovarian cohort, the corresponding hazard ratios were 0.581 and 0.589 
(both were non-significant, p=0.138 and p=0.153).  Similarly, for SNP rs35075952, in the lung 
cohort the hazard ratio associated with variant carriers in the lung cohort was 2.402 and 2.304 for 
the SNP Only and full models respectively.  In the ovarian cohort, the corresponding hazard ratios 
were 0.567 and 0.570 (both were non-significant, p=0.122 and p=0.132). 
TACSTD2 encodes the protein Trop-2 which is a carcinoma-associated antigen.  The antigen is 
a cell surface receptor that transduces calcium signals.  It is universally expressed in stratified 
squamous epithelia of many organs, including skin, oesophagus and cervix.  It is known as a 
carcinoma-associated antigen as it is frequently over-expressed in epithelial tumours.  For this 
reason, it is being considered as a molecular target for cancer therapy.  Similar to OMA1, 
TACSTD2 is theorised to play a role in cell apoptosis, and its over-expression is associated with 
chemo-resistance [250]. 
Our regional plot shows that the OMA1 and TACSTD2 SNPs are in strong linkage disequilibrium.  
Unfortunately, the exome chip used for genotyping has low coverage of SNPs and none of the 
other tagged SNPs was in strong enough LD to observe supporting association signals for either 
significant SNP.  The fact that the only other SNP in high LD with the top associated SNP also 
exhibited a similar statistical association with the phenotype supports the idea that one or both 
signals are possibly valid but without replication it remains a distinct possibility that one or both 
are chance findings. 
Given the greater number of PFS events as compared with OS events was surprising that we 
were able to detect OS-SNP associations but not PFS-SNP associations.  We attribute this to 
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error in the assessment of progression.  Unlike death (an unambiguous endpoint), there are 
several potential sources of measurement bias or variability common to the assessment of 
progression [251]. The exact date of progression cannot be known, since it is determined based 
on the types and timing of assessments.  At the point in time at which a patient is identified as 
being progressed, it is only known that the progression occurred at some point in the interval of 
time between the last negative progression assessment and the assessment at which progression 
was detected.  Within the patient records, progression date is recorded as the date of the 
evaluation at which progression was first evident.  While this is consistently an overestimate of 
PFS, the degree to which it is an overestimate is subject to patient variability in the frequency and 
timings of progression assessments.  Stochastic asymmetry between each genotype with respect 
to the frequency of assessment has the potential to introduce bias into SNP-PFS associations.  
Lastly, PFS is a composite endpoint including radiologic assessment, death, or symptomatic 
progression.  Consequently, ‘progression’ is an event prone to reading error by the interpreter of 
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Chapter 6. GWAS concordance 
Numerical quantities focus on expected values, graphical summaries on 
unexpected values. 
– John Tukey 
6.1 Abstract 
Background 
Complex diseases give rise to multiple and overlapping phenotypes.  It is common to 
analyse each phenotype separately which gives rise to multiple sets of SNP-phenotype 
association results.  This chapter develops a novel method to compare association 
signals from univariate SNP analyses to understand the concordance/discordance in 
signal strength and pattern of SNPs for association in two phenotypes. 
Methods 
The methods are tested on simulated data and an analysis of a previously conducted 
study which aimed to identify variants associated with toxicity response and survival in 
patients treated with platinum therapy for either lung or ovarian cancer. 
Results 
Assessing joint distribution of p-values from two association studies across a range of 
critical thresholds gives rise to a characteristic ‘moth plot’.  This plot comprises 4 curves 
– 2 power curves that describe the proportion of concordance between phenotypes and 
2 quadratic curves that characterise the discordance in association results between 
phenotypes.  The difference in maximum amplitude between the quadratic discordance 
curves describes the difference in the mean p-value between the two phenotypes.  Both 
the difference between the intercept of the concordance power functions and the 
maximal height of the discordance functions describe the correlation between the 
association signals of the two datasets. 
Conclusion 
This method provides a qualitative assessment method to graphically explore both the 
correlation and difference in association result distributions when comparing the results 





   




Genome-wide association studies (GWAS) have emerged as popular tools for identifying genetic 
variants that are associated with disease risk, quantitative phenotypes, and treatment response.  
Standard analysis of a case-control GWAS involves assessing the association between each 
genotyped SNP and phenotype.  However, it is clear that substantial pleiotropy exists in the 
human genome, with many SNPs contributing to multiple phenotypes [252]. Within the field of 
oncology, survival has traditionally been considered the gold-standard endpoint for cancer clinical 
trials [253]. Consequently, a large number of cancer GWAS studies have focused on the 
relationship between single nucleotide polymorphisms (SNPs) and the survival endpoints: overall 
survival (OS) [254-257] and progression free survival (PFS) [258-260].  More recently there has 
been a shift towards utilisation of GWAS studies to identify novel common genetic variations for 
drug-induced toxicity [251, 260-265].  Both survival and toxicity represent clinically relevant 
cancer outcomes, yet the link between each type of endpoint is poorly understood.  Recent GWAS 
advances have made it possible to jointly model the association between SNPs and several 
phenotypes [266-268].  While these methods are more powerful than univariate testing methods 
for detecting significant associations between SNPs and phenotypes, they do not characterise 
the genome-wide similarity of genetic architecture between phenotypes. 
We introduce a new method that compares the results of pair-wise univariate GWAS by exploring 
the concordance and discordance of association signals between two phenotypes.  This is 
achieved by assessing the proportion of concordant and discordant association results at a series 
of p-value thresholds.  The goal of this method is to provide a graphical tool that allows a 
researcher to simultaneously assess the similarity in the distribution of association tests between 
two phenotypes and to provide a measure of the correlation of p-values between phenotypes 
even when the distributions differ. 
6.3 Methods 
6.3.1 Concordance / discordance 
We assume an association study has been performed for two endpoints (phenotype 1, phenotype 
2), with p-values SNPs PE1 and PE2 for N SNPs.  To assess the similarity of association between 
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SNPs and two alternative endpoints, we define a 2 × 2 contingency table of possible outcomes 
for observations between the phenotypes at a fixed significance threshold (α).  These outcomes 
are provided in Table 6.3.1 give the proportion of SNPs classified into each cell, where A gives 
the number of SNPs where both 𝑃𝑝𝐸1≤ α and 𝑃𝑝𝐸2 ≤ α, B gives the number of SNPs where 𝑃𝑝𝐸1 ≤ 
α and 𝑃𝑝𝐸1> α, and similarly for C and D.     
 Table 6.3.1 Proportion of SNPs categories by α significance threshold for the association 
results between two phenotypes 
  Phenotype 2 
  p ≤ α p > α 
Phenotype 1 
p ≤ α 𝐴  𝐵 
p > α 𝐶 𝐷 
 
The table offers a snapshot of all SNPs at a single α-threshold.  We seek to explore how the 
relative proportions of each cell change across α-thresholds. 
A key feature of this method is understanding how the frequency/proportion of each cell of the 
contingency table is expected to change by α, under different assumptions of the p-value 
distribution for each phenotype, and the correlation between them.  Assuming that the GWAS p-
values from each phenotype are approximately uniformly distributed, then at a low α-threshold 
very few SNPs will fall into cell ‘A’ category and the majority of SNPs will have p>α for both 
phenotypes and therefore in the ‘D’ category.  As the threshold increases the proportion of SNPs 
in A, B and C is expected to increase until a threshold of p=0.5 when there should be equal 
number of SNPs in each category (A, B, C and D) (see Figure 6.3.1). 
   




Figure 6.3.1 Schematic for SNP classification by phenotype, where alpha threshold controls the 
number of SNPs that fall within each category. 
This figure is illustrative and makes no assumptions about the underlying distribution of p-values.  
The proportion SNPs within each category at a given threshold will depend on the specific 
distributions of the p-values.  
 
The relative proportion of each cell can be calculated by dividing each cell by the total number of 
examined SNPs (A+B+C+D).  When the α-threshold is close to zero, no SNP has a p-value from 
either phenotype that is below the threshold and all SNPs lie in the D category.  When the α-
threshold is close to one, all of the SNPs have a p-value less than α in both phenotypes and the 
proportion of SNPs in category A is one. 
Under the null hypothesis of no association at any SNP for either phenotype, and no correlation 
between the test statistics for phenotypes 1 and 2, the relationships between the proportions of 
SNPs in [𝐴 𝐵 𝐶 𝐷] can be easily constructed. 
Assuming p-values have a uniform U(0,1) distribution, then: 
P(𝑃𝐸i≤ α) = α, for i = 1, 2.  
Given 𝑃𝐸1 and 𝑃𝐸2 are independent,  
A = P(𝑃𝐸1≤ α, 𝑃𝐸2≤ α) = P(𝑃𝐸1≤ α) P(𝑃𝐸2≤ α) = α
2 
B = P(𝑃𝐸1≤ α, 𝑃𝐸2> α) = P(𝑃𝐸1≤ α) P(𝑃𝐸1> α) = α
 (1- α) 
And similarly, C=B, D=1-A.   
Figure 6.3.2 plots the relative proportion of each category against α-threshold.  Hereafter we refer 
to this type of plot as a ‘moth’ plot. 
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We hypothesise that both the correlation between p-values from each phenotype and 
distributional differences between the p-values from each phenotype will alter the shape and 
intercept of the contingency cell functions in the moth plot.  To explore this hypothesis, we create 
simulated p-value results that are detailed in the next section. 
 
Figure 6.3.2 Moth plot showing the relative proportion of SNPs in each contingency table across 
a varying α threshold. 
A increases as the α threshold increases, and D decreases. B & C both increase from zero until 
an alpha threshold of 0.5 after which the curves decline. All lines intercept at (0.5,0.25).   
 
6.3.2 Simulation  
To explore the behaviour of the moth plot further, we performed a simulation study for test 
statistics in two phenotypes, varying the level of association within a phenotype and the 
correlation between phenotypes.  We simulated data at 3 levels of correlation (0, 0.5 and 0.9) 
between p-values.  Each scenario was simulated for 30,000 SNPs under both a null (H0) and 
alternative hypotheses (HA).  Polygenic phenotypes are characterised by modest allele 
frequencies shifts at many loci [269].  The consequence of this is a shift in the distribution of 
association p-values away from a uniform distribution with more SNPs having lower p-values; we 
refer to this phenomenon as ‘polygenic component’; that is to say that there are multiple 
associations of varying strengths between SNPs and the phenotype being studied.  In comparing 
the pattern of association between SNPs across two phenotypes, the H0 becomes: there is no 
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difference in the distribution of p-values (polygenic component) between Phenotype 1 and 
Phenotype 2; while HA can be written as: there is a difference in the distributions between p-
values for Phenotype 1 and Phenotype 2.  Note that this definition is independent of the p-value 
distribution for the phenotypes.    
To generate correlated data from the uniform distribution it was necessary to generate correlated 
data from the normal distribution using Cholesky decomposition and then transform the normal 
values to uniform using the cumulative distribution function transformation. 
The process for simulating GWAS results is described by the following steps: 
1) Generated a 𝑗 𝑥 2 (Z) matrix of two uncorrelated Gaussian random variables 
𝑁(0,1), where 𝑗 is the number of SNPs to be compared between the phenotypes.   
2) Define the covariance matrix ∑, from the required correlation between phenotypes. 
3) Find the root of  ∑, i.e. a matrix C such that 𝐶𝐶𝑇 = ∑. 
4) The target matrix of correlated values is then defined by  𝐶𝑍.  
5) Normal distribution values can then be transformed to uniform through the 
cumulative distribution function. 
 
6.3.2.1 Null model 
Under the null hypothesis, either there are no true associations in either GWAS dataset, or the 
polygenic components are similar between the compared phenotypes.  We considered two ‘null’ 
scenarios:  
1) Neither phenotype GWAS set has any signal of association:  p-values of 
association were generated from 𝑁(0,1) distributions for both phenotypes. 
2) Both phenotypes show a similar signal of association.  To approximate this, SNP 
association p-values were generated from (𝑁(0.1,1) distributions for both 
phenotypes. 
 
6.3.2.2 Alternate model 
The alternate hypothesis is that SNPs associated with one phenotype are not associated with the 
second phenotype.  We considered an alternate hypothesis scenario where p-values of 
association were generated from a 𝑁(𝑖, 1) distribution in the first phenotype and from a 𝑁(0,1) 
distribution for the second phenotype, with i=0.1, 0.2 for different strengths of association. 
For each simulation model, p-value distributions were plotted for each phenotype.  Inflation in test 
statistics were assessed by calculating the genomic control inflation factor, λ, defined as the mean 
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test statistic on a chi-square distribution.  This is a standard measure in genetic studies, and under 
no inflation, λ=1.   
There are many other possible alternative hypotheses that could be modelled here, and different 
assumptions for the underlying distribution of test statistics within a GWAS study.  Here we have 
focussed on the simplest approach to give an initial indication of the utility of the moth approach 
for correlated phenotypes.  Moth plots were assessed for each simulation, by correlation between 
phenotype, and characteristic changes in the plot were noted.  All the simulation and analyses 
were conducted using SAS v.9.4 software.  Figures were plotted using R software v.3.0. 
6.3.3 Application to cancer data 
These methods were then applied to genome-wide analysis of the lung and ovarian cancer data 
from Chapter 5.  Associations between the safety phenotypes and SNP allele count were tested 
using logistic regression.  Associations between the efficacy phenotypes and allele dosage were 
tested using Cox proportional hazard models.  Both Cox and logistic models incorporated 5 
ancestry principal components, age, gender and cisplatin subclass as covariates (see Chapter 
5).  
6.4 Results  
6.4.1 Simulation study 
Under the null hypothesis, histograms for simulated p-values with underlying test statistic 
distributions of 𝑁(0,1) and 𝑁(0.1,1) in both phenotypes are shown in Figure 6.4.1 and Table 6.4.1, 
for correlations of 0, 0.5, and 0.9.  The histograms confirm that the distribution of p-values for both 
phenotypes is similar and approximately uniformly distributed.  Simulating from the 𝑁(0.1,1) 
distribution results in lower p-values.  This is confirmed by the λ (genomic inflation factor), which 
is close to one for the 𝑁(0,1) simulation but inflated for the 𝑁(0.1,1) simulation with λ ≈ 1.1.  In 
each case, the p-value correlations across phenotypes are as expected.   
Figure 6.4.2 and Table 6.4.2 show the distribution of the simulated p-values across varying 
correlation for both ‘alternate’ models.  The distribution of p-values is dissimilar for each 
phenotype.  In both simulations, phenotype 1 has a higher frequency of lower p-values while (𝜆 =
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 1.091 & 1.190 for   𝑁(0.1,1)𝑎𝑛𝑑 𝑁(0.2,1) respectively).  By contrast, phenotype 2 exhibits a 
uniform distribution of p-values (𝜆 ≈ 1.00). 
The moth plots corresponding to each data simulation, allow us to interpret the impact of test 
statistic distribution and correlation (Figure 6.4.3).  The top-left panel replicates Figure 6.3.2 as it 
represents a moth plot comparing phenotypes when there is no correlation in the p-values 
between phenotypes and no association (p-values for both phenotypes are independent, and 
from a uniform distribution U(0,1)).  Using this panel as a reference we observe the following 3 
effects: 
1) Increasing correlation between phenotypes reduces the maximum amplitude of B & 
C and increases the intercept of the A-D intersection.  
2) Differences in the p-value distribution between phenotypes create a difference in 
the maximum amplitude of B and C (as phenotype 1 had lower p-values, this 
increases the maximum amplitude of the B-function vertex and reduces the 
amplitude of the C-function vertex, i.e. individual SNP p-values are more likely to be 
below the α-threshold in phenotype 1 and above the α-threshold in phenotype 2). 
3) The phenotype pooled mean of p-values controls the α value at which A and D 





   





Figure 6.4.1 Null simulations: Histograms showing simulated p-value distributions. 
In panel I the simulated p-values for both phenotypes are drawn from 𝑁(0.1,1) distributions prior to conversion to 𝑈(0,1) through the cumulative distribution function.  
In panel II the simulated p-values for both phenotypes are drawn from 𝑁(0.1,1).  As both phenotypes p-values are from the same distributions the frequency of SNPs 
within each histogram bin is similar both between phenotypes.  As expected, panel II shows a higher frequency of SNPs with lower p-values.   
 
   




Figure 6.4.2 Alternate simulations: Histograms showing simulated p-value distributions. 
In both panel I and panel II the p-values for Phenotype 2 are generated from a 𝑁(0,1) distribution.  In panel I the simulated p-values for Phenotypes are drawn from 
𝑁(0.1,1) distribution.  In panel II the simulated p-values for Phenotype 2 are drawn from 𝑁(0.2,1).  In both panels Phenotype 1 is biased towards lower p-values as 
compared with Phenotype 2.  
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Table 6.4.1 Descriptive statistics for simulated p-values under null hypothesis models 






















0 Phenotype1 0.49952 0.998 0.49695 0.0000724 0.99996 
0.00024 
 Phenotype2 0.50102 1.006 0.50413 0.0000844 0.99997 
0.5 Phenotype1 0.49952 0.998 0.49695 0.0000724 0.99996 
0.48192 
 Phenotype2 0.50138 1.010 0.50294 0.0000165 0.99993 
0.9 Phenotype1 0.49952 0.998 0.49695 0.0000724 0.99996 
0.89108 

















0 Phenotype1 0.47134 1.091 0.45714 0.0000482 0.99993 
0.00024 
 Phenotype2 0.47283 1.100 0.46429 0.0000563 0.99995 
0.5 Phenotype1 0.47134 1.091 0.45714 0.0000482 0.99993 
0.48192 
 Phenotype2 0.47319 1.103 0.46310 0.0000106 0.99990 
0.9 Phenotype1 0.47134 1.091 0.45714 0.0000482 0.99993 
0.89108 





   




Table 6.4.2 Descriptive statistics for simulated p-values under alternate hypothesis models 

































Phenotype1 0.47134 1.091 0.0000482 0.99993 
0.00024 
Phenotype2 0.50102 1.007 0.0000844 0.99997 
0.5 
Phenotype1 0.47134 1.091 0.0000482 0.99993 
0.48192 
Phenotype2 0.50138 1.010 0.0000165 0.99993 
0.9 
Phenotype1 0.47134 1.010 0.0000482 0.99993 
0.89108 

































Phenotype1 0.44331 1.190 0.0000317 0.99990 
0.00024 
Phenotype2 0.50102 1.010 0.0000844 0.99997 
0.5 
Phenotype1 0.44331 1.190 0.0000317 0.99990 
0.48192 
Phenotype2 0.50138 1.010 0.0000165 0.99993 
0.9 
Phenotype1 0.44331 1.190 0.0000317 0.99990 
0.89108 
Phenotype2 0.50026 1.003 0.0000207 0.99998 
 
   




Figure 6.4.3 Moth plots for all of the simulation scenarios. 
The first and last rows plot the null simulations (Phenotype 1 ~ 𝑁(0,1) = Phenotype 2 ~ 𝑁(0,1) and Phenotype 1 ~ 𝑁(0.1,1) = Phenotype 2 ~ 𝑁(0.1,1) respectively).  
The second and third rows contain the alternate simulations (Phenotype 1 ~ 𝑁(0.1,1) ≠ Phenotype 2 ~ 𝑁(0,1) and Phenotype 1 ~ 𝑁(0.2,1) ≠ Phenotype 2 ~ 𝑁(0.1,1) 
respectively).  
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6.4.2 Cancer data – efficacy and safety phenotypes 
The genetic summary statistics from the ovarian and lung cancer cohorts were explored using the 
moth plots for the four primary phenotypes previously assessed: survival endpoints of OS and 
PFS, and safely endpoints of GID and NEU.   
6.4.2.1 Interpreting the data from the moth plots 
The moth plots for each pair-wise combination of these endpoints, split by cohort, are shown in 
Figure 6.4.4. Using the information from section 6.4.1 we assert the following from the figure:  
Lung cohort 
1) In the comparison of PFS and OS 
a. PFS and OS are correlated as indicated by B and C vertices being lower than 
the A-D intercept. 
b. The B and C overlap, indicating that the distribution of p-values is similar 
between phenotypes 
c. The A-D intercept is below 0.5 indicating that the distributions of OS and PFS 
are biased towards lower p-values. 
2) In the comparison of OS vs. safety endpoints – (GID and Neu) there is slight separation 
between B and C (with B slightly higher) indicating that the p-values are higher in the 
safety endpoints and that OS does not have the same distribution of p-values as the 
safety endpoints.  
3) With the exception of OS and PFS, the vertex of B-C meets the height of the intercept 
of the A-D functions implying that apart from OS and PFS, the correlation between 
phenotypes is close to zero. 
 
Ovarian cohort 
4) In the comparison of PFS and OS 
a. B and C vertices are lower than the A-D intercept indicating that PFS and OS 
are correlated. 
b. B and C overlap, this indicates that the distribution of p-values is similar 
between phenotypes 
c. The A-D intercept is below 0.5 indicating that the distributions of OS and PFS 
are biased towards lower p-values. 
5) In the comparison of OS vs. safety endpoints – (GID and Neu) there is slight separation 
between the B and C functions (B slightly higher), indicating that the p-values are not 
uniformly distributed in the safety endpoints, and also that OS does not have the same 
distribution of p-values as the safety endpoints. 
6) In the comparison of PFS vs. safety endpoints – (GID and Neu) there is separation 
between the B and C (B slightly higher) indicating that the p-values are higher in the 
safety endpoints and also that PFS does not have the same distribution of p-values as 
the safety endpoints. 
7) With the exception of OS and PFS, the four curves, A, B, C, D intersect at (0.5,0.25) as 
seen under the null hypothesis in the simulated data, implying that the correlation 
between these phenotypes is close to zero. 
8) In the comparison of the safety endpoints (GID and Neu) the A-D intercept is above 
α=0.5 on the x-axis implying that the mean of p-values across both phenotypes is 
greater than 0.5.  
 
   




9) The vertices of B-C are lower in the lung cohort as compared with the ovarian cohort 
indicating the correlation between OS and PFS is stronger in the lung cohort. 
10) The separation between B-C vertices in the comparison of efficacy and safety 
endpoints is greater in the ovarian cohort as compared with the lung cohort implying 
that the differences in distribution between efficacy and safety endpoints is more 
pronounced in the ovarian cohort data. 
 
Figure 6.4.4 Moth plots comparing each phenotype by cohort. 
OS=overall survival, PFS=progression free survival, GID=gastrointestinal disorder, 
Neu=Neutropenia.   
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We can assess the validity of our assertions using a series of exploratory data analysis techniques 
for each phenotype, including summary statistics, histogram plots and correlations.  Figure 6.4.5 
shows the distribution of p-values for all four (two efficacy: PFS and OS; and two safety: GID and 
Neu) cancer endpoints by cohort; Table 6.4.3 presents the descriptive statistics for each endpoint 
and Table 6.4.4 presents the correlation between endpoints. 
Figure 6.4.5 shows that our assertions regarding the distributional differences between efficacy 
and safety endpoints and between cohorts are upheld.  Both efficacy endpoints in both cohorts 
show systematic bias towards lower p-values (μ = 0.474, 0.478, 0.482 and 0.491 for OS and PFS 
endpoints in the ovarian and lung cohorts respectively) (similar in distribution to Phenotype 1 from 
our alternate simulations).  Moreover, this shift is more pronounced in the ovarian cohort as 
compared with the lung cohort (λ = 1.16, 1.14, 1.09 and 1.04 for OS and PFS endpoints in the 
ovarian and lung cohorts respectively).  Both safety endpoints in both cohorts are approximately 
uniformly distributed, similar in shape to the null simulations with 𝑁(0,1))(μ = 0.525, 0.506, 0.502 
and 0.495; λ = 0.952, 0.948, 0.994 and 0.994) for GID and Neu endpoints in the ovarian and lung 
cohorts respectively).   
Table 6.4.4 confirms that OS and PFS are the only two endpoints exhibiting a correlation markedly 
different from zero and that the correlation is greater in the lung cohort (ρ=0.2014 and ρ=0.3872 








   





Figure 6.4.5 The histograms show the distribution of p-values for the association tests of each phenotype by cohort.    
   




Table 6.4.3 Descriptive statistics for the efficacy and safety endpoints. 
Cohort N Variable Mean (μ) Minimum Maximum Lambda (𝝀) 
Ovarian 28961 
OS 0.474 1.13E-06 0.999914 1.16026 
PFS 0.478 3.54E-06 0.999991 1.14258 
GID 0.527 1.56E-05 0.999945 0.95176 
NEU 0.506 3.15E-05 0.999983 0.94792 
Lung 29258 
OS 0.482 2.23E-06 1 1.09337 
PFS 0.491 3.52E-06 0.999917 1.04988 
GID 0.502 4.09E-05 0.999998 0.99354 




Table 6.4.4 Correlation between p-values from alternate phenotypes 
Spearman Rank Correlation 
 
OS PFS GID NEU 
  
Ovarian 
OS 1 0.204 0.003 0.022 
PFS 0.387 1 -0.001 0.012 
GID 0.000 0.004 1 0.001 







      
   




We introduce a framework exploring the similarities and differences of genetic association results 
from individual phenotype analyses.  We have shown that it is possible to capture in a single 
graphic both correlation and distributional differences between results from two phenotypes, and 
this moth plot effectively combines the information from histograms, summary statistics and 
correlation tables. 
The value of this method is to provide an easily produced graphic that can summarise several 
aspects of the concordance/discordance between univariate genotype-phenotype association 
results.  In GWAS testing the association between genetic variants and phenotypes, each one-
at-time, has remained the method of choice, even in studies where multiple phenotypes are 
collected.  Such studies typically report the subset of SNPs achieving genome wide significance 
by phenotype and discuss the similarity or difference in this subset [270] without exploring the 
wider implications of the concordance/discordance (e.g. [271]). More recently, methods have 
been developed to conduct association analysis of multiple traits in a genome-wide association 
study – a multivariate GWAS [266, 272].  The multivariate methods provide a measure of the 
shared genetic variance through a correlation analysis between genetic portions of variability 
(where significant genetic correlation indicates shared genetic variance).  While these methods 
have been demonstrated to provide greater power to detect genotype-phenotype associations 
(and pleiotropic effects) again researchers are left discussing the significant results relative to the 
univariate analyses.  Consequently, our method of comparing GWAS results is applicable to both 
historical and modern methods offering a means of interrogating the genome-wide data when 
joint analyses methods do not yield replication or pleiotropy. 
Currently, our descriptions of the moth plots are qualitative.  This method could be expanded to 
provide quantitative descriptions matching λ and ρ parameters through employing non-linear 
regression techniques to provide accurate estimates of the B and C vertices along with the co-
ordinates of the A-D intercept.  Quantification of key function parameters could potentially allow 
for the formulation of single metric parameters that would further simplify the interpretation of the 
moth plots, or the derivative metric could even replace the moth plot.  More importantly, a 
nonlinear regression may offer a way of mapping ‘significant’ differences between B and C 
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vertices to ‘significant’ differences in the mean of the study results being compared.  Currently, 
the qualitative nature of this method does not offer this link.  
The widespread use of ‘statistical significance’ as a definite measure of a scientific finding has 
degraded p-values into ‘significant’ and ‘non-significant’ categories [273]. Within this binary 
interpretation, statistical tests are generally called significant, with rejection of the null hypothesis, 
if the p-value falls below a predefined alpha value.  It is therefore implicit that any significant result 
greater than alpha is non-significant no matter how close or far away to the critical threshold. 
This binary interpretation of significance results protects against an increased prevalence of 
scientific findings that provide at best, weak evidence against the null hypothesis and 
consequently represent the consensus viewpoint of medical researchers and biostatisticians 
[274]..  While we support this perspective in the identification to disease associated variants, our 
method treats each signal (irrespective of its distance from genome wide significance) as equally 
informative and continues the idea of using p-value as a continuous measure of evidence against 
the null rather than as a binary decision rule [275-279]. 
Genome-wide association studies classically focus on the small subset of SNPs that achieve 
significance at the stringent significance level of 5e-08.  This threshold reflects traditional nominal 
significance with this p-value achieved by chance in only 5% of null genome-wide studies.  
However, many SNPs with p-values below this threshold may still be associated with the 
phenotype, when the trait is highly polygenic and the study has limited power. Other analysis 
methods use a similar genome-wide strategy to the moth plots, supporting our hypothesis that 
genome-wide information, regardless of p-value, gives valuable insights. For example, polygenic 
risk scores (PRS) combine risks across SNPs to create a measure of genetic liability for each 
individual.  These risk scores can be constructed including only genome-wide SNPs, but 
extensive experience across disorders shows that including SNPs with more liberal p-values 
increases the predictive ability of these scores.  Indeed, many studies include all SNPs in 
constructing PRS, regardless of association p-value.    
Gastrointestinal disorder (nausea, vomiting) and neutropenia are common adverse events 
associated with the use of platinum therapy in both lung cancer [280, 281] and ovarian cancer 
[98, 119] patients.  In our data, a substantial proportion of patients experienced both 
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gastrointestinal and neutropenic events across both cohorts during their treatment.  As these two 
AEs often occur in conjunction, we hypothesised that the phenotypic correlation would arise from 
an underlying genetic correlation.  We expected to find a moderate correlation in the genetic 
association signals between these two safety phenotypes.  It is therefore surprising that the 
association signals exhibited such low correlation across both cohorts of data. With the caveat 
that there is only limited power to detect SNP associations in these cohorts, we might cautiously 
interpret these results as evidence of low genetic correlation between the variants that give rise 
to each phenotype. Alternatively, as both gastrointestinal disorders and neutropenia have 
symptoms that can be managed through the use of concomitant medications it is possible that 
shared genetic architecture is being masked as not all susceptible patients are exhibiting the 
phenotype.  Of course, the simplest explanation that none of the SNPs tagged in our study are 
associated with either safety phenotype. This would explain both the lack of significant results 
and the low genetic correlation. The exome-wide genotype data for these cohorts will also have 
limited our power to detect genetic correlation, which might be detectable with full genome-wide 
genotyping.   
The low correlation between efficacy and safety association results fails to support our earlier 
hypothesis (Chapter 3) that safety and efficacy are linked. If adverse event sensitivity is conferred 
through genetic variation, then variant-carrying patients should be more likely to experience DLTs 
and consequently have poorer survival outcomes. The strongest observed genetic correlation 
was between overall survival and progression free survival, but the evidence was still low despite 
the high phenotypic correlation between the endpoints of overall survival and progression free 
survival.  Within lung cancer, very few factors ameliorate the post-progression decline in patient 
health and therefore the post-progression time to death should not vary greatly between patients.  
This means that time to progression and time to death should have similar distributions and 
therefore high correlation.  Moreover, a subset of patients will experience undetected progression 
events and their PFS time will be identical to their OS time (𝑟𝑠 = 0.800; Spearman rank Correlation 
(𝑟𝑠)of patient patients experiencing both OS and PFS events).  The low correlation between 
genetic association signals between these two intertwined phenotypes highlights the challenges 
in interpreting genetic results.  The definition of separate phenotypes is largely based upon 
historical clinical perspectives and may not be grounded in current biological perspectives.  A 
strong correlation between variants associated with OS and variants associated with PFS would 
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need to be interpreted as evidence of variant pleiotropy arising from similarity of phenotypes.  The 
low correlation observed supports the perspective that only association p-values below a 
reasonable alpha threshold can be used to assess genetic correlation.     
Despite these limitations, the moth plot may be a useful exploratory data analysis addition to the 
epidemiological toolbox, since it allows rapid, easily interpretable interrogation of 
concordance/discordance of association results. 
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Chapter 7. Sample size calculations for repeated measures 
experiments – a review 
7.1 Abstract 
Estimating the required sample size is an integral step in study design [282]. Methods to calculate 
the required sample size for cross sectional experimental designs are well understood and 
supported by widely available software [283]. However, advances in analysis methods for 
repeated measures data have left a gap between the practice of the sample size calculation 
during the planning of clinical trials and the complexity of the experimental designs and analysis 
methods most frequently employed.  In this chapter, we compile available sample size 
calculations for continuous outcomes of repeated measures data, with a baseline score and at 
least one follow-up measure collected on each participant.  We include three extensions to 
calculate the required sample size when: (1) the baseline score is part of the outcome vector, (2) 
baseline score is considered as a covariate; and (3) the analysis is based upon change from 
baseline scores.  
7.2 Introduction 
Much of medical research aims to estimate the causal relationships between interventions and 
patient outcomes. Randomised Controlled Trials (RCTs) have become one of the main tools that 
researchers use to achieve this aim [284-286].  
Cross sectional RCTs are usually set up with the objective of estimating the impact of a novel 
intervention in a sample of subjects at a single time point. By contrast, repeated measures RCTs 
track the trajectory of response (change-over-time or slope of response) to tested interventions 
by collecting multiple measurements from each subject across time.  Repeated measurement 
designs are generally considered more efficient for determining a treatment effect as compared 
with cross sectional designs; collecting repeated measurements can increase statistical power for 
a fixed number of subjects [287]. 
When setting up any RCT, one of the most critical tasks is to calculate the sample size that will 
be used for the trial [288]. This is to ensure that the planned sample is large enough to detect 
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clinically relevant differences in outcomes between comparator groups (treatment and control 
group).  A sample size that is too small leads to an underpowered study, which will have a high 
probability of failing to reject the null hypothesis, even when the intervention has a clinically 
meaningful effect.  Overpowered studies, with samples larger than required, may potentially 
expose a larger pool of individuals to an untested treatment; these studies will be more logistically 
complex, potentially take longer to complete and delay conveying important information to 
clinicians and patients [289].  Consequently, the optimal sample size for a trial is a ‘goldilocks’ 
problem that requires balancing the number of patients to ensure a sufficient number to provide 
adequate power while minimising the number of patients exposed to an inferior treatment [289, 
290]. 
Despite the gain in efficiency associated with repeated measures designs, there are several 
complications in determining the appropriate sample size.  Repeated measurements taken from 
the same subject tend to be correlated, and the correlations must be accounted for in calculating 
the sample size.  Failure to account for intra-patient correlation between the repeated 
measurement outcomes, or incorrect specification of the correlation, can result in erroneous 
sample size estimates.  For the analysis of repeated measures data, both generalised linear 
mixed-effects models and marginal models provide robust analysis tool to deal with subject 
correlation of response across repeated measures.  
There are two aspects of the intra-correlation that form part of a robust repeated measures sample 
size calculation: 1) the correlation strength, and 2) the correlation structure.  The correlation 
strength and structure among repeated measurements within a subject can be estimated from 
previous studies, a pilot study, or an educated speculation based on investigator's experience. 
A further complication to repeated measures sample size calculation is introduced by the 
parameterization of the baseline measurement.  As inclusion of the baseline as a predictor or 
response has the potential to alter the statistical efficiency of the analysis method, it should be 
accounted for in the sample size calculation.  
7.2.1 Some general notation 
To aid in the statistical discussion below it is helpful to present the notation for various aspects of 
longitudinal design.  We index the N subjects in the longitudinal study as: 
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𝑖 = 1,… ,𝑁 
 
For G+1 treatment groups, the total number of patients can be partitioned into the subset of 





For a balanced study design in which all subjects have complete data, and are measured at the 
same time points, such that all subjects have an equal number of observations, we index the 
assessment occasions as: 
𝑘 = 0,… , 𝑇 observation time points 
Such that the total number of time points is equal to 𝑇 + 1 = 𝑚.  Additionally, we use 𝑘 and 𝑙 to 
denote two separate time points. 






)  all measurements for subject 𝑖 
Such that: 







 is the overall mean  





 is the mean for group 𝑗 at time 𝑘 
7.3 Methods 
7.3.1 Pre-post designs 
A pre-post design is a repeated measures experiment in which all the subjects are measured at 
baseline (pre-treatment), and then once again at some time point after (post-treatment).  The pre-
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treatment data are intended to measure any differences that existed before the treatment 
administration while the post-treatment data are used to test if the treatment influenced the 
response variable.  In general there are three non-repeated measures methods commonly used 
to analyse pre-post data [291]:  
1) Use only the post-treatment assessment ignoring the pre-treatment responses: 
POST; 
2) Use the patient specific change scores (post-treatment minus pre-treatment): CSA; 
3) Use the baseline/pre-treatment scores as a covariate along with treatment with the 
post-treatment measurement as the response variable: ANC.  
 
Overall and Starbuck [292] and Overall [293] explored how to choose the sample size for pre-
post design experiments, with consideration for how the baseline measurement is incorporated 
into the analysis.  The sample size formulae presented in sections 7.3.1.2 and 7.3.1.3 are based 
upon their work. 
Similar to cross sectional studies, we need the following information to obtain sample size 
estimates for pre-post repeated measurement studies: 
1) The type I error (𝛼) 
2) The power (1 − 𝛽) 
3) The clinically meaningful difference between two treatment groups estimated as the 
difference between group means at the post-baseline measurement (𝜇11 − 𝜇01). Where 
𝜇01 and 𝜇11 represent the means at the post-treatment measurement for the control (0) 
and active (1) treatment groups respectively. 
4) The variance of the post-baseline responses (𝜎2) 
 
Additionally, due to the repeated measures aspect, depending on how the baseline measurement 
is used, pre-post sample sizes also make use of: 
5) The correlation between pre-treatment and post-treatment responses across both 
treatment groups (𝜌) 
 
7.3.1.1 POST  
In a randomised clinical trial, pre-treatment means are expected to be approximately equal across 
treatment arms.  Consequently, the baseline measurement is often ignored and the mean 
difference between treatment groups at the post-treatment measurement can be used to compare 
the treatment effect [291] using a two-sample mean test. 
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For this type of analysis, the sample size required for a given level of alpha and power is estimated 













 and 𝑧1−𝛽 are the 100 (1 −
𝛼
2
) 𝑡ℎ and 100(1 − 𝛽)𝑡ℎ percentiles of the standard normal 
distribution, n is the sample size per group.  Equation (7.3.1) can be rearranged to solve for power 
given a fixed sample size: 













While it is reasonable to assume that pre-treatment / baseline values will be balanced, chance 
variation can often result in some doubt concerning the true treatment effect and it is therefore 
not uncommon that investigators will use the change from baseline as the outcome of primary 
interest on which to compare treatment groups. 
The sample size for testing the difference in change scores between two treatment groups can 
be obtained using the means at the post-treatment (𝜇11 − 𝜇01), the common error variance (𝜎
2) 
estimated from either the baseline or final assessment time point, and the pre-post assessment 
correlation (𝜌).  Owing to the regression-to-the-mean phenomenon [296, 297], the variance of the 
difference score between the first and the last measurements can be written as [295]: 
 𝜎𝐶𝑆𝐴






















Equation (7.3.4) shows that the sample size for testing difference scores between two treatment 
groups is equal to that for testing the significance between the raw post-treatment scores 
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multiplied by 2(1 − 𝜌).  This means that when the correlation between pre- and post-
measurements is less than 0.5, the use of change scores will result in an inflated sample size as 
compared with using the raw post-treatment scores.  Conversely, when the correlation between 
pre- and post- measurement is greater than 0.5, the use of change scores will give greater power 
for a fixed sample size than using the raw post-treatment scores. 















Entering the baseline score as a covariate to adjust for baseline differences is frequently heralded 
as the gold standard for the analysis of repeated measures data.  The inclusion of baseline score 
as a covariate can also be applied to difference score analysis.  Both cases will yield identical 
results.  If 𝜌 is the correlation between pre-treatment and post-treatment assessment time points 
then the proportion of variance accounted for by the baseline covariate is equal to 𝜌2.  The error 
variance remaining after removing the variance associated with the pre-treatment score is 
therefore [295]: 
 𝜎𝐴𝑁𝐶
2 = (1 − 𝜌2)𝜎2 
(7.3.6) 
Where 𝜎2 is the common within subject variance.  The sample size estimate per group for testing 



















Equation (7.3.7) shows that the sample size for testing either the post-treatment means or 
difference scores between two treatment groups, after adjusting for baseline, is equal to that for 
testing the significance between the raw post-treatment scores multiplied by (1 − 𝜌2).  The 
adjustment that is made is the correlation between the covariate and the response variable [288].  
Therefore, for any value of 𝜌 > 0, adjusting for baseline will result in greater power for a fixed 
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sample size as compared with analysing only the raw post-treatment measurements.  Similarly, 
inclusion of the baseline as a covariate will result in greater power for a fixed sample size as 
compared with the analysing the change scores for any value of 𝜌 < 1. 
Overall and Starbuck provide a detailed discussion on the differences between including or 
excluding baseline as a covariate in the analysis of change scores.  Within this discussion they 














Equation (7.3.8) can be interpreted as: the sample size for testing difference scores between two 
treatment groups without baseline score adjustment is equal to that for testing the significance of 
the difference between treatment groups with baseline score adjustment multiplied by 2/(1 + 𝜌).  
This means that for all values of 𝜌 < 1, for a fixed level of power, the required sample size when 
using baseline as covariate will be less than the sample size required if change scores are used 
to analyse the data.  Interestingly the formula also indicates that when the correlation between 
the pre- and post-measurements is zero, using baseline as covariate offers almost twice the 
efficiency of analysing the data using change scores.  
Rearrangement of equation (7.3.7) yields the power calculation for a fixed sample size using the 
baseline as a covariate: 









 (7.3.9)  
 
7.3.2 Multi-follow-up repeated measures (beyond pre-post) 
We use the term multi-follow-up repeated measures to describe a repeated measures experiment 
in which patients are assessed at baseline, randomised, and then undergo more than one 
assessment during the treatment period.  Overall and Doyle (1994) provided sample size formulas 
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for repeated measurement designs and Overall (1996) used simulation to examine the effects of 
different sample sizes.  The equations presented below are adapted from their work. 
Sample size calculations of multi-follow-up experiments require inputs that differentiate them from 
the sample size methods for pre-post studies, namely: 
(1) the contrast vector appropriate for the hypothesis being examined (𝑎) (see section 
7.3.2.1) 
(2) the mean difference between treatment groups can no longer be represented by a 
single value and instead the difference between treatment groups at each time point, is 
quantified with a vector (𝑑) 
(3) the intra-subject correlation matrix for the repeated measurements (𝐶) 
 
7.3.2.1 Orthogonal polynomial contrasts 
Researchers examining repeated measures RCT data might be interested in whether the 
response pattern across time is linear, quadratic, cubic, and so on.  The treatment difference 
across time will then be analysed based upon the observed pattern of response, i.e. whether 
treatments differ with regard to linear, quadratic or cubic trend.  This treatment comparison is 
achieved using orthogonal polynomial components for time.  Within the context of repeated 
measures experiments, the phrase orthogonal polynomial refers to a coding of time such that 
polynomial components are statistically independent of one another.  In the special case of a 
linear trend over time, the slope of the regression line appropriately summarises the rate of 
change of outcomes over time.  Again assuming a linear trend over time, the difference in 
longitudinal rates of change (slopes) between treatment groups is captured by the interaction 
between the treatment and time from the model estimates [298]. For each subject, rates of change 
or trends can be constructed by applying appropriately chosen weighting coefficients to the 
repeated measurements.  Table 7.3.1 presents the orthogonal contrast coefficients across a 
range of m used to explore whether the rates of changes across time are the same among 
treatment groups or whether there is no significant interaction effect between time and treatment 
group.
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(𝒎 = 𝑻+ 𝟏) 








 𝑘 = 0 𝑘 = 1 𝑘 = 2 𝑘 = 3 𝑘 = 4 𝑘 = 5   
2 -1 +1     0 2 
3 -1 0 +1    0 2 
4 -3 -1 +1 3   0 20 
5 -2 -1 0 +1 +2  0 10 
6 -5 -3 -1 +1 +3 +5 0 70 
 
Sample size estimates for testing a difference in the rates of change can be obtained by using 
linear trend scores that are constructed by applying linear orthogonal polynomial coefficients to 
the repeated measurements.  The linear orthogonal polynomial coefficients are also called linear 
contrast coefficients.  The linear orthogonal polynomial coefficients (𝑎𝑗) are equally spaced, and 
sum to zero: 




The difference between linear trend means for two treatment groups can be calculated by 
applying the linearly weighted coefficients to the differences between treatment means at each 
measurement time point: 






Where 𝑑𝑘 is the difference between treatment means at the 𝑘
𝑡ℎ (𝑘 = 0,… , 𝑇) measurement time, 
which is equivalent to the difference in the observed means for treatment groups 1 (𝜇1𝑘) and 0 
(𝜇0𝑘) at the  𝑘
𝑡ℎ measurement time.   
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7.3.2.2 Correlation structures 
The correlation matrix (𝐶) describes the variance adjusted covariance matrix for patient errors 
(𝑒) across the assessment time points.  That is the vector 𝑒𝑖𝑗𝑘, defined as 𝑒𝑖𝑗𝑘
′ = (𝑒𝑖𝑗0,𝑒𝑖𝑗1,…,𝑒𝑖𝑗𝑇) is 
assumed to be multivariate normal, 𝑀𝑉𝑁(0, 𝑅), where 𝑅 is the covariance matrix amongst the 𝑒𝑖𝑗𝑘 
within the 𝑖𝑡ℎ subject. 
Three common covariance models for correlated errors are: 
Independent errors 𝑅 = Iσ2 
Compound Symmetry (CS) 𝑅𝑖 = 𝜎
2𝐶 = 𝜎2 [
1 𝜌 ⋯ 𝜌
𝜌 1 ⋯ 𝜌
⋮ ⋮ ⋱ ⋮
𝜌 𝜌 ⋯ 1
] 






1 𝜌 ⋯ 𝜌𝑇−1
𝜌 1 ⋯ 𝜌𝑇−2
⋮ ⋮ ⋱ ⋮





Unstructured (UN) 𝑅𝑖 = 𝜎
2𝐶 = 𝜎2 [
1 𝜌01 ⋯ 𝜌0𝑇
𝜌10 1 ⋯ 𝜌1𝑇
⋮ ⋮ ⋱ ⋮
𝜌𝑇0 𝜌𝑇1 ⋯ 1
] 
 
Where 𝜌𝑘𝑙 = 𝑐𝑜𝑟𝑟(𝑌𝑖𝑘, 𝑌𝑖𝑙) for the 𝑖
𝑡ℎ subject at times 𝑘 and 𝑙. Note that the diagonal elements of 
the correlation matrix will be 1 (since they are the correlation of a time point with itself). The 
correlation matrix is also symmetric since the correlation of time point 𝑘 with timepoint 𝑙 is 
represented twice in the correlation matrix (once with 𝑘 as the row and 𝑙 as the column and again 
with 𝑘 as the column and 𝑙 as the row); i.e. 𝜌𝑇0 = 𝜌0𝑇. 
The independent structure assumes that there is no correlation between the errors across 
observation time-points.  The AR(1) correlation structure assumes an exponentially decaying 
pattern of correlation according to the temporal distance between the repeated measurements 
(i.e. the correlation between baseline and early assessment time points is greater than the 
correlation between baseline and the final assessment time point) [299].  By contrast, the CS 
correlation structure assumes a constant correlation between two distinct measurements 
regardless of temporal distance (i.e. the correlation between baseline and the first assessment 
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time point is the same as the correlation between baseline and the last assessment time point).  
The unstructured covariance matrix assumes no temporal pattern to the correlation structure.  
The sample size for the multi-follow-up design can then be calculated, using the following 6 pieces 
of information: 
1) The type I error (𝛼) 
2) The power (1 − 𝛽) 
3) The variance of the post-baseline responses (𝜎2) 
4) A contrast vector appropriate for the hypothesis being examined (𝑎), as presented in 
Table 7.3.1 
5) A vector of the expected mean difference between treatment groups at each time point 
(𝑑) 
6) And the intra-subject correlation matrix for the repeated measurements (𝐶) 
 
In general, there are three repeated measures methods commonly used to analyse multi-follow-
up repeated measures data:  
1) Use both the pre-treatment assessment response and all post-treatment assessments 
in the response vector: RMA; 
2) Use the patient specific change scores (each post-treatment assessment minus pre-
treatment): CSA;  
3) Use the baseline/pre-treatment scores as a covariate in the analysis of post-treatment 
measurements: ANC.  
 
Below we present sample size formula for multi-follow-up designs for the RMA, CSA and ANC 
baseline analysis methods [300, 301]. 
7.3.2.3 RMA 
The sample size for testing a difference in the rates of change between two treatment groups 







Where 𝑎 is the vector of linearly increasing time coefficients for example, 𝑎′ = (−1,0,1) for a 
design in which 𝑚 = 3, 𝐶−1 is the inverse of the intra-subject correlation matrix of the repeated 
measurements, and 𝑑 is the vector of differences between treatment group means across 
assessment time points.   
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Rearrangement of equation (7.3.12) yields the power calculation for a fixed sample size using the 














The linear trend scores are not generally independent of baseline values like simple pre-post 
difference scores.  Therefore, the ANCOVA can be used to correct for dependence of linear trend 
scores on baseline differences as in the case of simple pre-post difference scores.  
The correlation between the baseline measure and a weighted combination of repeated measures 












Where 𝜌𝑘0 is the 𝑘
𝑡ℎ element in the first column of the correlation matrix between repeated 
measurements, with the diagonal elements 𝜌𝑘𝑙 = 1. 
Within the context of GLS the correlation between baseline scores and the slope of repeated 






Where 𝑎(1) = [1,0,… ,0], a vector of length 𝑚 with the first entry (for baseline) equal to 1 and all 
remaining elements equal to zero. 
Therefore, the sample size per group for testing the difference in linear trends with baseline 
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Currently within the literature is no generic formulate developed for calculation of sample size for 
a multi-follow-up change score analysis.  This likely relates to the fact that calculation of change 
scores potentially alters the correlation strength and structure, resulting in a discordance between 
the correlation matrix of raw scores and the correlation matrix of change scores.   
Let 𝑦0 represent the baseline measurement, and 𝑦𝑘 and 𝑦𝑙 represent the responses at two post 
baseline measurements with 𝑘 ≠ 𝑙 . 
The correlation between the two change from baseline scores 𝑦𝑘 − 𝑦0 and   𝑦𝑙 − 𝑦0 is given by 
[302]: 
 
𝐶𝑜𝑟𝑟(𝑦𝑙 − 𝑦0, 𝑦𝑘 − 𝑦0)
=











To illustrate the disruption of the correlation matrix let us assume a hypothetical trial in which 𝑚 =







The discordance between raw and change scores is easily illustrated if we assume that there is 
zero correlation between 𝑦0, 𝑦1 and 𝑦2 and to simplify let us assume that 𝜎𝑦0 = 𝜎𝑦𝑘 = 𝜎𝑦𝑙 = 1 
𝐶𝑜𝑟𝑟(𝑦𝑙 − 𝑦0, 𝑦𝑘 − 𝑦0) = 𝜌𝑙−0,𝑘−0 =
𝜌𝑘𝑙 − 𝜌𝑘0 − 𝜌𝑙0 + 1
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This simple example shows that for any compound symmetry correlation structure (including the 
absence of correlation between response time points), the correlation of the change scores will 
be equal to 0.5.  This specific correlation strength and structure is harder to predict when the 
correlation structure of the raw scores is complex (i.e. autoregressive or unstructured).   Equation 
(7.3.18) reveals that the correlation matrix of change scores will not match the correlation of raw 
scores and this added complexity is likely the reason that a generic sample size formula for multi-
follow-up using change scores has not been developed. 
7.4 Discussion 
Determining the sample size in repeated measures designs is complicated by the need to 
estimate the correlation of repeated measurements taken from the same subject.  Furthermore, 
the use of the baseline measurement in the analysis of repeated measures data further 
complicates sample size estimation process.  This review illustrates different uses of the baseline 
measurement in computing power for both pre-post and multi-follow-up repeated measures 
experimental designs.  
The formulae presented show a clear distinction between methods of sample size for pre-post 
designs and multi-follow-up designs.  When there are only two measurements, a pre-post design, 
change score analysis is less efficient than analysing only the post-treatment measurements if 
the correlation between the baseline score and endpoint score is less than 0.5 [303].  Using the 
baseline as a covariate in the analysis of post-treatment measurements is more efficient than 
either the change scores, or post-treatment only analyses across all values of correlation are 
greater than zero.  
For the analysis of multi-follow-up data, it is not clear if the use of change scores, or baseline as 
a covariate offers an efficiency gain over retaining the baseline measurement as part of the 
response vector.  This is because 1) removal of the baseline response, either by inclusion as a 
covariate (ANC) and or through the calculation of change scores (CSA) will reduce the dimensions 
of the correlation matrix as compared with analyses that keep the baseline as a response; and 2) 
using change scores will alter the correlation structure as compared with the raw scores.  The 
impact of these two features will likely depend on the correlation structure of the raw scores.  
Previous researchers have demonstrated that the required sample size always decreases as the 
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number of measurements per subject increases under the compound symmetry (CS) correlation 
[299].  By contrast, making additional measurements from each subject may increase required 
sample size under AR(1) correlation structure [299, 301, 304].  
In the next chapter, I will assess the relative efficiency of these baseline analysis approaches 
needs for various correlation structures within the multi-follow-up setting. 
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Chapter 8. Sample size calculations for repeated measures 
longitudinal studies 
8.1 Abstract 
This chapter explores the basic factors that determine an appropriate sample size by contrasting 
methods for its calculation incorporating intra-patient correlation of response data.  We found that 
the number of study assessment time points, level of intra-patient correlation and correlation 
structure all influence the required number of subjects to maintain a fixed type-I and type-II error 
rate.  There is no reduction in sample size associated with moving from a study with a single 
follow-up time point (pre-post design) to a study with baseline and two follow-up measures; 
however further increases in the number of post-baseline patient assessments reduces the 
required number of subjects to achieve statistical power.  Failure to account for the correlation 
and the use of sample size methods that focus only on the mean treatment difference at the end 
of the trial may result in a large over-estimate of the required number of subjects per treatment 
group and consequently may result in a gross misallocation of trial resources.   
8.2 Introduction 
Clinical trials often use parallel-group longitudinal designs in which patients are randomly 
assigned between treatment groups, evaluated at baseline, administered with the intervention(s) 
being examined and then evaluated again at intervals across a treatment/follow-up period of fixed 
duration [305]. Such trial designs yield multiple or ‘repeated’ measurements on each subject [297, 
306].  There are two distinct advantages to longitudinal trials as compared with a cross sectional 
design: 1) control for baseline imbalances [307, 308] and 2) increased power for a fixed sample 
size [303, 309].  The hypothesis of primary interest is usually the difference between treatment 
groups in both the pattern and magnitude of change from baseline with respect to the primary 
endpoint.  It follows that the analysis methods employed to the data collected from such a trial 
would aim to elucidate the difference between treatment groups with respect to the average rate 
of change measured from the slopes of the regression lines fitted to the mean response patterns.  
A critical step in planning such a clinical trial is determining the sample size that will detect an 
effect of a given magnitude, or to estimate the power with which effect of particular magnitude 
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can be detected given a fixed sample size [310, 311].  A sample size insufficient for the effect 
size will result in reduced power to detect a clinically meaningful difference.  Conversely, an 
inflated sample size potentially exposes patients to inferior treatments.  Both insufficient and 
inflated sample sizes represent trial inefficiency and a waste of resources, for this reason accurate 
estimation of required sample size remains paramount in trial design [312, 313]. 
When the outcome variable is measured only once for each experimental unit (subject), methods 
for determining power and sample size are well-established and relatively straight forward to 
calculate [314]. By contrast, when a repeated measures experimental design is employed the 
estimation of the appropriate sample size is complicated by estimation of the structure and 
strength of the within patient correlation of repeated measurements [292]. Typically, there is little 
to no information on these additional parameters at the time of study planning [315] and the 
assumptions used in the sample size calculation are little more than guesses.  The consequences 
of under- or over-estimating the intra-patient correlation of responses are complicated, and will 
likely depend on both the effect size and number of repeated measurements. 
In this chapter, we contrast methods for calculating sample size for studies with repeated 
measurements of normally distributed continuous responses.  We consider a range of post 
baseline assessment time points and intra-patient response correlation and two alternate 
correlation structures.  In addition to examining the specific sample size requirements we consider 
the implications of incorrectly assuming a given correlation structure.  The methods and results 
have direct implications for the design of clinical trials. 
8.3 Methods 
8.3.1 Notation 
We will continue with the notation outlined in section 7.2.1.  Additionally, we use 𝐷𝑘 to denote the 
difference between group means at time point k, i.e 𝐷𝑇 is the difference between group means at 
the final assessment time point:  
(𝐷𝑇 = 𝜇1𝑇 − 𝜇0𝑇) 
Increasing the number of repeated measurements within a trial can result in following patients for 
a longer time or more frequent assessment within a fixed observation (T).  The latter is the 
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perspective used throughout our work: that is, in moving from 𝑚 = 2 → 𝑚 = 3 → ⋯ → 𝑚 = ∞, 
both the difference between groups at the final assessment time point (𝜇1𝑇 − 𝜇0𝑇 = 𝐷𝑇) and the 
correlation between baseline and the final assessment time point (𝜌0,𝑇) remains equal irrespective 
of the number of patient assessments (Figure 8.3.1).  This has two important consequences: 
firstly, the interval of time between assessment time points must decrease with increasing 𝑚  or 
the slope of each treatment arm would decrease, and secondly, we cannot explore baseline 
imbalance in these calculations and keep 𝐷𝑇 constant.      
Lastly, we define the slopes of each treatment arm as: 
 
 
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 ∶ 𝑆𝑙𝑜𝑝𝑒0 = 
𝜇0𝑇 − 𝜇00
𝑇





And the difference in slopes between treatment arms is: 𝑆𝑙𝑜𝑝𝑒1 − 𝑆𝑙𝑜𝑝𝑒0 = ∆.  For the reasons 
mentioned previously, we fix the intercept at 0 for both treatment arms:  
 















 𝑆𝑙𝑜𝑝𝑒1 − 𝑆𝑙𝑜𝑝𝑒0 = 𝜇1𝑇 − 𝜇0𝑇 = 𝐷𝑇 = ∆ (8.3.3) 
 
 
   




Figure 8.3.1 Hypothetical trial scenarios. 
m:2 has only has one follow-up measurement, m:3 and m:4 have two and three follow-up 
measurements respectively.  Each panel has the same initial difference (𝐷0), final difference (𝐷𝑇) 
for the treatment groups.  The treatment specific slopes (𝑆𝑗) are calculated from 𝑆𝑗 =
(𝜇𝑗𝑇 − 𝜇𝑗0) 𝑇⁄ .  Consequently, by reducing the interval between assessments, more frequent 
follow-up, the treatment specific slopes remain constant across panels. 
 
8.3.2 Sample size equations 
8.3.2.1 Two sample t-test 
The equation for estimation of the sample size required for adequate power in testing the 
significance of difference between means is given by [294, 313]: 
 𝑛 =






Where 𝜎2is the common variance in the comparator groups, 𝑧1−𝛼 2⁄  is percentile of the standard 
normal distribution corresponding to the desired alpha level (the Z score beyond which the smaller 
area under the normal curve is equal to α for a one-sided test or α/2 for a two-sided test) and  
𝑧1−𝛽 is percentile of the standard normal distribution corresponding to the desired power.  
Hereafter we refer to Equation (8.3.4) as the TT method (derived from its use in calculating the 
sample size used in t-tests). 
8.3.2.2 Repeated measures sample size 
In the case of repeated measurements, the equation for estimation of the sample size required 
for adequate power in testing the significance of difference between means is given by [300, 313]: 
   














The numerator (𝜑𝑐) is a quantity describing the contrast weighted difference in means between 
comparator groups at a particular time point: 





The denominator (𝜎𝑐) is a combination of the sum of contrast weighted common variance at each 
time point and the sum of each distinct time point pair combination (i.e. time points 𝑘 and 𝑙, where 












Hereafter we refer to equations (8.3.5) as the OD method, abbreviated from the authors initials. 
8.3.2.2.1 Contrast coefficients 
A repeated measures design examining only the effect of treatment over time results in one 
repeated ‘within-subject’ fixed factor – time, one ‘between-subjects’ factor – treatment and the 
cross of the ‘within-subject’ and ‘between-subject’ factors.  This yields three separate null 
hypotheses relating to each factor and the cross of factors.  The general omnibus test from an 
ANOVA only tells you if one or more of these null hypotheses has been rejected, but does not 
inform you of which specific hypotheses.  Orthogonal contrasts allow the total sum of squares 
(SST) to be partitioned (i.e. decompose from the uninformative H0 of the omnibus ANOVA) into 
meaningful and targeted comparisons of the treatment means at each time point, or one for each 
contrast: 
 𝑆𝑆𝑇𝑜𝑡𝑎𝑙 = 𝑆𝑆𝑐o𝑛𝑡𝑟𝑎𝑠𝑡1 + 𝑆𝑆𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡2…+ 𝑆𝑆𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡𝑖   (8.3.9) 
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This partitioning of SST among its degrees of freedom is a consequence of the orthogonality of 
the contrasts.  The contrast coefficients are obtained by orthogonal polynomial coefficients to the 
repeated measurements.  Table 7.3.1 in the previous section presents the linear coefficients for 
equally spaced assessment time point.  Of note, the sum of all contrast coefficients squared is 
always equal to the negative of twice the sum of each contrast coefficient multiplied by the 









8.3.2.3 Covariance structures 
The covariance between the responses between two time points - 𝜎𝑘𝑙 is a function of the variance 
and correlation.  Often there is a trend or pattern in the correlation between response time points 
which yields a variance/covariance structure (hereafter called simply the covariance structure).  
Two common covariance structures often encountered in medical data are compound symmetry 
(CS) and autoregressive (AR(1) – hereafter referred to as AR).  CS correlation structure assumes 
a uniform correlation positive correlation between all assessment time points while the AR 
correlation structure assumes that the correlation between responses on the same patient decay 
towards zero as the time separation between the responses increases (see section 0).   
8.3.3 Parameters examined 
In repeated measures linear regression, the variable of interest is usually the treatment difference 
in the change from baseline – i.e. the difference in slopes between treatment arms (∆).  
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Table 8.3.1 Parameters used in sample size calculations 
 
Table 8.3.1 lists the values of parameters used in each of the sample size methods.  We 
considered three alternate values for the effect size (∆): 0.1, 0.25 and 0.5.  The correlation 
coefficient ranged between 0 and 0.75 in increments of 0.25.  Five different number of assessment 
time points (𝑚) were considered: 2- 6. 
Therefore, design parameters covered 120 different situations: 5 (number of repeated measures) 
x 3 (values of the slope difference) × 4 (values of correlation strength) ×2 (correlation structures).   
For each of the 120 different trial scenarios we calculated the required sample size per group 
using the TT method (8.3.4) and again using the OD method (8.3.5).  For both sample size 
calculations, the value of the intercept was fixed at 0 and the variance (𝜎2) was chosen to be 1 
at all 𝑚 time points.  Consequently, each examined effect size can be thought of as a Cohen’s-D 
effect size.  Alpha was set at 0.05 and beta at 0.2, corresponding to conventional design 
parameters of 5% Type-I error and 80% power.   
8.4 Results 
8.4.1 Sample size estimation 
Table 8.4.1 shows the required sample size  given various numbers of assessments (𝑚) effect 
sizes (∆), correlation strengths (𝜌0,𝑇) and correlation structures (AR(1) and CS) assuming 𝛽 = 0.2 
(80% power) and 𝛼 = 0.05 (5% Type-I error).  The ‘TT method’ column provides the sample size 
calculation using (8.3.4), and is based only on the difference between treatment group means at 
Number of Assessment 
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the final assessment time point (𝑚 − 1).  Consequently, for a fixed α and power, the estimated 
sample size (𝑛) is insensitive to changes in the number of assessment time points (𝑚), intra-
patient correlation strength (𝜌0,𝑚−1) and correlation structure.  The autoregressive(1) columns 
display the required sample size calculated using equation (8.3.5) across alternate correlation 
strengths assuming an AR(1) correlation structure.  Similarly, the compound symmetry columns 
display the required sample size per group calculated using equation (8.3.5) across alternate 
correlation strengths assuming a CS structure.  
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Table 8.4.1 Sample sizes for various combinations of effect size (∆) and assessment time points. 
  Correlations between the baseline and final assessment time point are 0, 0.25, and 0.75.  Results were calculated assuming both an AR(1) and CS correlation 
structure.  The TT method refers to the required sample size calculated using only the difference between group treatment means at the final patient assessment 








Autoregressive(1) Compound Symmetry 
Correlation Strength (𝝆𝟎,𝑻) 
0 0.25 0.5 0.75 0 0.25 0.5 0.75 
2 
0.1 1570 1178 785 393 1570 1178 785 393 1570 
0.25 252 189 126 63 252 189 126 63 252 
0.5 63 48 32 16 63 48 32 16 63 
3 
0.1 1570 1178 785 393 1570 1178 785 393 1570 
0.25 252 189 126 63 252 189 126 63 252 
0.5 63 48 32 16 63 48 32 16 63 
4 
0.1 1413 1204 804 402 1413 1060 707 354 1570 
0.25 227 193 129 65 227 170 114 57 252 
0.5 57 49 33 17 57 43 29 15 63 
5 
0.1 1256 1235 824 411 1256 942 628 314 1570 
0.25 201 198 132 66 201 151 101 51 252 
0.5 51 50 33 17 51 38 26 13 63 
6 
0.1 1122 1263 841 418 1122 841 561 281 1570 
0.25 180 202 135 67 180 135 90 45 252 
0.5 45 51 34 17 45 34 23 12 63 
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Figure 8.4.1 provides a graphical representation of the information contained within Table 8.4.1.  Both 
the table and figure show that larger effect sizes require smaller sample sizes across all three sample 
size calculation methods.  When the correlation structure is compound symmetry (CS) the reduction is 
sample size is directly proportional to the increase in correlation.  Using the derivation of 𝜎𝑐
2 from (8.3.8), 




























































= 1 − 1𝜎𝑘𝑙 
This means that each percentage increase in correlation is matched with a percent decrease in sample 
size irrespective of the number of time points.  When the correlation structure is autoregressive, the 
effect upon sample size is less obvious.  Increasing the intra-patient correlation and number of repeated 
measures can reduce the required sample size, however, the effects of each are not consistent.  We 
draw attention to two distinct features of Figure 8.4.1: 
1) There is no difference in the estimated sample size from associated with increasing the 
number of repeated measures from 2 to 3 (m=2 →m=3) 
2) For AR(1), data the change in sample size between 𝜌=0 →𝜌=0.25 is always less than the 
reduction in sample size associated with 𝜌 changing between 0.25 →1  
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(∑ 𝑐𝑘(𝜇0𝑘 − 𝜇1𝑘))
𝑚−1
𝑘=0
2  (8.4.1) 
 












   




Figure 8.4.1 Relationship between sample size and correlation strength across alternate effect size and number of repeated measures. 
TT presents the estimated sample size using the mean difference between treatment groups at the final assessment time point.  Both AR(1) and CS use the 
repeated measures sample size calculation assuming AR(1) and CS correlation structures.
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The numerator represents the multiplication of the contrast coefficients and covariance between 
alternate time points.  The denominator is the contrast coefficient for a given time point multiplied by 
the treatment mean difference at that time point.  Table 7.3.1 shows that the baseline (𝑘 = 0) and final 
(𝑘 = 𝑇) contrast coefficients are -1 and 1 respectively for both 𝑚 = 2 and 𝑚 = 3.  For a fixed ∆, the 
group mean difference both at baseline and final assessment will be the same for 𝑚 = 2 and 𝑚 = 3, 
then these quantities will be the same.  The addition of a 0 contrast coefficient will not add to either the 
numerator or the denominator of equation (8.3.7) and hence it stands to reason that the estimated 
sample size for 𝑚 = 2 and 𝑚 = 3 are equal. 
The second phenomenon relates to the observed correlation in AR(1) structures.  Table 8.4.2 shows 
the covariance matrix for AR(1) with 6 time points for 𝜌0,𝑚−1=0, 𝜌0,𝑚−1=0.25 and 𝜌0,𝑚−1=0.5. 
Table 8.4.2 Covariance matrices for AR(1) for 𝜌0,𝑚−1 = 0, 0.25 and 0.5 







1 0 0 0 0 0
0 1 0 0 0 0
0 0 1 0 0 0
0 0 0 1 0 0
0 0 0 0 1 0













1 0.76 0.57 0.44 0.33 0.25
0.76 1 0.76 0.57 0.44 0.33
0.57 0.76 1 0.76 0.57 0.44
0.44 0.57 0.76 1 0.76 0.57
0.33 0.44 0.57 0.76 1 0.76













1 0.87 0.76 0.66 0.57 0.50
0.87 1 0.87 0.76 0.66 0.57
0.76 0.87 1 0.87 0.76 0.66
0.66 0.76 0.87 1 0.87 0.76
0.57 0.66 0.76 0.87 1 0.87








For lower correlation values between the first and last time point, the disparity between the earlier and 
later time point correlation strengths is greater.  As the earlier time points contribute more to the 




𝑘=0  quantity is 
increased at low correlation, which results in an inflation of the required sample size to achieve a given 
level of power.  Further increases in the correlation strength between the first and last time point have 




𝑘=0  (Table 8.4.3) and consequently the required sample size 
to achieve a given level of power is decreased. 
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0 70.00 70.00 
0.25 52.50 78.81 
0.5 35.00 52.47 
0.75 17.50 26.08 
 
8.4.2 Inflation of the sample size 
Table 8.4.4 shows the ratio of the sample size calculated from the TT method relative to the sample 
size calculated using the repeated measures OD method.  A value of one indicates that both the sample 
size based upon the final group mean difference (TT method) is the same as the estimated sample size 
using the repeated measures formula (OD method); a value of 2 indicates that the sample size 
calculated based upon the final difference in groups means is twice the required sample size achieve 
80% power estimated from the repeated measure formula.  Hence, values above 1 represent the 
inefficiency using the TT method to calculate the sample size.  Under all examined conditions the 
estimated sample size using OD the method (8.3.5) is less than or equal to the required sample size 
estimated from the TT method (8.3.4).  The inefficiency of using (8.3.4) to estimate the sample size is 
exacerbated by both intra-patient correlation and increasing the number of assessment time points.  
The TT method and OD method estimate similar sample size requirements when the intra-patient 
correlation is zero and there are less than 4 patient assessments.  In an experiment with baseline and 
5 follow-up assessments, if the true intra-patient correlation and correlation structure are 0.75 and 
compound symmetry, then the indicated sample size calculated based upon only the final group mean 
difference would be ~5 times the sample size required to provide 80% power. 
   









Autoregressive(1) Compound Symmetry 
Correlation Strength 
0 0.25 0.5 0.75 0 0.25 0.5 0.75 
2 
0.1 1.00 1.33 2.00 3.99 1.00 1.33 2.00 3.99 
0.25 1.00 1.33 2.00 4.00 1.00 1.33 2.00 4.00 
0.5 1.00 1.31 1.97 3.94 1.00 1.31 1.97 3.94 
3 
0.1 1.00 1.33 2.00 3.99 1.00 1.33 2.00 3.99 
0.25 1.00 1.33 2.00 4.00 1.00 1.33 2.00 4.00 
0.5 1.00 1.31 1.97 3.94 1.00 1.31 1.97 3.94 
4 
0.1 1.11 1.30 1.95 3.91 1.11 1.48 2.22 4.44 
0.25 1.11 1.31 1.95 3.88 1.11 1.48 2.21 4.42 
0.5 1.11 1.29 1.91 3.71 1.11 1.47 2.17 4.20 
5 
0.1 1.25 1.27 1.91 3.82 1.25 1.67 2.50 5.00 
0.25 1.25 1.27 1.91 3.82 1.25 1.67 2.50 4.94 
0.5 1.24 1.26 1.91 3.71 1.24 1.66 2.42 4.85 
6 
0.1 1.40 1.24 1.87 3.76 1.40 1.87 2.80 5.59 
0.25 1.40 1.25 1.87 3.76 1.40 1.87 2.80 5.60 
0.5 1.40 1.24 1.85 3.71 1.40 1.85 2.74 5.25 
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8.4.3 The consequence of correlation structure misspecification 
As previously presented in equation (7.3.13), the power for a fixed sample size can be obtained by 













Where 𝑎 is the vector of increasing contrast coefficients presented in Table 7.3.1,  i.e. 𝑎′ =
[−3 −1 1 3] for 𝑚 = 4, 𝐶−1 is the inverse of the intra-subject correlation matrix of repeated 
measurements and 𝑑 is the vector of group mean differences at each time point i.e. 𝑑 =
[0 0.083 0.167 0.25] for ∆= 0.25.   
Figure 8.4.2 presents the power calculations using the sample size estimated by correlation structure 
misspecification, that is the power that you would have if you estimated your sample size assuming CS 
structure when in actuality the true intra-patient correlation structure was AR(1) (and vice versa).  These 
were calculated using the sample size estimates from Table 8.4.1 and equation (7.3.13).  The full results 
of these calculations are presented in Appendix D. 
The results show that for a fixed ∆ and 𝜌0,𝑚−1 > 0, the loss or gain in power association with 
misspecification is primarily a function of the number of assessment time points.  Misspecification of 
AR(1) structure as CS at the time of sample size calculation results in a reduction of power proportional 
to the number of patient assessments.  By contrast, misspecification of CS structure as AR(1) during 
the sample size estimation will result in increased power beyond 80%.  
   




Figure 8.4.2 Power calculations under correlation structure misspecification. 
The AR(1) column present the power calculation results using the sample size estimation assuming CS 
structure and the CS column presents the power calculation using the sample size estimation assuming 
AR(1) structure.  Misspecification of the correlation structure results in a loss of power when there is an 
assumed CS correlation structure and an ‘actual’ AR(1) correlation structure.  Conversely, 
misspecification results in a power gain when the assumed correlation structure is AR(1) and the true 
correlation structure is CS.  The gain or loss in power is largely insensitive to correlation strength beyond 




   




One of the most important aspects in clinical research design is the sample size estimation [295, 
316].  Despite the wealth of literature regarding the need for trials to employ appropriate sample 
size calculations, sample size and statistical power remain relevant topics for biostatisticians 
today.  Statistical inference of a trial relies upon an appropriate sample size in order to derive 
precise, accurate and robust conclusions.  Presumably for this reason, the British Medical Journal 
and the regulatory authorities, including the FDA and the Committee for Proprietary Medicinal 
Products (CPMP 1995) in the EU, all require a justification on the planned study size [317].  Their 
reasons are captured in the guidelines of the international conference on harmonisation (ICH E9):  
essentially – if too few subjects are involved the study is potentially a misuse of time as realistic 
medical differences are unlikely to be distinguished from chance variation.  Too large a study can 
be a waste of resources and in addition it is unethical to exposure patients to inferior medicine 
[318]. 
In the design of a randomised clinical trial with repeated measures of the outcome variable, the 
appropriate sample size calculation requires estimates of the variance of the outcome measure 
and the correlations among the measurements over time.  In the absence of information regarding 
the intra-patient outcome correlation researchers frequently calculate the required sample size 
per group using methods appropriate for a two-sample t-test; a practice that is considered ‘ultra’ 
conservative by assuming that there is zero correlation between the baseline and follow-up 
measures [315, 319]. 
In any successful superiority trial, the patients in the control arm will have received an inferior 
treatment.  If the patient group allocation is equal, this will be half of the study patient population.  
Even if the trial is unsuccessful (i.e. fails to establish superiority), then the experimental group has 
still been exposed to a new drug with potential unknown side effects.  For these reasons, we 
contend that ultra-conservatism in the sample size is potentially unethical, and trialists calculating 
sample size should make every effort to minimise the number of exposed patients while 
maintaining power to detect clinically relevant effects.  Ideally, assessments of the intra-patient 
correlation strength and structure will become routine in all early phases of clinical development 
and larger phase II and phase III studies will be able to exploit this information.  
   
   
184 
 
One important observation our results is that, under the AR(1) correlation structure, making 
additional measurements does not always reduce sample size requirement.  Increasing the 
number of assessment measurements beyond m = 3 results in an increased sample size to 
maintain power when the correlation is intermediate-low (0.25).  This counter-intuitive property 
has been observation by previous researchers who have attributed it to a theoretical property of 
the AR(1) model [299, 304].  This finding indicates that analysts should carefully consider the 
number of patient assessment in repeated measures trials where the response may is expected 
to exhibit AR(1) properties.  While it may be tempting to conclude that for data with AR(1) structure 
and a moderate level of correlation, any design that has more than 2 measurements per patient 
would be sub-optimal, Zhang and Ahn [320] explored missing data with AR(1) models and 
concluded that increasing the number of measurements might be beneficial when the data suffer 
from missingness. A second important observation from this work is that increasing the number 
of assessment time-points from m=2 to m=3 has no impact upon the power of the study to detect 
treatment effect.  This counterintuitive observation relates to the 2nd contrast coefficient of the 
linear trend being equal to zero.  However, as the specific contrast coefficients are a function of 
both the spacing of measurement assessments as well as the expected response pattern, if the 
time points are not evenly spaced, or if the regression model was not limited to a linear trend then 
this contrast coefficient would have a non-zero value and the addition of the additional 
assessment measurement may be expected to increase power within the study. 
Our results indicate that in the absence of information regarding the correlation structure and 
strength calculation of the required sample size assuming zero correlation and an AR(1) 
correlation structure can still take advantage of the repeated measures while still reducing the 
sample size when the number of post baseline assessments exceeds three.  The choice of the 
specific number of repeated measures may reflect either a desire to characterise the time course 
of patient symptoms and/or to increase the precision of the estimate.  If the former is true, then 
the number of repeated measures will and should depend on the investigators’ expertise in patient 
safety monitoring.  Alternatively, if the desire is to increase the precision of the estimate then our 
results indicate that there is no advantage in moving from a pre-post design to baseline and two 
follow-up assessments for a fixed sample size.  This implies that the application of study 
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resources to improve precision might be better spent on more patients rather than increased 
monitoring if it is not possible to collect more than two post baseline responses. 
This work has several important limitations that can be viewed as areas for future work and/or 
refinement.  Firstly, we did not investigate empirically the increase in sample size associated with 
low correlation strength in the AR(1) structure.  As sample size and power are directly linked, this 
result implies that low correlation with AR(1) will have less power than zero correlation.  Future 
work could explore this through simulation.  Secondly, we did not examine the influence of missing 
data.  Patient attrition is an important factor when performing longitudinal studies.  This topic has 
been studied previously in [313, 321-324].  Galbraith et al. [322] suggested computing the sample 
size requirement using 90% power when 80% power is intended thereby maintaining adequate 
power under moderate patient attrition.  Similarly, Hedeker et al. [313] suggested inflating N by 
1/(1 − f), where f is the greatest rate proportion of attrition at any of the assessment time points.  
Lastly, all the analysis models assumed a linear effect over time of treatment which simplifies the 
framework for the study but may be unrealistic.  Extensions to this would be simulating a nonlinear 
effect over time, in particular, a treatment effect that decreases over time.  The analysis could 
then use more flexible models to capture information that is lost when the linear model does not 
adequately describe the true underlying treatment effects in the data.  Presumably, if we simulate 
with linear we would potentially lose power and precision.  The magnitude of which could be 
investigated.  Similarly, we have assumed equally spaced time points of assessment.  Many trials 
may wish to monitor patients more frequently at the start of the observation period as compared 
with later during the trial.  While it is possible to construct contrast coefficients for unequally 
spaced time points, our results are not generalisable to situations in which the assessment time 
points are not evenly spaced. 
In conclusion, sample size calculation is a very important aspect of any study.  It should be done 
at the time of planning a study, based on the type of the research question and study.  More work 
is needed to understand the impact of study assumptions upon the required sample size and 
power.  Furthermore, given the impact of intra-patient correlation upon power it should become 
standard for longitudinal studies to report details regarding the correlation parameters both at the 
time of study planning and retrospectively to see how the assumptions matched the observation.  
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Chapter 9. The analysis of longitudinal data 
9.1 Abstract 
Longitudinal experimental designs frequently collect multiple observations of an outcome across 
time on a set of subjects within a given study. The data from such studies are commonly referred 
to as ‘repeated measures’.  Frequently observations from the same subject are positively 
correlated. Consequently, statistical analysis of repeated measures data must account for this 
correlation.  In this review, we explore two analysis methods commonly employed when analysing 
repeated measures data: 1) the marginal model, and 2) the mixed effect model.  The methods 
are described within the context of linear regression however both techniques are also applicable 
to non-linear data scenarios.  Extensions of the linear model to account for alternate baseline 
analysis strategies are also described. 
9.2 Overview of analysis methods 
Clinical trials frequently employ a repeated measurements design in which individuals are 
randomly assigned between two (or more) treatment groups, measured at baseline, and then 
measured at fixed intervals throughout a specified treatment period [300]. In such an experiment 
the primary goal is usually to explore the change in response over time and the factors that 
influence change [325].  
A distinctive feature of repeated measures data is that they are ‘clustered’ – observations from 
the same patient (cluster) will typically exhibit positive correlation [326]. Thus, to analyse these 
data ignoring this correlation, would contradict the crucial assumption of independence that is the 
cornerstone of simple linear regression [74, 326-328].  Consequently, statistical models for 
repeated measures data must explicitly describe and account for this correlation.  Several 
approaches have been proposed to quantify treatment group differences in outcomes that arise 
from repeated measures studies.  Most of the approaches can be grouped into one of two classes:  
marginal models (also known as population-average models) and mixed models (also known as 
subject-specific models) [329]. 
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We will briefly compare each approach for the methods in which they account for intra-patient 
correlation of measurements. 
9.3 Marginal model 
Marginal or population-averaged models represent an extension of generalised linear models 
[330] to longitudinal data in which the within-subject correlation among the repeated responses 
from the same individual are incorporated into the model [331]. Marginal models describe how 
the mean response in the population changes over time and how these changes are related to 
fixed effect covariates [327]. Within this context, the term marginal refers to the fact that the model 
for the mean response at each occasion depends only on fixed effect covariates, and not on any 
random effects.  This contrasts with mixed-effects models, where the mean response depends 
not only on fixed effects but also on subject specific random effects (this will be discussed in 
further in 9.4).  A key aspect of marginal models is that the mean response and within-subject 
association are modelled separately.  Consequently, the accuracy of model estimates is not 
altered in any way by the assumptions made about the structure or magnitude of the within-
subject association and it is the precision of model estimates that incorporates the within-subject 
correlation. 
It is difficult to pinpoint the origin of marginal models within the literature [327]. In the case of linear 
models, both the repeated-measures-ANOVA [332] and MANOVA [333] analysis methods fit 
within the framework of marginal models [327]. Like marginal models, repeated-measures-
ANOVAs are also capable of modelling intra-subject correlation, however such models assume 
that the covariance structure is compound symmetry and that the variance is constant across time 
[327, 328].  While the MANOVA model allows for a flexible variance-covariance structure for the 
repeated measures and non-constant variance, it requires complete data for all subjects and 
identical measurement occasions [328] .  Consequently, marginal models represent a more 
flexible form of repeated-measures-ANOVA and/or MANOVA where complex covariance 
structures, non-constant variance, and non-identical measurement times are permitted.  
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9.3.1 Hypothetical trial example 
To illustrate how marginal models work, consider a hypothetical parallel group randomised control 
trial (RCT) of two treatments, where the primary response variable (𝑌) is a continuous variable.  
The primary response variable 𝑌𝑖𝑘 (for 𝑖th subject, at the 𝑘th measurement, 𝑖 = 1,… ,𝑁;  𝑘 =
0,… , 𝑇) is scheduled to be observed at regular intervals for assessing change from baseline.  In 
this scenario, we consider the common case of repeated measures RCT design in which the 
primary response variable is measured once during the baseline period (prior to randomisation), 
and 𝑇 times dusting the treatment period (post randomisation), hence 𝑘 =  0 indexes the pre-
randomisation baseline measurement and 𝑇 is the number of post-randomisation observations 
for each subject which combined create a 𝑇 + 1 dimension vector of response for subject 𝑖: 
 
𝑌𝑖 = ( 𝑌𝑖0   ⏟
baseline data




Assuming an average linear trend for 𝑌 as a function of time, a multivariate regression model of 
the treatment effect upon change from baseline can be obtained by assuming the elements 𝑌𝑖𝑘 in 
𝑌𝑖 satisfy: 
𝑌𝑖𝑘 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽1𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 
  
With the assumption that the error components 𝜀𝑖𝑘 are normally distributed with mean zero. 
As a departure from the notation in the previous section, in this model, 𝑥1𝑖 denotes the subject 
treatment group assignation, where: 
𝑥1𝑖 = {
1, if the 𝑖th subject is assigned to the treatment group 
0, if 𝑖𝑡ℎ the subject is assigned to the control group
 
This change in notation allows us to drop j from the response and predictor subscript and aids in 
the clarity of the presentation. 
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𝑥2𝑘 represents the time point of the observation where:  
𝑥2𝑘 = {
𝑘, for k >  0 (𝑎𝑓𝑡𝑒𝑟 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑠𝑎𝑡𝑖𝑜𝑛) 
0, for k = 0 (before randomisation)
 
In vector notation, we get:  
𝑌𝑖  =  𝑋𝑖𝛽 + 𝜀𝑖 
A design matrix 𝑋𝑖 incorporating an intercept, treatment, time and treatment by time interaction 
would result in  𝛽′ = (β0, β1, β2, β3) and 𝜀𝑖
′ = (ε𝑖0, ε𝑖1, … , ε𝑖𝑇) 
The model is completed by specifying an appropriate covariance matrix 𝑉𝑖 for 𝜀𝑖, which estimates 
the variance-covariance of observations within 𝑌𝑖, leading to the multivariate model [74, 334]: 
𝑌𝑖  ~  𝑁(𝑋𝑖𝛽, 𝑉𝑖) 
If 𝑉𝑖 = 𝜎
2𝐼𝑇, where 𝐼𝑇 is an identity matrix of dimension 𝑇, then the model above would correspond 
to a simple linear regression model in which all 𝑌𝑖𝑗𝑘 observations are assumed to be independent, 
i.e. ignoring the potential for observations within a subject to be correlated.  (Specification of the 
𝑅 matrix relaxes the assumption that within-subject errors are independent.) 
The marginal model replaces the identity matrix of the residuals with a parameterized working 
correlation matrix 𝑅, such that 𝑉𝑖 = 𝑅𝑖.  To address correlated data, the working correlation matrix 
imposes structural constraints and it is necessary to specify the structure of correlation before it 
is possible to calculate the estimated correlation strength between time points.  The choice of 
correlation structure depends on both prior knowledge of the endpoint as well as the observed 
data [74, 335]. The simplest model is the independent covariance model, where the within-subject 
error correlation is zero, and hence 𝑉𝑖 = 𝜎
2𝐼𝑇.  The most complex is the unstructured covariance 








1 𝜌01 𝜌02 ⋯ 𝜌0𝑇









Where 𝜌𝑘𝑙 = 𝑐𝑜𝑟𝑟(𝑌𝑖𝑘, 𝑌𝑖𝑙) = for the 𝑖
𝑡ℎ subject at times 𝑘 and 𝑙. 
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It is important to select an appropriate covariance model to infer accurate conclusions from 
repeated measures data analysis [336]. Failure to account for correlation by using a model that 
is too simple can potentially increase the Type I error rate by underestimating standard errors of 
the model coefficients [336].  Choosing a covariance structure that is too complex reduces both 
the power and efficiency of the analysis [337].  Both Diggle [338] and Wolfinger [335] recommend 
that analysts first explore the data using more complex (i.e. UN or AR) covariance structures. This 
helps avoid misspecification biases that can occur with models that are too simple.  One common 
strategy employed by trialists for selecting the correct covariance structure is to fit a few possible 
candidate structures and then compare them using various information criteria [336]. 
9.4 Mixed models 
Mixed-effect regression models (MRMs) are a popular choice for the analysis of longitudinal data.  
The underlying premise of linear mixed models is that some subset of the regression parameters 
varies randomly from one individual to another.  Within this context, factor effects are considered 
random if they are used in the study to represent only a sample of a larger set of potential levels.  
In a mixed model, the mean response is modelled as a combination of fixed effects (factors which 
are shared by all individuals in the study i.e. treatment, time and their interactions) and subject 
specific random effects that are unique to an individual.    
Like marginal models, MRMs do not have restrictive assumptions concerning assessment times 
across patients and the variance-covariance structure of the repeated measures [339, 340].  
MRM’s are considered to be robust to missing data and can easily account for time-varying 
covariates [339].  However, the primary reason why some researchers favour these models over 
marginal models is their ability to estimate change for each subject, hence their alternate moniker, 
‘subject-specific models’.  The ability to estimate individual change across time is particularly 
useful in identifying subjects that deviate from the average treatment group trend [339]. Since 
their introduction by Laird and Ware [75], variants of MRM’s have been developed under a variety 
of names: random coefficient models [341], mixed models [335, 342].  random regression models 
[340] models [340]. 
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Continuing our hypothetical trial example from the previous section let us consider a mixed model 
in which each subject is considered to have a random intercept and slope.  Assuming an average 
linear trend for 𝑌 as a function of time, a multivariate regression model of the treatment effect 
upon change from baseline can be obtained by assuming the elements 𝑌𝑖𝑘 in 𝑌𝑖 satisfy: 
𝑌𝑖𝑘 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽1𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘⏟                    
Fixed Effects




𝜏0𝑖 = {is the intercept deviation for subject 𝑖, and     
𝜏1𝑖 = {is the slope deviation for subject 𝑖 
If individuals did not deviate at baseline or in slope, then the 𝜏0𝑖 and 𝜏1𝑖 terms would equal 0.  
However, it is more likely that subjects will have positive or negative deviations from the 
population average intercept and/or slope and hence the 𝜏0𝑖 and 𝜏1𝑖 terms will deviate from 0.  
The most common form for the distribution of these terms is the normal distribution with mean 0 
and variances 𝜎𝜏0 and 𝜎𝜏1.  The variance term 𝜎𝜏0 represents the spread of the subject intercept 
terms while the 𝜎𝜏1 variance terms represents the spread of the subject slopes over time. 
This model assumes that the errors of measurement are conditionally independent, which is to 
say that errors of the response observations are independent conditional on the random 
individual-specific effects of 𝜏0𝑖 and 𝜏1𝑖.  
Let 𝑞 denote the number of random effects in the model, as this model has two random effects 
(intercept and slope), 𝑞 = 2.  In vector notation, we get:  
𝑌𝑖  =  𝑋𝑖𝛽 + 𝑍𝑖𝑢𝑖 + 𝜀𝑖 
Where 𝛽 denotes fixed effects with design matrix 𝑋𝑖 (like the marginal model), 𝑢𝑖 represents the 
𝑞 × 1 vector of random effects with design matrix 𝑍𝑖 of dimensions 𝑇 × 𝑞, and 𝜀𝑖 is the 𝑇 × 1 vector 
of random error.  
Both the random effects (𝑢𝑖) and error 𝜀𝑖 are expected to be normally distributed with mean 0, 
and variances D and R respectively, that is 𝑢𝑖~𝑁(0, 𝐷), and 𝜀𝑖~𝑁(0, 𝑅𝑖).  While both the 𝐷 and 𝑅𝑖 
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matrices are covariance matrices they have different dimensions.  The 𝑅𝑖 matrix is of dimension 
𝑇 × 𝑇, while the 𝐷 variance-covariance matrix is of dimension 𝑞 × 𝑞, i.e. if there were only one 
random effect per subject then 𝐷 would be a 1 × 1 matrix, and for our example where we have 
both a random intercept and slope, 𝐷 would be a 2 × 2 matrix. 
Again, the mixed model is completed by specifying an appropriate covariance matrix 𝑉𝑖,  
𝑌𝑖  ~  𝑁(𝑋𝑖𝛽, 𝑉𝑖) 
only now the 𝑉𝑖 matrix must account for the covariance between random effects as well as the 
covariance between subject errors.  Hence the multivariate model can be written as: 
𝑌𝑖  ~  𝑁(𝑋𝑖𝛽, 𝑍𝐷𝑍
′ + 𝑅𝑖) 
Like the 𝑅𝑖 matrix from the marginal model, a covariance structure must be specified for the 
variance-covariance matrix for the random effects (𝐷).  Typically, when the 𝐷 matrix is used to 
specify the covariance of the 𝑌𝑖𝑘 repeated measures, the structure of 𝑅𝑖 is reduced 𝜎
2𝐼𝑇 however 
it is possible to model the variance-covariance of observations within 𝑌𝑖 through both the 𝐷 and 
𝑅𝑖 matrices simultaneously within the mixed model framework. 
9.5 How to choose between a marginal and mixed model 
Lui et al. [343] examined the use of 𝐷, 𝑅 or both matrices simultaneously to model intra-patient 
correlation under three commonly used covariance structures - unstructured (UN), compound 
symmetry (CS), and auto-regressive (AR(1)).  Based upon the results of their simulations, the 
authors concluded that using only the 𝑅 matrix (marginal model) is recommended for data with 
either unstructured or compound symmetry covariance structure.  For autoregressive data, if the 
variance of the random between subject effects is significant, then using both the 𝐷 and 𝑅 
matrices results in accurate estimation of model parameters however using a marginal model 
rather than a mixed model with both 𝑅 and 𝐷 matrices specified had similar Type I and II error 
rates.  Similarly, other authors have found that when the within-subject error covariance matrix 
specification (𝑅) was combined with a 𝐷 matrix of random intercepts and slopes models often do 
not converge; this has been attributed to over specification, since large numbers of sometimes 
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redundant covariance elements can result when both the 𝐷 and 𝑅 matrices are used within a 
model [337, 344, 345]. 
9.6 Baseline analysis strategies 
One common feature of repeated measures RCTs that complicates the analysis is the presence 
of a baseline measurement.  Baseline values of the outcome variable collected prior to 
randomisation and treatment administration are almost ubiquitously measured in clinical trials.  
While there are several reasons why the baseline measurement might be collected, the primary 
reason is to ensure that treatment groups are comparable prior to the administration of the 
intervention under examination.  If the baseline outcome values are similar between treatment 
arms this reassures reviewers that the randomisation was successful and that differences in the 
outcome following treatment administration likely relate to the differences in treatment rather than 
the populations contained within each treatment group.  Despite the reason for the baseline 
collection, statisticians are typically reluctant to test the equality of baseline values between 
treatment groups.  Such a test, if performed, appears topically to represent a test of the 
randomisation process.  However, any test will have a type I error associated with its performance 
and it may be expected that if a difference between treatment groups is observed it may not reflect 
a failing of the randomisation.  Instead statisticians typically have sought ways to assess the 
treatment effect once removing any observed baseline imbalance.  Consequently, the question 
arises as to how to handle the baseline measurement in the measurement in the assessment the 
patterns of change in the mean response over time are the same in the treatment groups. 
Fitzmaurice et al. [326] outlines four common strategies used to incorporate the baseline value in 
repeated measures analysis:  
1) Retain it as part of the outcome vector and make no assumptions about group 
differences in the mean response at baseline (RMA). 
2) Retain it as part of the outcome vector and assume the group means are equal at 
baseline (cLDA). 
3) Subtract the baseline response from all the remaining post-baseline responses and 
analyse the change from baseline (CSA). 
4) Use the baseline value as a covariate in the analysis of the post-baseline responses 
(ANC). 
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We will consider each method in turn continuing with the hypothetical trial scenario outlined in 
section 9.3.1, a situation in which we have randomised subjects into two groups, a treatment and 
a control group.  
A regression model for the RMA is given by: 
𝑌𝑖𝑘 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 
 
Where 𝑌𝑖𝑘 is the response score for subject 𝑖 (𝑖 = 1,… , 𝑛) at time 𝑘 = (0,… , T).  𝑥2𝑘 denotes the 
time point of assessment at 𝑘 = (0,… , T), and 𝜀𝑖𝑘 is the patient by time error vector. 
The RMA has also been called the longitudinal data analysis (LDA) [325], however as previously 
noted, with the absence of missing data and identical observation periods, this model is identical 
to a repeated-measures-ANOVA and hence we have used the abbreviation RMA to identify it 
throughout our work.  
The cLDA (constrained longitudinal data analysis) model was proposed by Liang and Zeger [325] 
represents a modification of the RMA in which the baseline values are assumed to be equal in 
the intervention groups (𝛽0
∗). Utilising the same notation as above, the regression model for the 
cLDA is given by: 
𝑌𝑖𝑘 = 𝛽0
∗ + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 
 
Both these first two strategies retain the baseline measurement as part of the outcome vector but 
differ in the assumptions about the mean response at baseline.  The first strategy corresponds to 
a standard analysis of the response profiles using all available data without any constraints on 
the group means at baseline [326]. This is the method of analysis introduced in sections 9.3 and 
9.4.  The second strategy corresponds to an analysis of response profiles using all available data 
where the treatment group means at baseline are constrained to be equal.  In randomised 
controlled trials (RCTs), it may be expected that random assignment of patients to treatment 
groups will result in baseline balance and thus both methods may be expected to yield similar 
results.  By contrast, in observation trials where there is no reason to assume that that comparator 
groups will be similar at baseline the cLDA strategy may not be appropriate [326]. 
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The third strategy (CSA) uses change from baseline scores as the response variable rather than 
the raw response observations.  A regression model for the change score is given by: 
𝑑𝑖𝑘|k > 0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 
Where: 
𝑑𝑖 = (𝑌𝑖1 − 𝑌𝑖0, 𝑌𝑖2 − 𝑌𝑖0… , 𝑌𝑖𝑇 − 𝑌𝑖0) 
The fourth strategy (ANC) analyses the post-baseline response measurements and incorporates 
the baseline response by including it as a covariate.  A regression model for the ANCOVA is given 
by: 
𝑌𝑖𝑗𝑘|k > 0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝛽4𝑌𝑖0 + 𝜀𝑖𝑘 
Where 𝑌𝑖0 represents the baseline response measurement for subject 𝑖. 
Both the third (CSA) and fourth (ANC) analysis strategies do not use the baseline measurement 
as part of the response vector.  This has important consequences for experiments in which 𝑇 =
1, and is discussed further in section 9.7.1. 
9.6.1 A fifth analysis option – analysis of covariance of change scores 
Several authors have pointed out that there is no difference between an analysis of change scores 
using the baseline as covariate and an analysis of raw scores using baseline as covariate.  As 
both response vectors differ by 𝑌𝑖0, and both analyses estimate model effects that are adjusted 
for 𝑌i0 they produce the same regression coefficients for the effect of treatment, time and their 
interaction of treatment and time.  If we assume that there are only two repeated measures (a 
Pre-Post design) it can be shown that:  
ANCOVA on difference scores {
𝑑𝑖 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑌𝑖0 + 𝜀𝑖
𝑌𝑖1 − 𝑌𝑖0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑌𝑖0 + 𝜀𝑖
𝑌𝑖1 = 𝛽0 + 𝛽1𝑥1𝑖 + (1 + 𝛽2)𝑌𝑖0 + 𝜀𝑖
 
 
ANCOVA on difference scores{𝑌𝑖1 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑌𝑖0 + 𝜀𝑖 
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As can be seen from the above equations, there is no difference between the two alternative 
models in terms of the treatment effect [328]. 
9.7 Baseline analysis methods – examples from the literature 
The statistical literature is filled with debate regarding the merits and appropriateness of each of 
these methods.  Below we summarise some of the findings from studies comparing alternate 
baseline analysis strategies 
9.7.1 The choice between analysis strategies – ANC vs CSA  
The simplest possible longitudinal design comparing two treatment groups consists of a single 
pre-randomisation baseline measurement and a single post-randomisation response 
measurement; i.e. 𝑘 = 0,1; where 𝑘 =  0 indexes the pre-randomisation baseline measurement 
and 𝑘 =  1 indexes the post-randomisation measurement.  Such trials are often referred to a Pre-
Post designs.  A critical feature of Pre-Post designs is that if the baseline measurement is not 
included as part of the response vector (as is the case with the ANC and CSA analysis strategies) 
then the resulting model is no longer a repeated measures analysis and simple linear regression 
techniques can be used to estimate the effect of treatment upon the post-baseline response.  
Perhaps for this reason, within Pre-Post designs, the treatment effects on mean change from 
baseline are typically assessed using either an analysis of covariance (ANC) in which the baseline 
measurement is used as a covariate or using a change from baseline model (CSA).  As previously 
noted in section 9.6.1, the model estimates of the treatment effect from the ANC method would 
be the same with either the post-baseline value or the change from baseline value as the 
dependent variable however for simplicity we refer to the former only.   
The choice in strategies was first discussed by Frederic M. Lord in 1967 [346] and consequently 
has become known as Lord’s Paradox [346]. In his paper, Lord outlined a hypothetical dataset in 
which the two groups under comparison differed at baseline and both changed in response 
equally over time and thus differed by the same amount at the follow-up observation; that is the 
slope of change was similar between groups.  Using, simple regression analysis methods, he 
noted that the analysis of the change from baseline scores yielded a non-significant result, 
reflecting the similarity of the change from baseline in both groups, while the ANCOVA indicated 
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a significant difference between groups at the final assessment.  The difference in results may be 
attributed to the fact that for pre-post designs, the estimate of the treatment effect is equal to the 
difference at baseline (i.e. the difference in intercepts between groups) plus the difference in 
change (i.e. the difference in group slopes); or alternatively, the ANCOVA compares only the final 
difference between groups.  Conversely, the estimate of the treatment effect from the change 
score model is equivalent to the difference in change between baseline and follow-up 
assessments.  The significant result observed in the ANCOVA model may therefore be attributed 
to the differences observed at baseline while the non-significant results of the change score 
analysis indicate that once removing the baseline imbalance, both treatment groups changed by 
a similar amount over the observation period.  Despite this result, many statisticians in the health 
sciences still believe that when baseline measurements are correlated to post-baseline 
measurements, adjusting for baseline using ANCOVA removes conditional bias in treatment 
group comparisons due to chance baseline imbalances [347, 348].  Breukelen [349] explored the 
similarities and differences between the ANC and CSA analysis methods and concluded that the 
methods differ because ANCOVA assumes absence of a baseline difference between comparator 
groups.  Hedeker and Gibbons [328] note that change score analysis and ANCOVA answer 
different questions within a Pre-Post Design. Change score analysis tests if the average change 
is the same between the groups, whereas ANCOVA tests if the post-test average is the same 
between groups conditional on the baseline mean response being the same between the groups.  
Despite this conclusion Egbewale et al. [87] compared the bias precision and power of analysis 
of variance (ANOVA), change-score analysis (CSA) and analysis of covariance (ANCOVA) in 
response to baseline imbalance. The authors concluded that rather than the ANCOVA being 
biased in the presence of baseline imbalance, it was the ANOVA and CSA that led to biased 
estimates, although it should be noted that their definition of bias was difference from the 
ANCOVA estimate.  In 2013 Breukelen again revisited Lord’s Paradox in an article aptly titled: 
“ANCOVA versus change form baseline in nonrandomised studies: The difference” [350]. In this 
article, the author points out that non-randomised trials do not have the expectation of baseline 
balance between comparator groups, and as the ANCOVA method is sensitive to baseline 
imbalance, then it should not be used in nonrandomised studies.  Indeed, the perspective that the 
expectation of baseline balance (i.e. randomisation) is sufficient to justify the use of ANCOVA is 
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one that has been championed by several prominent statisticians within the health sciences [77, 
350, 351]. 
Given this sensitivity to baseline imbalance it may be hard to understand the widespread 
popularity of the ANCOVA.  Undoubtedly its use relates to two factors: 1) in the absence of 
baseline imbalance the ANCOVA has the greatest statistical power (efficiency) as compared with 
any of the 4 analysis methods outlined in the beginning of this section; and 2) change scores are 
subject to regression to the mean which reduces their efficiency. 
Proponents of the ANCOVA have demonstrated through both simulation and analysis of trial data 
that for pre-post designs, the ANCOVA has the highest statistical power; meaning the ANCOVA 
is the most statistically efficient method to analyse a continuous outcome with a baseline 
measurement [244, 352-358].  Adjustment for the baseline covariate reduces the residual 
variance from 𝑣𝑎𝑟(𝑌∙1) to 𝑣𝑎𝑟(𝑌∙1 |𝑌∙0), the conditional variance of 𝑌 after regression on the 
baseline covariate (𝑌∙0).  This can be expressed as var(𝑌∙1 |𝑌∙0) =  (1 − 𝜌
2)var(𝑌), where 𝜌 is the 
correlation between post- (𝑌∙1) and baseline (𝑌∙0) response measurements [359]. Therefore, the 
principal effect of covariance adjustment for the baseline response is to increase the precision of 
treatment contrasts by multiplying the residual variance by the factor (1 − 𝜌2). 
Several authors highlight that when change scores are used to account for differences between 
groups at baseline, they do not control for baseline imbalances between groups.  This is because 
subjects with low scores at baseline tend to improve more than those with high scores, a 
phenomenon known as regression to the mean [297]. In general, the variance of a change score 
can be calculated using the following general equation: 
 
var(D) =  var(𝑌∙1 − 𝑌∙0) = var(𝑌∙1)2(1 − 𝜌) 
 
Consequently, regression to the mean will increase the variance of the change score relative to 
the raw response variable when the correlation between pre- and post-measurements is less than 
0.5.  Therefore, the reduction in the efficiency of the CSA method relative to the ANC is 
exacerbated by low correlation and ameliorated by high correlation.  Vickers [291] undertook 
simulations to compare differences in statistical power between change scores, percentage 
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change scores and the analysis of covariance (ANCOVA) and concluded  that change scores are 
an acceptable alternative to ANCOVA if correlation between baseline and post-treatment scores 
is high. 
9.7.2 The choice between analysis strategies – ANC vs cLDA  
Liang and Zeger [325] used mixed models to compare ANC and cLDA methods in the analysis of 
data collected in clinical trials with a pre-post design.  The authors demonstrate the similarity of 
the estimates obtained by regressing the change (post-pre) on the pre-value and on the treatment 
group and the estimate obtained from a repeated measures analysis in which both the pre- and 
post-values are considered responses and regressed on a pre-post indicator and pre-post by 
treatment group interaction.  The authors conclude that the cLDA is advantageous as compared 
with the ANC as the cLDA model can include all randomised subjects with either a baseline value 
or a postbaseline value and therefore may avoid the bias for estimating within-group mean 
changes an improve the eﬃciency for estimating between-group mean differences observed at 
postbaseline time points [360]. Recently Coffman et al. [361] compared the ANC, cLDA and RMA 
marginal models in the analysis of pre-post RCT data.  The authors support the view that the 
cLDA may be regarded as the method of choice over ANCOVA and RMA analysis methods. 
There are surprisingly few studies that compare baseline analysis strategies when there is more 
than one follow-up assessment (i.e. when T >1).  While Liang and Zeger [325] discuss the 
applicability of the cLDA approach to multiple post-values and also to discrete data models the 
article does not contain a systematic comparison of each method’s efficiency. Lui et al. [347] 
compare the ANCOVA model with the cLDA using marginal models in simulations studies for 
which there are 4 assessment time-points (including baseline).  The authors demonstrate that 
both the ANCOVA and the cLDA models provide unbiased estimate for the treatment difference, 
although the cLDA model is consistently more powerful than the ANCOVA model.  The efficiency 
loss of the ANCOVA model as compared with the cLDA is partially attributed to treating the 
baseline values as fixed, which results in an underestimation of the of the mean estimates, where 
the degree of underestimation depends on both the correlation between baseline and follow-up 
measurements as well as the variability of the baseline measurement [347]. Lu [360] again 
revisited the cLDA and longitudinal ANCOVA comparison using simulated data with four repeated 
measures per subject to explore the efficiency of the two models in the setting of arbitrary missing 
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data.  The author again concluded that if the baseline value is subject to missingness, the cLDA 
strategy is shown to be more efficient for estimating the treatment differences at postbaseline 
time points than the longitudinal analysis of covariance.  
9.8 Conclusions 
Longitudinal studies, employing repeated measurement study design are both common and 
favoured in the health and medical sciences as well as in pharmaceutical studies.  Such studies 
provide insight into both the ontology of disease and the response profile to new and existing 
therapies.  The past few decades have generated significant advances in the analysis of 
longitudinal data.  Both marginal and mixed models offer trialists tools by which repeated 
measures data can be analysed to account for intra-subject measurement correlation.  
When analysing repeated measures data there appears to be no consensus on how best to 
incorporate subjects baseline measurements.  A significant portion of literature has been devoted 
to comparing the ANC and CSA baseline analysis strategies within a pre-post design setting 
however it is unclear if the similarities and differences between the methods are sustained when 
there are multiple follow-up assessments.  While less common, there are a few articles that have 
explored the cLDA and the ANC in both the pre-post and multi-follow-up settings, however the 
strength and weaknesses of the RMA and CSA methods in a multi-follow-up setting have not 
been characterised.  To date there has been no systematic review of the analysis strategies 
across varied correlation strength, structure and number of time assessment time-points.  Given 
that removal of the baseline from the response vector relegates pre-post ANC and CSA analyses 
to simple linear regression, it not clear how the model estimate interpretations might change with 
the introduction of time and time by treatment interaction terms that are necessary for longitudinal-
ANC and longitudinal-CSA models when 𝑇 > 1.  The work in the following chapters seeks to 
explore some of these gaps in the literature.   
In the following two chapters, we explore how both the accuracy (Chapter 10) and efficiency 
(Chapter 11) are altered depending on how the baseline measurement is incorporated into the 
analysis of longitudinal data using marginal model analysis methods.  Specifically, we will explore 
the impact of correlation and number of assessment time points upon power and bias.  
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Chapter 10. Interpreting the regression coefficients – a 
comparison of statistical methods for the analysis of 
repeated measures 
The greatest value of a picture is when it forces us to notice what we 
never expected to see. 
– John Tukey 
10.1 Abstract 
Background 
The analysis of repeated measures data still represents a challenge for clinical trials 
collecting repeated measurements on each subject.  While general linear models have 
emerged as the standard for analysing repeated measures data, there are several 
commonly employed strategies for handling the baseline measurement: 1) retain it as 
part of the outcome vector (RMA); 2) use the baseline measurement as a covariate in 
the analysis of the post-baseline measurements (ANC); 3) subtract the baseline 
measurement from all the post-baseline measurements and then analyse the change 
scores (CSA). The study objective was to compare the interpretation of parameter 
estimates from each analysis method as they pertain to known trial parameters. 
Methods 
Using simulation, we generated five hypothetical trial scenarios involving two treatment 
arms with an underlying autoregressive structure to the correlation of subject errors.  
Each trial scenario differed with respect to the baseline imbalance and the pattern of 
treatment group response.  Trial scenarios were then repeated varying the levels of 
intra-subject correlation and number of subject measurement time points. We then 
compared each model estimate to the simulation trial parameters. 
Results 
The regression coefficients from each of the three analysis methods return different trial 
parameters.  The link between trial parameters and model estimates is consistent within 
the RMA method irrespective of the number of follow-up assessments in the trial 
design.  By contrast, the number of follow-up time points creates alternate interpretation 
of parameter estimates for both the ANC and CSA analysis strategies.  When there is 
only one follow-up assessment the 𝑡𝑖𝑚𝑒 and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 × 𝑡𝑖𝑚𝑒 coefficients from the 
RMA correspond to the 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficients from the CSA strategy.  
The 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  coefficient from the ANC strategy captures information about both the 
intercept and slope difference between treatment arms (i.e. the difference between 
treatment arms at the final assessment time point).  When there is more than one 
follow-up assessment, all three methods have a similar interpretation of the 
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 × 𝑡𝑖𝑚𝑒  coefficient - the difference in slope between the two treatment arms. 
Conclusions 
The interpretation of parameter estimates from all three methods is not equivalent.  The 
degree of concordance partially depends on the number of assessment time points.  
From an analysis perspective, the distinction between having a single and multiple 
follow-up assessments is a key feature that should be used to inform the choice of how 
to handle the baseline measurement.  
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10.2 Introduction  
A longitudinal study refers to a trial or investigation in which patient outcomes are collected at 
multiple follow-up times.  Longitudinal studies might collect data over time from alternate patients 
(cohort) or from multiple assessments on the same subjects (Figure 10.2.1).  If the same subjects 
are measured repeatedly then the longitudinal study will yield multiple or ‘repeated’ 
measurements [74].  Repeated measures experiments are common within medicine and the 
preferred method of design for clinical trials evaluating new interventions.  In repeated measures 
clinical trials, following screening, subjects are randomised to receive either a treatment or a 
control.  They then are given a baseline evaluation, receive their assigned treatment, and are 
then followed for a period of time during which they will receive one or more assessments 
pertaining to the outcome variable relating to the indication under investigation.  The distinction 
between having a single or multiple follow-up assessments is a key feature of our results and 
discussion and therefore we refer to experiments in which there is a single follow-up as a ‘pre-
post’ [303, 362], and experiments in which there are two or more follow-up assessments as ‘multi-
follow-up’.  In both cases, the primary efficacy measure is often the pattern or trajectory of change 
from baseline to the last pre-specified visit assessment in which the outcome/response variable 
is measured. 
 
Figure 10.2.1 Different subcategories of longitudinal studies 
 
The analysis of repeated measures data still represents a challenge for clinical trials collecting 
repeated measurements on each subject.  While general linear models (both mixed and marginal) 
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consensus about how to handle the baseline value.  The statistical properties of baseline 
adjustment methods are complex and often poorly understood [363].  Much of the discussion 
surrounding the choice of analysis is rendered inaccessible to all but a handful of subject matter 
experts as the problem is usually discussed within the context of Lord’s Paradox [346].  A literature 
review [364] of 50 clinical trials from top medical journals (e.g. British Medical Journal, Journal of 
the American Medical Association, The Lancet, and New England Journal of Medicine) revealed 
the use of several alternate baseline adjustment methods.  It is our contention that the lack of 
consistency, or at very least a justification of the chosen method stems from the fact that there is 
little guidance for the overwhelming majority of researchers performing longitudinal analyses.  
Furthermore, the lack of consistency in the literature on the analysis of baseline measures further 
obfuscates the relative merits of each method. 
In this paper we consider three ways of handling the baseline value (adapted from [326]): 
1) Retain the baseline measurement as part of the outcome vector (RMA);  
2) Use the baseline measurement as a covariate in the analysis of the post-baseline 
measurements (ANC) 
3) Subtract the baseline measurement from all of the remaining post-baseline 
measurements and then analyse the change scores (CSA).   
It is our contention that many researchers analysing repeated measures have limited 
understanding of the implications for alternate methods of baseline adjustment.  Moreover, there 
is a lack of appreciation for how baseline adjustment methods interact with intra-patient 
measurement correlation and frequency of patient assessment. 
Therefore, our goal is to describe, discuss, and demonstrate how to interpret the regression 
coefficients from each analysis strategy.  We simulated hypothetical trial scenarios by levels of: 
baseline imbalance; treatment effect; within-subject correlation and number of follow-up 
measurements.  We analyse each trial scenario using each of the three baseline adjustment 
methods above and then compare the regression coefficients against the trial design parameters. 
10.2.1 Notation 
We continue with the notation outlined in the previous Chapter 9, i.e. we let 𝑌𝑖𝑘 represent a 
response observed at time 𝑘 for observation 𝑘 = 0,… , 𝑇 on subject 𝑖 = 1,… ,𝑁.  For scalar 
representation 𝑥1𝑖 is used to denote the treatment group assignment for the 𝑖
th subject (𝑥1𝑖=0 for 
control and 𝑥1𝑖=1 for active).  𝑥2𝑘 is used to denote the specific time point of assessment, hence 
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𝑥2𝑘 = 0 for the baseline measurement and  𝑥2𝑘 = 𝑇 for the time at final assessment for 𝑚 = 𝑇 +
1 follow-up time points in 𝑛 patients.   
As much of this work has to do with the comparison of treatment group means we continue the 
notation from section 7.2.1 and represent the mean response for treatment group 𝑗 at time 𝑘 as 
𝜇𝑗𝑘.  To aid in the presentation of our results we define the intercept (group mean at baseline) of 
the control and active arms as: 𝜇00 = 𝐼0 for intercept of the control group and 𝜇01 = 𝐼1 intercept of 
the active group.  The difference between groups at baseline is 𝐷0 = 𝐼1 − 𝐼0.  Similarly, the mean 
difference between treatment arms at final assessment is 𝐷𝑇 = 𝜇1𝑇, − 𝜇0𝑇.  In contrast to the 
previous chapter, we now consider baseline imbalance, the effect of which is that 𝐷𝑇 ≠ ∆, instead 
we reserve effect size (∆) to denote the difference in slopes between treatment groups (∆= 𝑆1 −
𝑆0), where the slope is calculated as 𝑆𝑗 = (𝜇𝑗𝑇 − 𝜇𝑗0) 𝑇⁄   .  Our perspective is that increased patient 
assessments (𝑚) result in more frequent patient assessment rather than prolonged patient 
assessment and hence when exploring trials with different numbers of assessment time points 
the slope is kept constant between trial scenarios by reducing the time between assessment 
points (see Figure 10.2.2). 
 
Figure 10.2.2 Hypothetical trial scenarios. 
m:2 has only has one follow-up measurement, m:4 has three follow-up measurements.  Each 
panel has the same initial difference (𝐷0), final difference - effect size (∆) for the treatment groups.  
The treatment specific slopes (𝑆𝑗) are calculated from 𝑆𝑗 = (𝜇𝑗𝑇 − 𝜇𝑗0) 𝑇⁄ .  Consequently, by 
reducing the interval between assessments, more frequent follow-up, the treatment specific 
slopes remain constant across panels. 
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10.2.2 Baseline adjustment analysis options 
We consider three analytical approaches before/after data that are commonly used: 1) repeated 
measures analysis including the baseline value for each patient in the response vector (RMA), 2) 
analysis using the post treatment administration response as the outcome and using the baseline 
measurement as a covariate or predictor (ANC), and 3) analysis of difference scores (CSA).  
Below we detail the algebraic form of each strategy. 
10.2.3 Analysis strategies as regression models 
10.2.3.1 Repeated measures analysis (RMA) 
In the repeated measures analysis, the baseline value of the response variable in a series of 
repeated measures may be modelled simply as one of the repeated outcome measures:   
 𝑦𝑖𝑘 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 (10.2.1) 
 
Where 𝑦𝑖𝑘 is the response score for person 𝑖 (𝑖 = 1,… , 𝑛) at time point 𝑘 (𝑘 = 0,… , 𝑇), (0=pre and 
T = final assessment), and 𝜀𝑖𝑘 is the patient by time error matrix. 
10.2.3.2 Analysis of covariance (ANC) 
In the repeated measures analysis of covariance, the baseline value of the response variable is 
modelled as a covariate.  The principle of this analysis is to adjust the scores of the dependent 
variable considering the influence of the baseline covariate. 
This model differs from the RMA is two ways: 1) each patient now has a vector of responses that 
does not include baseline (𝑘 = 1,… , 𝑇) and 2) in addition to the intercept (𝛽0), treatment (𝛽1), 
time (𝛽2) and treatment by time interaction (𝛽3), the model contains a parameter for the baseline 
measurement (𝛽4𝑦𝑖𝑗0): When there is more than one follow-up assessment (i.e.𝑚 > 2) the 
ANCOVA can be written in regression form as follows: 
 𝑦𝑖𝑘|𝑘>0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝛽4𝑦𝑖0 + 𝜀𝑖𝑘 (10.2.2) 
 
Where 𝑦𝑖𝑘 is the response score for person 𝑖 (𝑖 = 1,… , 𝑛)  at time point 𝑡 (𝑡 = 1,… , 𝑇).  Note that 
the vector of time points now ranges from 1,…𝑇 instead of 0, . . 𝑇 as a consequence of the baseline 
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becoming a covariate.  For a pre-post design, the inclusion of baseline as covariate results in the 
removal of time (𝑥2𝑘)  and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 (𝑥1𝑖𝑥2𝑘) terms from the model: 
 𝑦𝑖1 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽4𝑦𝑖0 + 𝜀𝑖1 (10.2.3) 
 
Note that even though there only 3 coefficients in the model we still denote the coefficient 
associated with the baseline response measurement as 𝛽4. 
10.2.3.3 Change score analysis (CSA) 
In the analysis of change score the baseline measurement for each patient is subtracted from 
each post-baseline response measurement.  Similar to the ANC, the principle of this test is to 
adjust for potential baseline imbalance, however, unlike the ANC approach this model does not 
include the baseline covariate on the right-hand side of the equation: 
 𝑦𝑖𝑘|𝑘>0 − 𝑦𝑖0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘 + 𝛽3𝑥1𝑖𝑥2𝑘 + 𝑒𝑖𝑘 (10.2.4) 
 
Similar to the ANC, for the CSA method, the vector of response time points now ranges from 
1,…𝑇; and hence for a pre-post design, the model does not include a 𝑡𝑖𝑚𝑒 (𝑥2𝑘)  𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×
 𝑡𝑖𝑚𝑒 (𝑥1𝑖𝑥2𝑘) term in the model: 
 𝑦𝑖1 − 𝑦𝑖0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝜀𝑖 (10.2.5) 
 
10.2.4 Covariance  
Correlation between measurements on the same subject result in a covariance structure imposed 
upon the errors during the estimation of model coefficients (this is covered in more detail in the 
next chapter).  A general covariance structure is denoted as: 
 







Where 𝜎𝑘𝑙 is the covariance between measurements at times 𝑘 and 𝑙 on the same subject, and 
𝜎𝑘𝑘 = 𝜎𝑘
2 is the variance at time 𝑘.  Assuming a fixed common variance between time points 𝑘 
and 𝑙 this can be rewritten as: 
   














10.2.4.1 Autoregressive (AR(1)) 
Autoregressive covariance structure specifies that covariances between intra-patient response 
observations decrease with increasing distance between observations [343, 365].  This is to say 
that observations on the same patient are increasingly independent when farther apart. 
 As our simulation work fixed the correlation between the first and last time point then the 








Where 𝑘 and 𝑙 are time points of subject observation, 𝑚 is the total number of subject assessment 
time points (including baseline) and 𝜌 is the desired correlation level between the baseline and 
final assessment time points.  Table 10.2.1 shows an example AR(1) correlation matrix for 𝜌 =
0.25 and 𝑚 = 4.   
Table 10.2.1 AR(1) intra-patient response correlation matrix between time points 
 for 𝜌=0.25 and m=4 
  Time point 𝒍 









 0 1 0.63 0.40 0.25 
1 0.63 1 0.63 0.40 
2 0.40 0.63 1 0.63 
3 0.25 0.40 0.63 1 
 
   




10.3.1 Data simulation  
To compare the performance of the three strategies for handling baseline scores in a marginal 
model repeated measures analysis, we carried out a simulation study. The primary aim of this 
study was to assess the coefficients of the RMA, ANC and CSA methods under alternate trial 
conditions.  Within the simulations we created alternate trial conditions by manipulating: the 
number of assessment time points, baseline imbalance, difference effect size and pre-post 
correlation strength.  Model coefficients from the analysis were then recorded for each approach, 
under each condition. 
Each dataset is based on the settings described in 10.3.2 using the following assumptions: 1) 
each dataset is based on two treatment groups (active and control coded as 1 and 0 respectively), 
2) all data are completely observed for all patients, 3) all measurement time points are equally 
spaced, 4) the variance at each time point was equal between treatment groups and constant 
across time, 5) each treatment arm contained 10,000 subjects to minimise error from the model 
estimates. We chose this balanced situation so that we can illustrate the model coefficients from 
each analysis strategy relative to data design without complications introduced by missing, 
unbalanced data or sample size limitations.  All data generation were performed using SAS v.9.4.  
We used the SAS MIXED procedure (SAS Institute Inc. 2008) within SAS STAT [154] for all 
marginal model analyses.  Appendix E contains portions of the SAS code used in the analyses. 
10.3.1.1 Data simulation process 
The data simulation consisted of the following steps: 
1) A correlation matrix (𝐶) was constructed for each trial scenario (see Table 10.3.1).  
2) Using Cholesky decomposition a matrix was identified such that 𝑈𝑇𝑈 = 𝐶. 
3) Random sampling from a 𝑁(0,1) distribution was used to generate an 𝑛 𝑥 𝑚 matrix of 
uncorrelated errors (𝐸𝑢).  
4) We generated correlated errors (𝐸𝑐) from uncorrelated (𝐸𝑢) by multiplication with the 𝑈 
matrix (𝐸𝑐 . = 𝐸𝑢𝑈). 
5) The time point specific responses for each patient were calculated using the treatment 
specific intercepts and slopes from the design Table 10.3.1. 
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10.3.2 Design parameters 
Table 10.3.1 lists the values of trial parameters used in the simulated datasets.  These trial 
parameters (𝑰𝟎, 𝑰𝟏, 𝑺𝟎, 𝑺𝟏) , describe the degree to which the two simulated treatment arms differ 
at baseline (𝑫𝟎), and also difference between treatment arm response over time ∆.  The value of 
the intercept and slope varied between 0 and 0.25 for both treatment arms.  As the variance was 
set to one for both treatment groups and all time points, then the values of the intercepts and 
effect sizes (Δ) are equivalent to a Cohen-D effect size.  The value of the intercept and slope 
varied between 0 and 0.25 for both treatment arms.  As the variance was set to one for both 
treatment groups and all time points, then the values of the intercepts and effect sizes (Δ) are 
equivalent to a Cohen-D effect size.   
Table 10.3.1 Simulated parameters 
Design 
Number 
𝑰𝟎 𝑰𝟏 𝑺𝟎 𝑺𝟏 𝑫𝟎 = 𝑰𝟏 − 𝑰𝟎 ∆ = 𝑺𝟏 − 𝑺𝟎 
1 0 0.25 0.25 0 0.25 -0.25 
2 0 0.25 0 0 0.25 0 
3 0 0.25 0 0.25 0.25 0.25 
4 0 0 0.25 0 0 -0.25 
5 0 0 0 0 0 0 
6 0 0 0 0.25 0 0.25 
7 0.25 0 0.25 0 -0.25 -0.25 
8 0.25 0 0 0 -0.25 0 
9 0.25 0 0 0.25 -0.25 0.25 
 
Figure 10.3.1 provides a visual representation of the mean treatment response for each simulated 
data set.  Each parameter set (design number) was repeated for five different intra-patient 
correlation levels (0,0.25,0.50, 0.75 and 0.99), and three different number of assessment time 




   




Figure 10.3.1 Shows the mean treatment group response over time for each simulated dataset. 
Parameter set is mirrored across the diagonal reversing treatment group assignment to each trial 
parameter. 
  
   




Figure 10.4.1-Figure 10.4.5 show the estimates returned for example simulated datasets.  The 
examples have been chosen to represent treatment arm differences from the following four 
categories: 1) null, 2) baseline imbalance, 3) effect difference and 4) combination of effect 
difference and baseline imbalance (see Table 10.4.1). 









At baseline Effect size 
10.4.1 5 𝐼0 = 0,   𝐼1 = 0,   S0 = 0,  𝑆1 = 0 No No 
10.4.2 6 𝐼0 = 0,   𝐼1 = 0,   S0 = 0,  𝑆1 = 0.25 No Yes 
10.4.3 1 𝐼0 = 0,   𝐼1 = 0.25,   𝑆0 = 0.25,  𝑆1 = 0 Yes Yes 
10.4.4 2 𝐼0 = 0,   𝐼1 = 0.25,   𝑆0 = 0,  𝑆1 = 0 Yes No 
10.4.5 3 𝐼0 = 0,   𝐼1 = 0.25,  𝑆0 = 0,  𝑆1 = 0.25 Yes Yes 
 
Table 10.4.2 summarises the relationship between the beta coefficient and the design 
parameters.  Two columns of statistics are provided for each analysis model.  Firstly, an 
interpretation of the results for when there are more than two patient assessment time points (i.e. 
4 or 6).  The second grouping of statistics provides the estimate interpretation when there are 
only 2 patient assessment time points.  Below we detail each coefficient for each analysis method. 
10.4.1 RMA 
The RMA analysis method has a similar interpretation of the regression coefficients irrespective 
of the number of time points.  The intercept coefficient (𝛽0) captures the control arm intercept (𝐼0); 
and the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient (𝛽1) is the difference in intercept between the two treatment arms 
(𝐼1 − 𝐼0).  Similarly, the time coefficient (𝛽2) is the slope of the control arm (𝑆0) while the coefficient 
for the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 interaction (𝛽3) estimates the difference in slopes between treatment 
arms (𝑆1 − 𝑆0).  
10.4.2 CSA 
When there are more than two assessment time points, the CSA analysis method returns a zero 
estimate for the intercept and treatment coefficients (𝛽0 and 𝛽1respectively).  The time coefficient 
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captures the slope of the control arm (𝑆0) and the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 interaction coefficient (𝛽3) 
estimates the difference in slopes between treatment arms (𝑆1 − 𝑆0). 
When there are only two assessment time points (baseline and one follow-up) then the 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 
coefficient (𝛽0) captures the slope of the control arm (𝑆0) while the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 interaction 
coefficient (𝛽1) estimates the difference in treatment arm slopes (𝑆1 − 𝑆0).  
10.4.3 ANC 
Table 10.4.3 and Figure 10.4.6 both present the average correlation between baseline and all 
subsequent time points for the null model.  The expected value was calculated by summing the 
correlation between baseline and each subsequent measurement and then dividing by the 
number of post baseline measurements (see Appendix F).  The expected and observed values 
are identical when there are only 2 time points but the observed value is fractionally higher than 
the expected value for both 4 and 6 time points.    
The value of the baseline coefficient plays an important role in the estimation of the regression 
coefficients for both intercept and treatment.  When there are more than two time points, at zero 
correlation, the 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 coefficient is equal to the intercept for the control arm (𝐼1).  As the 
correlation increases this value decreases proportionally to the increase in the 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 coefficient 
multiplied by the intercept of the control group (𝐼1) such that at perfect correlation between 
baseline and subsequent measurements the value of 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 would be zero.  Similarly, at zero 
correlation and more than two time points, the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient is equal to the difference in 
intercepts between the treatment arms (𝐼1 − 𝐼0) with increases in correlation resulting in a 
decrease in the coefficient magnitude proportional to the increase in 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 multiplied by the 
difference in intercepts ((𝐼1 − 𝐼0) × 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒). 
When there is only a baseline and one follow-up assessment (2 time points), at zero correlation, 
the 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 coefficient is equal to the sum of the intercept and slope for the control group (𝑆0 +
𝐼0).  Increases in correlation result in a decrease in the coefficient value proportional to the 
baseline coefficient multiplied by the intercept for the control arm (𝐼0 × 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒).  At zero 
correlation, the treatment coefficient is equal to the sum of the slope and intercept differences 
between treatment arms ((𝑆1 − 𝑆0) + (𝐼1 − 𝐼0)).  An increase in correlation results in a decrease 
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in the treatment coefficient equal to the 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 coefficient multiplied by the difference in 
treatment arm intercepts (𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × (𝐼1 − 𝐼0)). 
   




Figure 10.4.1 Observed model coefficients against correlation from design number 5. 
Datasets with a no baseline imbalance and null slope difference: 𝐼0 = 0,   𝐼1 = 0,   𝑆0 = 0,  𝑆1 = 0.  The baseline coefficient from the ANC strategy increases with 
correlation.  The pattern of increase varies against the number of time points.  When there are two time points, the magnitude of the baseline coefficient increases 
linearly with correlation.  When there are more than two time points the increase in the baseline coefficient is less than the increase in correlation with a ‘diminishing 
returns’ pattern.  
 
   




Figure 10.4.2 Observed model coefficients against correlation from design number 6. 
Datasets with no baseline imbalance and a positive slope difference between treatment arms: 𝐼0 = 0,   𝐼1 = 0,   𝑆0 = 0,  𝑆1 = 0.25.  When there are 2 time points the 
difference between treatment slopes is captured by the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient for both the ANC and CSA methods and by the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 × 𝑡𝑖𝑚𝑒 coefficient for the RMA 
method.  When there are more than 2 time points, the slope difference is captured by the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 × 𝑡𝑖𝑚𝑒 interaction for all three baseline strategies (RMA, ANC, 
CSA).  
 
   




Figure 10.4.3 Observed model coefficients against correlation from design number 1. 
Datasets with a positive intercept difference (the active group starts with higher values than the control group) and a negative slope difference (the control group has 
a slope while the active group does not change over time):  𝐼0 = 0,   𝐼1 = 0.25,   𝑆0 = 0.25,  𝑆1 = 0.  The treatment coefficient from the ANC method decreases with 
increasing correlation.  
 
 
   




Figure 10.4.4 Observed model coefficients against correlation from design number 2. 
Datasets with a positive intercept difference (the active group starts with higher values) and a null treatment effect (both active and control groups have a zero slope): 
𝐼0 = 0,   𝐼1 = 0.25,   𝑆0 = 0,  𝑆1 = 0.  The treatment coefficient from the ANC method decreases with increasing correlation.  The specific value of the ANC treatment 
coefficient is between the values observed in the RMA (𝜌 = 0) and the CSA (𝜌 = 1) analyses.   
Correlation 
 
   




Figure 10.4.5  Observed model coefficients against correlation from design number 3. 
Datasets with a positive intercept difference (the active group starts with higher values) and a positive slope difference (active has a positive slope and control group 
has a zero slope): 𝐼0 = 0,   𝐼1 = 0.25,   𝑆0 = 0,  𝑆1 = 0.25.  The treatment coefficient from the ANC method decreases with increasing correlation.  The specific value of 
the ANC treatment coefficient is between the values observed in the RMA (𝜌 = 0) and the CSA (𝜌 = 1) analyses. 
Correlation 
 
   




Table 10.4.2 Regression coefficients interpretation 
Parameter Coefficient Pre - Post Multi-follow-up 
RMA ANC CSA RMA ANC CSA 
Intercept 𝛽0 𝐼0 𝑆0 + 𝐼0(1 − 𝛽4) 𝑆0 𝐼0 𝐼0(1 − 𝛽4) 0 
Treatment 𝛽1 𝐼1 − 𝐼0 (𝑆1 − 𝑆0) + (𝐼1 − 𝐼0)(1 − 𝛽4) 𝑆1 − 𝑆0 𝐼1 − 𝐼0 (𝐼1 − 𝐼0)(1 − 𝛽4) 0 
Time 𝛽2 𝑆0 N/A N/A 𝑆0 𝑆0 𝑆0 
Treatment x Time 𝛽3 𝑆1 − 𝑆0 N/A N/A 𝑆1 − 𝑆0 𝑆1 − 𝑆0 𝑆1 − 𝑆0 
Baseline (𝑦∙∙0) 𝛽4 N/A Average intra-patient correlation
† N/A N/A Average intra-patient correlation† N/A 
† see Table 10.4.3 
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Table 10.4.3 The expected† and observed average intra-patient correlation between baseline and all subsequent measurements for the null model 
Correlation 
𝒎 = 𝟐 𝒎 = 𝟒 𝒎 = 𝟔 
Expected Observed Error Expected Observed Error Expected Observed Error 
0 0 1.01e-16 7.072e-3 0 1.16e-17 4.083e-3 0 3.85e-18 3.162e-3 
0.25 0.25 0.25 6.847e-3 0.426 0.432 5.077e-3 0.469 0.486 4.706e-3 
0.5 0.50 0.50 6.124e-3 0.641 0.644 4.536e-3 0.673 0.679 4.192e-3 
0.75 0.75 0.75 4.677e-3 0.828 0.829 3.42e-3 0.844 0.846 3.154e-3 
 









   




Figure 10.4.6 The expected and observed average intra-patient correlation between baseline and all subsequent measurements. 
Panels A, B, and C are datasets that have the same ‘null’ design parameters (𝐼0 = 0,   𝐼1 = 0,   ∆0= 0,  ∆1= 0) but differ in the number time points of assessment.  
Similarly, panels D, E and F all have the same ‘effect’ design parameters (𝐼0 = 0,   𝐼1 = 0.25,   ∆0= 0,  ∆1= 0.25) but differ in the number of time points.  The clear circles 
in each graph show the observed 𝛽 estimates relating to the baseline parameter at each level of correlation.  The dashed line shows the expected average correlation 
between the baseline values and all subsequent time points (see Appendix D). 
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10.5 Discussion  
This simulation study has examined the effect of baseline imbalance and number of patient 
assessments on the interpretation of model coefficients as they pertain to known trial parameters.  
We revealed that the regression coefficients of 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 from each of the three analysis 
methods relate to alternate trial parameters.  Even within the same analysis method, both CSA 
and ANC coefficients describe alternate trial parameters depending on if there is one or more 
than one follow-up assessment.  When there is only one follow-up assessment (pre-post) the 
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient of the CSA measures the difference in slopes between while the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
coefficient of the ANC measures the: slope difference + (baseline imbalance – correlation 
between pre-post measurements × baseline imbalance).  The discrepancy between the 
interpretation of the treatment coefficient between change scores and inclusion of the baseline 
score as a covariate has been discussed for a long time in statistical literature [77, 346, 350, 366, 
367], and is most frequently presented as Lord’s Paradox [346]. Essentially the argument 
recognises that the ANC method reports as the measure of treatment effect the group difference 
at final assessment by definition the combination of baseline imbalance and slope difference 
between treatment arms).  It has been argued [77] that this does not negate the validity of the 
treatment effect measured by the ANC method as the observation of baseline imbalance is not 
the same as ‘true’ baseline imbalance.  While baseline imbalance may reflect a prognostic factor 
unaccounted for in the randomisation, it may also occur by chance alone.  If we accept the latter 
is the case, then as a normally distributed random process sometimes the baseline imbalance 
will ‘increase’ the power of the ANCOVA and sometimes it will ‘decrease’ the power; it follows that 
across all the many trials employing this analysis method the technique is ‘unbiased’.  
Consequently, to employ the ANC in the analysis of repeated measures data requires only the 
expectation of no baseline imbalance rather than the observation of no baseline imbalance.  This 
paradigm has resulted in the widely accepted recommendation that the ANCOVA is an 
appropriate test for randomised trials [297, 368], where randomisation would achieve the 
expectation of baseline balance, and an inappropriate test procedure for observation trials where 
there can be no expectation of baseline balance between comparator groups owing to the lack of 
randomisation [368, 369].  In reality, the ‘expectation’ of no imbalance is very hard to achieve 
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owing to limits on the number of prognostic factors incorporated into the randomisation (see 
Introduction), and it may be hard to fully justify the expectation of baseline balance when analysing 
and presenting the results of an individual trial.  Proponents of ANC point out that the change 
scores used in the CSA analysis method are subject to ‘regression to the mean’, a phenomenon 
that refers to the tendency for subjects who have below average pre-scores tend to have higher 
post-scores, and for those above average at pre-test tend to have lower post-scores.  Regression 
to the mean alters the variance of change scores proportional to the intra-subject correlation 
strength, if the correlation is low using the change score will add variation and the treatment 
coefficient is less likely to show a significant result.  Conversely, if the correlation is high the 
change score will have reduced variance and the treatment coefficient is more likely to be 
significant [297]. 
While we are not the first authors to discuss the discrepancy between ANC and CSA coefficient 
interpretation we hope that this work has helped elucidate the impact that correlation between 
pre- and post- measurements has upon the treatment estimate in the ANC model.  Moreover, we 
believe that describing the model estimates relative to trial parameters may aid researchers in the 
interpretation of model coefficients. 
Where there is more than one follow-up measurement (multi-follow-up trial design), the 
interpretation of the model coefficients for both the ANC and CSA is altered.  Within the multi-
follow-up setting, the  𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑇𝑖𝑚𝑒 interaction coefficient measures the slope difference 
between treatment arms across all three analysis methods (RMA, ANC and CSA).  Similarly, in 
the multi-follow-up setting the 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient captures the difference in treatment arms for 
both the RMA and ANC methods, although it should be noted that as the ANC treatment estimate 
is multiplied by (1 − 𝛽4), then it will be smaller than the treatment estimate from the RMA when 
the average correlation between baseline and follow-up assessments is greater than zero.  For 
the CSA method, the trial parameters described by the 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 terms in a pre-
post design is instead described by the 𝑡𝑖𝑚𝑒 and 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 interaction terms in a multi-
follow-up design.   
In contrast to the CSA and ANC methods, the RMA has consistent interpretation of regression 
coefficients irrespective of the number of follow-up measurements (pre-post and multi-follow-up) 
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and accurately characterises any baseline imbalance (treatment coefficient) as well as the 
difference in slopes (𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 coefficient) between comparator groups.  This 
consistency allows for the direct comparison of model coefficients between pre-post and multi-
follow-up trials.  Moreover, if we accept that a regression estimates should describe the data then 
only the RMA method allows for recreation of the mean treatment responses at baseline and over 
time from the model coefficients, both the ANC and CSA methods do not allow for data 
visualisation.  
A statistical interaction occurs when the effect of one independent variable on the dependent 
variable changes depending on the level of another independent variable.  A 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 
interaction is equivalent to asking whether the expectation of change in response over time 
changes depending on the treatment received.  If the change over time (slope) of effect for the 
control group is different from the effect of time on active, then there is an interaction.  As standard 
statistical practice is to ignore the ‘significance’ of a main effect in the presence of an interaction 
between them it would appear that all three methods offer similar results when there is more than 
one follow-up assessment.  This assertion of course ignores power, and it is important to note 
both the ANC and CSA analysis methods exclude the baseline measurement from the response 
vector of each patient.  In the next chapter, we explore the effect that this has upon the power of 
studies to meaningfully detect significant trial effects.  In recent published literature, the use of 
ANCOVA as the analysis method of choice for determining the treatment effect while controlling 
for any baseline imbalance has been advocated by several authors [297, 349, 353, 354, 370, 
371].  Our results do not support this view and we are not sure that perceived definition of ‘control’ 
for baseline imbalance matches the expectation of many researchers who employ this analysis 
method to their data.  The addition of baseline as a covariate produces a coefficient that 
approximates the average correlation between time points.  While this would conceivably reduce 
the residual variation (a topic explored further in the next chapter), we do not observe evidence 
that inclusion of the baseline as a covariate produces more accurate estimates of patient change 
over time between groups, which we believe is the intended effect for the majority of researchers.   
To summarise, in this section we have reviewed three strategies to handle the baseline 
measurement in the analysis of longitudinal data.  The RMA strategy retains the baseline value 
as part of the outcome.  This method has consistent interpretation of regression coefficients 
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irrespective of the number of follow-up measurements.  The other two baseline strategies (ANC 
and CSA) do not use the baseline value as part of the outcome.  Both of these methods have 
alternate interpretation of regression coefficients depending on the number of follow-up 
measurements.  Moreover, the ANC method does not separate information regarding the baseline 
and slope difference between treatments arms when there is one follow-up measurement.  We 
conclude that in both randomised and observational trials, the RMA methods should be the 
analysis strategy of choice.  
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Chapter 11. Baseline as a covariate or dependent variable 
in standard error of the model estimates  
All models are wrong, but some are useful. 
– George E. P. Box 
11.1 Abstract 
Background 
Analysis of variance (RMA), change-score analysis (CSA) and analysis of covariance 
(ANC) are three commonly employed methods for the analysis of repeated measures 
data.  Numerous studies have reported the conditions in which all three methods yield 
unbiased coefficient estimates however few studies have quantified the differences 
between methods in the calculation of the standard error of the coefficient estimates, 
particularly in a multi-follow-up design.  As the standard error has direct implications for 
precision of estimates derived from these methods of analysis it defines their relative 
statistical power. 
Methods 
We consider the design and covariance matrices from each baseline analysis method in 
pre-post and multi-follow-up scenarios.  We explore how the alternate parametrisation 
of the baseline measurement impacts the variance of the model estimates.  Simulation 
results are presented for support of theoretical calculations for example scenarios  
Results 
For pre-post studies, the estimated treatment effect from the ANC is more precise than 
the estimated treatment effect from the RMA and CSA methods.  Consequently, the 
ANC is more powerful than the RMA and CSA methods.  The difference in power 
between methods is ameliorated by high intra-patient correlation between pre- and 
post- measurements.  For multi-follow-up studies, the precision of the treatment effect is 
greatest in the RMA method.  The RMA has markedly improved power compared with 
the ANC and CSA when the correlation structure of the data is compound symmetry 
and marginally improved power when the correlation structure is autoregressive. 
Conclusions 
Researchers need to carefully consider the number of assessment time points and 





   




Much of the research in medical science is based upon longitudinal designs that involve repeated 
measurements of a variable of interest from each participating patient.  Such experiments usually 
collect a baseline value of the response variable and one or more response variable assessments 
after a treatment intervention.  In repeated measures clinical trials, a crucial analytic decision is 
whether to adjust for the baseline measurement of the response variable.   
In this section, we continue to review procedures for the inclusion of baseline in the analysis of 
repeated measures data; these are:  
1) Include the baseline in the outcome vector (RMA); 
2) Remove the baseline measurement from the outcome vector and include it as a 
covariate (ANC);  
3) Subtract the baseline measurement from each subsequent measurement for each 
patient and then analyse the change scores (CSA). 
 
The decision of which method to employ is driven by two statistical concerns 1) Bias and 2) Power.  
If treatment groups are not similar at baseline then it may introduce bias in the form of an estimate 
of the treatment effect that deviates from its true value [372]. The ANC model is one of the most 
commonly used statistical methods for the analysis of change for pre-post designs and there is a 
wealth of statistical literature establishing the equality of ANC and CSA estimates [77, 87, 349, 
373].  In Chapter 9 we established the validity of this claim on the assumption that baseline values 
are unbiased between treatment groups.  Articles advocating the use of ANC for the analysis of 
pre-post trials frequently point out that the change scores used in CSA analysis are subject to 
regression to the mean, and hence the ANC is the more powerful method as the residual variance 
is decreased through inclusion of the baseline as a covariate [77, 296, 297, 374]. 
Generally speaking, the power of the test represents the probability of detecting differences 
between the groups being compared when such differences exist.  When testing regression 
coefficients, it is convenient to consider power as a consequence of: 1) the effect size, and 2) 
standard error of estimation. 
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The relationship between these two aspects is expressed clearly by the Wald test.  For any given 





= 𝑡 ≈ 𝑧1−𝛼 + 𝑧1−𝛽 
(11.2.1) 
 
Where ?̂? is the estimate of the model coefficient, which is approximately normally distributed with 
standard error (√𝑣𝑎𝑟(?̂?) = 𝑆𝐸(𝛽)).  The standard deviation of the estimate of a regression 
coefficient measures how precisely the model estimates the coefficient's unknown value.  Smaller 
values of the standard error indicate a more precise estimate.  The Wald test is used to test the 
null hypothesis that a regression coefficient 𝛽 is 0: 
 𝐻0: 𝛽 = 0 (11.2.2) 
 
Thus, for a fixed type I error (𝑧1−𝛼), the power will be high if the effect size  𝛽 is large and/or the 
standard error is small.   
In Chapter 9 we established the conditions that yield equality in the accuracy of the model 
coefficients however even when each baseline analysis method yields similar coefficient 
estimates this does not mean that all three baseline analysis strategies will have equivalent 
power.  The focus of this section is on comparing the precision of alternate baseline analysis 
strategies by comparing how each strategy calculates variance of the estimated model 
parameters (i.e. 𝑆𝐸(?̂?)).  To accomplish this, we have several objectives: 
The first is to review the analysis of longitudinal data.  The second is to illustrate the decomposition 
of longitudinal models to their component matrices.  The third is to use these matrices to calculate 
the theoretical 𝑆𝐸(𝛽) over each baseline analysis strategy.  As our previous work established that 
the interpretation of the regression coefficients differs between pre-post and multi-follow-up 
designs, we separate these within our work here.  Much of the focus of this chapter is on the 
covariance matrix and the similarities and differences between baseline analysis strategies that 
yield differences in statistical power. 
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The chapter is organised as follows.  
1) Preliminary material about longitudinal models is recapped in Section 11.3.  
2) Section 11.4 reviews 𝑆𝐸(𝛽) calculations for pre-post experiments. 
3) Section 11.5 reviews 𝑆𝐸(𝛽) calculations for multi-follow-up experiments. 
4) Section 11.6 presents the results of a simulation study comparing the accuracy of the 
formulae reported in Sections 11.4 & 11.5. 
5) Concluding remarks appear in Section 11.7. 
11.3 Linear models for longitudinal data 
11.3.1.1 Notation 
We continue the notation outlined in section 7.2.1. and 9.3.1. 
Let 𝑌𝑖𝑘 denote the value of the response measured at time 𝑘 on subject 𝑖; 𝑖 = 1,… ,𝑁, and 𝑘 =
0,… , 𝑇.  Again, as time is coded with baseline as 0, there are 𝑇 post baseline assessment 
measurements and 𝑇 + 1 = 𝑚 total number of assessments time points.  For scalar 
representation 𝑥1𝑖 is used to denote the treatment group assignment for the 𝑖
th subject (𝑥1𝑖=0 for 
control and 𝑥1𝑖=1 for active).  Much of this work has to do with covariance between assessment 
time points and to aid in presentation we refer to separate time points using 𝑘 and 𝑙.  A general 
covariance structure is denoted as 𝑐𝑜𝑣(𝑌𝑖𝑘, 𝑌𝑖𝑙) = 𝜎𝑘𝑙, where 𝜎𝑘𝑙 is the covariance between 
measures at time 𝑘 and 𝑙, and 𝜎𝑘𝑘 = 𝜎𝑘
2  is the variance at time 𝑘.  The mean of 𝑌𝑖𝑘 is represented 
by 𝐸(𝑌𝑖𝑘).  Lastly, we use 𝑖 and ℎ to refer to separate subjects.  
11.3.2 Simple linear regression (SLR) 
As covered previously in section 9.3.1, in matrix notation, the regression equation for the ith 
subject takes the form: 
 𝑌𝑖 = 𝑋𝑖𝛽 + 𝜀𝑖 (11.3.1) 
 
Where 𝑋𝑖 is an 𝑛𝑖 × 𝑝 matrix of predictor variables, 𝛽𝑐 , 𝑐 = 0,1, … , 𝑝 are unknown regression 
coefficients (where  𝛽0 is the intercept).  In a simple (or multivariable) linear regression, it is 
assumed that 𝐸(𝜀𝑖) = 0, 𝑉𝑎𝑟(𝜀𝑖) = 𝜎
2, and  𝐶𝑜𝑣(𝜀𝑖 , 𝜀ℎ) = 0. 
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With 𝑛 independent subjects, we can organise the regression equations for each sample unit into 
a single model: 
 𝑌 = 𝑋𝛽 + 𝜀 
(11.3.2) 
 
Where 𝑌 is an 𝑛 ×  1 vector of subject responses, 𝛽 is an 𝑛 × (𝑝 + 1) matrix of predictor variables, 
and 𝜀 is an 𝑛 ×  1 vector of random errors for 𝑌. 
For this model, it is assumed that 𝐸(𝑌) = 𝑋𝛽 and 𝑣(𝑌) = 𝜎2𝐼 : 
 𝑌  ~  𝑁(𝑋𝛽, 𝜎2𝐼) 
(11.3.3) 
 
One common approach to estimate the 𝛽 vector is to choose a value of 𝛽 that minimises the sum 
of the squared residuals, this is commonly known as ordinary least squares (OLS). 
?̂? is used to denote the least squares estimate of 𝛽.  The formula for deriving this estimated vector 
is: 
 ?̂? = (𝑋′𝑋)−1𝑋′𝑌 
(11.3.4) 
Where 𝐸(?̂?) = 𝛽, and: 
 𝑉𝑎𝑟(𝛽) = 𝜎2(𝑋′𝑋)−1 
(11.3.5) 
 
The variance-covariance matrix of the OLS estimator, ?̂? is given by [375]: 
 




𝑣𝑎𝑟(𝛽0) 𝑐𝑜𝑣(𝛽0, 𝛽1) ⋯ 𝑐𝑜𝑣(𝛽0, 𝛽p)
𝑐𝑜𝑣(𝛽1, 𝛽0) 𝑣𝑎𝑟(𝛽1) ⋯ 𝑐𝑜𝑣(𝛽1, 𝛽p)
⋮ 𝑐𝑜𝑣(𝛽2, 𝛽1) ⋱ 𝑐𝑜𝑣(𝛽2, 𝛽p)






Where the standard errors of each model coefficient are given by the square root of the elements 
along the main diagonal of (11.3.6): 
  𝑆𝐸(𝛽) = √𝑑𝑖𝑎𝑔(𝑋𝑇𝑋)−1 
(11.3.7) 
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11.3.3 Multivariate linear regression with a marginal model 
A consequence of repeated measures designs is that measurements made on the same 
individual are often correlated.  As discussed in section 9.3, marginal models are an extension of 
the linear model that account for repeated response measurements from the same study 
participant [74]. The difference between the marginal model and a simple linear regression model 
is that the residuals (𝜺) are no longer assumed to be independent [74, 375, 376], instead the 
variance is assumed to be 𝑉𝑎𝑟(𝜀𝑖) = 𝑅𝑖.  Similar to simple regression, the residuals are still 
expected to sum to zero, 𝐸(𝜀𝑖) = 0.  These two assumptions are given by:  
 ε~𝑁(0, R) (11.3.8) 
 
The matrix R is an (𝑛 ∙ 𝑚)  × (𝑛 ∙ 𝑚) block diagonal matrix with repeating subunits blocks 𝑅𝑖 












Where each patient subunit 𝑅𝑖 shows the population averaged covariance between time points at 
which measurements are collected.  It follows that the dimensions of the 𝑅𝑖 matrix are defined by 
the number of patient measurement time points: 
 
𝑅𝑖 = [
𝜎00 𝜎01 ⋯ 𝜎0𝑇
𝜎10 𝜎11 ⋯ 𝜎1𝑇
⋮ ⋮ ⋱ ⋮




= 𝐶𝑜𝑣(𝜀𝑖𝑘,𝜀𝑖𝑙) = 𝑐𝑜𝑣(𝑦𝑖𝑘,𝑦𝑖𝑙)  
(11.3.10) 
 
As correlation is simply the variance adjusted covariance, the 𝑅𝑖 can be further decomposed into 




1 𝑝01 ⋯ 𝑝0𝑇





   




As the correlation matrix is symmetric (see section 7.3.2.2) it follows that the R matrix is also 
symmetric by design. We will return to discuss covariance structures in section 11.5.2 but for now 
it is only important to note that, as the covariance is a function of correlation, the specific elements 
of 𝑅𝑖 will vary based upon the correlation of errors between time points and that marginal models 
directly estimate the correlations among each individual’s residuals with the assumption that the 
residuals across different individuals are independent of each other [74, 377]. 
Owing to the correlation of measurements from the same patient, the estimation procedures from 
equations (11.3.4) and (11.3.5) are inadequate to estimate the model coefficients and their 
variance as they fail to account for the intra-patient correlation of response measurements.  Within 
a marginal model analysis framework, information regarding intra-patient measurement 
correlation strength and structure is incorporated into parameter estimation in a repeated 
measures analysis through the inclusion of the covariance matrix R such that: 
 ?̂? = (𝑋′𝑅−1𝑋)−1𝑋′R−1𝑌         
(11.3.12) 
 
And similarly, the variance of the estimates is calculated as: 
 𝑉𝑎𝑟(𝛽) = (𝑋′R−1𝑋)−1 
(11.3.13) 
 
As with simple linear regression, the standard errors of each model coefficient are given by the 
square root of the elements along the main diagonal of (11.3.6): 
  𝑆𝐸(𝛽) = √𝑑𝑖𝑎𝑔(𝑋𝑇R−1𝑋)−1 
(11.3.14) 
 
11.4 Pre-post designs 
In this section, we compare analytic methods for experimental data when there is a single baseline 
and a single follow-up measurement – pre-post design.  We focus on the situation where the 
comparison is between two groups: 𝑥1𝑖= 0 denotes membership to the control group; and 𝑥1𝑖= 1 
denotes that the patient is a member of the active or intervention group.  Furthermore, we assume 
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that there is no missing data and thus for each subject 𝑖 we have a baseline measurement 
denoted as 𝑦𝑖0 and a follow-up measurement denoted as 𝑦𝑖1. 
Table 11.4.1 presents the scalar forms of each baseline analysis option for pre-post data. 
Table 11.4.1 Analysis options for baseline using regression methods for a two group 
comparison of pre-post data 
Baseline analysis method Scalar model 
RMA 𝑌𝑖𝑘 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑘+𝛽3𝑥1𝑖𝑥2𝑘 + 𝜀𝑖𝑘 
ANC 𝑌𝑖1 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽4𝑌𝑖0 + 𝜀𝑖1 
CSA 𝑌𝑖1 − 𝑌𝑖0 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝜀𝑖 
 
As we highlighted in our previous chapter, each of these regression models provides parameters 
with different interpretations.  Specifically, for the ANC and CSA analyses the coefficient 𝛽1 
represents the difference in the mean response at follow-up comparing 𝒙𝟏𝒊= 1 to 𝒙𝟏𝒊= 0.  For the 
RMA analysis, the coefficient 𝛽3 captures the slope difference between treatment arms and is 
therefore the coefficient of interest as it captures treatment arm differences with respect to 
‘change’ from baseline.   
11.4.1 Scalar forms → matrix forms 
Using the scalar models from Table 11.4.1  we can form the design and response matrices 
corresponding to each analysis strategy (RMA, ANC and CSA).  Table 11.4.2 shows the design 
and response matrices for the RMA, ANC and CSA analyses in a pre-post design.  As both the 
ANC and CSA methods remove time from the model they have half the number of rows as the 
RMA in their design matrices and response vectors.  Additionally, the inclusion of 𝑡𝑖𝑚𝑒 (𝒙𝟐𝒌)  and 
𝑡𝑖𝑚𝑒 𝑋 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 (𝒙𝟏𝒊𝒙𝟐𝒌) as model parameters results in the RMA having a larger design matrix 
than either then ANC or CSA methods.
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Table 11.4.2 Pre-post design and response matrices 
Analysis 
Strategy 







1 𝑥11 𝑥20 𝑥11𝑥20
1 𝑥11 𝑥21 𝑥11𝑥21
⋮ ⋮ ⋮ ⋮
1 𝑥1𝑁 𝑥20 𝑥1𝑁𝑥20





























































11.4.2 Correlation (𝝆), covariance (𝑹) and inverse-covariance (𝑽) matrices 
As stated previously, the appropriate analysis of repeated measures data requires that the within-
subject correlation be accounted for.  A marginal model accomplishes this through the introduction 
of a variance-covariance matrix (hereafter referred to as just the covariance matrix) when 
estimating the variance of each of the model coefficients (𝛽′𝑠).  The covariance captures the 
variance adjusted correlation between of the response vector time points through estimation of 
the covariance between errors of assessment time points. 
Within the context of a pre-post design, the covariance matrix estimates the covariance of errors 
between the pre- and post-response vectors (𝑌0 and 𝑌1).  Assuming a common variance to both 
time points, we can construct the variance-covariance matrix using the following steps. 
Let R be a block diagonal matrix of (𝑛 ∙ 2) × (𝑛 ∙ 2) showing the sample correlation between pre- 
and post-response vectors: 
   














𝜌00(1) 𝜌01(1) 0 0 ⋯ 0 0
𝜌10(1) 𝜌11(1) 0 0 ⋯ 0 0
0 0 𝜌00(2) 𝜌01(2) ⋯ 0 0
0 0 𝜌10(2) 𝜌11(2) ⋯ 0 0
⋮ ⋮ ⋮ ⋮ ⋱ 0 0
0 0 0 0 0 𝜌00(𝑁) 𝜌01(𝑁)
























If we denote the inverse of each (𝑅𝑖)
−1 as 𝑉𝑖 then: 
 






Where each 𝑉𝑖 submatrix is composed of 4 elements denoting the inverse covariance between 





In which the number of rows (𝑘, 𝑘 = 0,1); and the number of columns (𝑙, 𝑙 = 0,1) is equal to 𝑚.      
If we assume that the variance of error at each time point is 1 then the covariance matrix is simply 
the inverse correlation matrix.  To illustrate the effect of correlation, Table 11.4.3 presents 
correlation matrices and their inverse for a range of correlation values (0 – 0.99) between pre- 
and post - measurements.  The first two columns present correlation and corresponding inverse 
covariance assuming an error variance of 1 for both pre- and post- response vectors.  From the 
inverse covariance matrix, we define three properties, which will be useful in later work: 1) the 
sum of all the elements in the covariance matrix (𝑤), 2) the variance of the post- response vector 
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] 1.005 50.25 50 
  
11.4.3 Inverse-covariance (𝑽) matrices – ANC, CSA and RMA 






However, as both ANC and CSA have the post time point in the outcome vector then: 
𝑉𝑖 = (𝜎
2𝑰)−1 
However, even if the variance of each response vector (𝑌0 and 𝑌1) are equal to 1, the variance of 
the error in both the CSA and ANC will ≠ 1.  Below I will discuss the reasons for each. 
11.4.3.1 CSA – regression to the mean 
Regression towards the mean refers to the statistical phenomenon whereby individuals with high 
pre-scores will tend to move down on the post-test, while individuals with low pre-test scores will 
tend to move up [296, 378, 379].  As a consequence, 𝑌0 will be negatively correlated with 𝑌1 and 
the reduction in variance of the change score will be proportional the strength of the correlation 
between pre and post measurements [297]: 
  var(𝑌1 − 𝑌0) = 𝜎1−0
2 = 𝜎0
2 + 𝜎1
2 − 2𝜌01𝜎0𝜎1 (11.4.4) 
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In repeated measures analysis, estimation of the standard error of the coefficients uses the 
inverse of the residual, which yields: 
 







To show how this quantity compares with the information presented in Table 11.4.3, let us assume 
that 𝜎0
2 = 𝜎1
2 = 1, equation (11.4.5) is reduced to: 
 





Table 11.4.4 shows the change in the variance of a pre-post test score across a range of 
correlation values.  It can be seen from the table that (see Appendix G): 
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) 0.99 50 50 
 
11.4.3.2 ANC – variance reduced 
To explain the variance calculation let us redefine the covariance matrix of the RMA with the 
following form:  
 

















2 ] (11.4.8)  
 
Equation (11.4.8) reveals that the total variance at pre- (𝜎0
2)  or post- (𝜎1
2) can be partitioned into 
residual variance (σ𝑒
2) and correlation variance (σ𝑎
2) ; where σ𝑎
2  is the within subject covariance 
created by the correlation, and residual or error variance (σ𝑒
2) is the variance ignoring the intra-
subject correlation [380].  
For the ANC (and CSA), there is only 1-time point, so the covariance matrix is simply: 
 R𝑖 = [𝜎1
2] (11.4.9) 
 
However, as the ANC coefficient of the baseline parameter estimates the correlation between 
pre- and post- values the total variance is adjusted for intra-subject correlation as the intra-subject 
correlation forms part of the model.  The more strongly correlated 𝑌0 and 𝑌1 are, the greater the 
reduction in the error variance.  The residual variance in the ANC is given by [381]: 
 R𝑖 = [𝜎1
2 − (𝜌10)
2] (11.4.10) 
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Table 11.4.5 shows the change in the variance of a pre-post test score across a range of 
correlation values.  It can be seen from the table that: 
𝑉𝑖 = 𝑢11 
Table 11.4.5 𝑉𝑖 matrix of the ANC method for a pre-post design 
Correlation - 𝝆 𝐑𝒊 = [𝟏 − 𝝆𝟎𝟏
𝟐 ] 𝑽𝒊 = (𝐑𝒊)
−𝟏 𝒖𝟏𝟏 
𝟎 1 1 1 
𝟎. 𝟐𝟓 0.9375 1.067 1.067 
𝟎. 𝟓𝟎 0.75 1.333 1.333 
𝟎. 𝟕𝟓 0.4375 2.286 2.286 
𝟎. 𝟗𝟗 0.0199 50.25 50.25 
 
Table 11.4.6 summarises the inverse covariance matrix used for each baseline analysis method 
in terms of the properties defined in Table 11.4.3. 
Table 11.4.6 Inverse covariance matrix - 𝑉 















































11.4.3.3 Comparison of 𝑺𝑬(𝜷) – pre-post design 
The standard error of the effect size estimates for each analysis method (RMA, ANC, CSA) can 
be derived from the (𝑋𝑇𝑉𝑋)−1 matrix for each analysis method, with full details presented in 
Appendix H.  For simplicity, I present only the terms corresponding to the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 coefficient 
for the CSA and ANC methods and the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 coefficient from the RMA (as these 
are the terms that capture the ‘change’ from baseline in each model).  It must be noted that for 
the RMA and CSA models it is possible to derive generic (𝑋𝑇𝑉𝑋)−1 matrices that are applicable 
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to all cases however for the ANC assumptions must be made regarding the baseline imbalance 
or the (𝑋𝑇𝑉𝑋)−1 has a zero determinant and is non-invertible. 
Table 11.4.7 𝑆𝐸(𝛽) for pre-post designs  
Analysis Strategy Model Parameter 𝑺𝑬(𝜷) 















Using the formulae for the 𝑆𝐸(𝛽) from Table 11.4.7 and the values from Table 11.4.3 it is possible 
to calculate expected values for the standard error of the model coefficients.  The results of these 
calculations are presented in Table 11.4.8.  The table shows that for a pre-post design, the 𝑆𝐸(𝛽) 
is identical for the CSA and RMA analyses across all correlation levels.  By contrast, when the 
correlation strength between pre- and post- measurements is less than 1.0, the 𝑆𝐸(𝛽) for the ANC 
is smaller than that of the CSA and RMA methods. 
Table 11.4.8 Theoretical 𝑆𝐸(𝛽) by analysis strategy – pre-post 







Standard Error of the Coefficient (𝑺𝑬(𝜷)) 
RMA ANC CSA 
0 2 1 
1
2
 0.20 0.1414 0.20 
0.25 1.6 1.067 
2
3
 0.1732 0.1369 0.1732 
0.5 1.3333 1.333 1 0.1414 0.1225 0.1414 
0.75 1.142 2.286 2 0.10 0.0935 0.10 
0.99 1.005 50.25 50 0.02 0.0200 0.02 
11.5 Multi-follow-up design  
A multiple follow-up design is a repeated measures experiment in which there is a single baseline 
measurement and follow-up is assessed more than once (two or more times).  As with the pre-
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post design, the primary efficacy measure is often the pattern or trajectory of change following 
treatment administration.  The purpose of using multi-follow-up design is to (a) provide continuous 
monitoring of patients for unwanted side effect to the treatment and (b) decrease intra-patient 
variability and thus increase statistical power [382]. 
As compared with a pre-post design there are three distinct analysis complications introduced by 
having more than one follow-up assessment: 1) model parameter changes, 2) covariance 
structure and 3) mathematical coupling. 
11.5.1 Model parameter changes  
In moving from a pre-post design to a multi-follow-up, the CSA and ANC models will now have 
𝑡𝑖𝑚𝑒 and t𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 terms. 
The design and response matrices are now as follows: 
Table 11.5.1 Multi-follow-up design and response matrices 







1 𝑥11 𝑥20 𝑥11𝑥20
⋮ ⋮ ⋮ ⋮
1 𝑥11 𝑥2T 𝑥11𝑥2T
⋮ ⋮ ⋮ ⋮





























1 𝑥11 𝑥21 𝑥11𝑥21 𝑦10
⋮ ⋮ ⋮ ⋮ ⋮
1 𝑥11 𝑥2T 𝑥11𝑥2T 𝑦1T
⋮ ⋮ ⋮ ⋮ ⋮
































1 𝑥11 𝑥21 𝑥11𝑥21
⋮ ⋮ ⋮ ⋮
1 𝑥11 𝑥2T 𝑥11𝑥2T
⋮ ⋮ ⋮ ⋮
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11.5.2 Covariance structure 
As previously introduced in section 11.4.2, the residuals consist of a matrix of values where the 
diagonals of the matrix are the residual variances at each time point and the off diagonals are the 
covariances between successive time points: 






2 𝜎01 ⋯ 𝜎0T
𝜎10 𝜎1
2 ⋯ 𝜎1𝑇
⋮ ⋮ ⋱ ⋮







The covariance structure refers to the pattern in covariance matrices.  Covariance structure is not 
relevant for pre-post analyses but is an important component of all multi-follow-up study analyses.  
Three commonly used covariance structures previously introduced in section 0 are the CS, UN 
and AR(1) structures. Table 11.5.2 summarises the covariance for the (𝑘, 𝑙)𝑡ℎ  element within each 
structure. 
Table 11.5.2 Common covariance structures 
Structure Description Parameters (𝒌𝒍)𝒕𝒉 element 
CS Compound Symmetry 2 𝜎1 𝑜𝑟 𝜎(𝑘=𝑙)
2  
AR(1) Autoregressive(1) 2 𝜎2𝜌|𝑘−𝑙| 
UN Unstructured 𝑚(𝑚 + 1)/2 𝜎𝑘𝑙 
 
11.5.3 Mathematical coupling 
Within the context of linear regression, mathematical coupling refers to a change in the correlation 
strength and structure of change scores.  Mathematical coupling occurs when one variable 
directly or indirectly contains the whole or part of another [383]. As the baseline measurement is 
subtracted from all subsequent measurements, and moreover the baseline measurement forms 
a larger part of response measurements closer to baseline than those farther away, then the 
correlation between change scores will be different from that of the raw response scores.  The 
correlation between a change score and the raw baseline measurement is given by [384]: 
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Equation (11.5.1) has been expanded to accommodate the correlation between two change 
scores by [302]: 
𝐶𝑜𝑟𝑟(𝑦𝑙 − 𝑦0, 𝑦𝑘 − 𝑦0|𝑘 ≠ 𝑙) =










As shown previously in section 0, if the original data structure is compound symmetry i.e.  𝜌𝑘𝑙 =














If the original data structure was autoregressive then the change in correlation is slightly harder 
to explain.  Consider a hypothetical study with 4 assessment time points, an AR(1) correlation 
structure and a correlation strength of 0.25 between the baseline and last assessment time point 
(see Table 11.5.3).  The correlation matrix of time points is symmetrical around the diagonal, 
meaning that the correlation between any two time points is defined only by the distance between 
time points (i.e. the correlation between 𝑘 = 0 and 𝑘 = 1 is the same as the correlation between 
𝑘 = 1 and 𝑘 = 2) – for this example, for a distance of 1 assessment the correlation is 0.63. 
Table 11.5.3 AR(1) correlation structure for 4 time points  
 
𝒀𝟎 𝒀𝟏 𝒀𝟐 𝒀𝟑 
𝒀𝟎 1.0 0.63 0.40 0.25 
𝒀𝟏 0.63 1.0 0.63 0.40 
𝒀𝟐 0.40 0.63 1.0 0.63 
𝒀𝟑 0.25 0.40 0.63 1.0 
 
Table 11.5.4 presents the correlation matrix of the correlation between the change scores 𝐷1, 𝐷2, 
and 𝐷3 (where =𝐷1 = 𝑌1 − 𝑌0, 𝐷2 = 𝑌2 − 𝑌0, 𝐷3 = 𝑌3 − 𝑌0) calculated using equation (11.5.2).  In 
contrast to the raw scores, the correlation is no longer symmetrical around the diagonal.  The 
table shows that the correlation between 𝐷1 and 𝐷2 (0.64) is not equal to the correlation between 
𝐷2 and 𝐷3 (0.73).  The implication of this is that the correlation structure of the change scores is 
no longer AR(1).
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Table 11.5.4 Correlation structure of the change scores from raw data with AR(1) structure 
 
𝑫𝟏 𝑫𝟐 𝑫𝟑 
𝑫𝟏 1.0 0.64 0.49 
𝑫𝟐 0.64 1.0 0.73 
𝑫𝟑 0.49 0.73 1.0 
 
Covariance matrix - The effect of coupling combined with the interaction between correlation 
structure and changes in variance associated with the baseline value in the ANC make a generic 
formulation of the covariance matrices complicated.  Instead, we will illustrate these effects 
through a hypothetical study with four assessment time points, a correlation strength of 0.25 
between the first and last assessment time point and a compound symmetry correlation structure 
(we have chosen compound symmetry as the computation of the residual variance is easier to 
follow). 
Here we revert to the notation introduced in section 11.4.3.2 where we consider each covariance 


































2 =  𝜌 
σ𝑒
2 = 𝜎2 − σ𝑎
2 = 𝜎2 − 𝜌 
(11.5.5) 
 
Equation (11.5.4) shows that the 𝑅𝑖 matrix contains only two specific values, the value of the 
diagonal elements and the value of the off diagonal elements; consequently the inverse of the 𝑅𝑖 
matrix (𝑅𝑖
−1 = 𝑉𝑖) will also have only 2 specific values.  Note however that the RMA covariance 
matrix will be of dimension 4x4 whereas the ANC and CSA covariance matrices are of dimension 
3x3.  After some matrix algebra, formulae for the diagonal and off diagonal elements of (𝑅𝑖)
−1 for 
each baseline analysis method can be obtained (Table 11.5.5).  
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Table 11.5.5 Diagonal and off-diagonal element values in the (𝑅𝑖)
−1 matrices 
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If we let 𝜎2(the total variance at each time point) be equal to 1 then the calculation for diagonal 
and off diagonal elements of the inverse covariance matrix for each analysis method are as 
follows: 
RMA 
 𝜎2 = σ𝑎
2 + σ𝑒
2 = 1 
σ𝑒
2 = 1 − 𝜌 = 0.75 
σ𝑎
2 = 𝜎2 − σ𝑒
2 = 0.25 
 
(11.5.6) 
The diagonal elements of 𝑅𝑖






3 × 0.25 + 0.75
0.752 + 4 × 0.25 × 0.75
=
1.5
0.752 + 4 × 0.25 × 0.75
= 1.429 
 






0.752 + 4 × 0.25 × 0.75
= −0.1905 
ANC 
The CS variance is reduced by the baseline response being a covariate proportional to the 
correlation therefore: 
 𝜎2 = 1 − 𝜌2 = 1 − 0.252 = 0.9375 =  σ𝑒
2 + σ𝑎
2    
σ𝑒
2 = 1 − 𝜌 = 1 − 0.25 = 0.75   
σ𝑎
2 = 𝜎2 − σ𝑒
2 = 0.9375 − 0.75 = 0.1875 =  𝜌 − 𝜌2 
 
(11.5.7) 
The diagonal elements of 𝑅𝑖






2 × 0.1875 + 0.75
0.752 + 3 × 0.1875 × 0.75
= 1.429 
 






0.752 + 3 × 0.1875 × 0.75
= −0.1905 
   




The CSA covariance matrix is subject to regression to the mean, consequently, as introduced in 
section 7.3.1.2, the total variance will be inflated by the degree of correlation in the raw data, 
therefore: 
 𝜎2 =  2(1 − 𝜌) = 1.5 = σ𝑒
2 + σ𝑎
2    
σ𝑒
2 = 1 − 𝜌 = 1 − 0.25 = 0.75 
σ𝑎
2 = 1.5 − 0.75 = 0.75 
(11.5.8) 
 
And the diagonal elements of 𝑅𝑖






2 × 0.75 + 0.75
0.752 + 3 × 0.75 × 0.75
= 1 
 






0.752 + 3 × 0.75 × 0.75
= −0.333 
Table 11.5.6 Summary of the calculated diagonal and off-diagonal elements of the (𝑅𝑖)
−1 
matrices 
 RMA ANC CSA 
Diagonal 
(𝑢𝑘𝑙|𝑘 = 𝑙) = 𝑢diag 
1.429 1.429 1 
Off Diagonal 
(𝑢kl|𝑘 ≠ 𝑙) = 𝑢off 
−0.1905 −0.1905 −0.333 
 
We can now use these values in order to see how the standard error of the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑥 𝑡𝑖𝑚𝑒 
coefficient differs between baseline analysis methods.  
For simplicity, I present only the terms corresponding to the 𝑆𝐸(𝛽) for the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑥 𝑡𝑖𝑚𝑒 
interaction (as these are the terms that capture the ‘change’ from baseline in each model).  It must 
be noted that the equations presented in Table 11.5.7 are applicable only to analysis scenarios 
in which there is compound symmetry between response time points.  
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Table 11.5.7 𝑆𝐸(𝛽) for treatment × time coefficient for multi-follow-up designs with compound 
symmetry correlation structure 
Analysis 
Strategy 
Model Parameter 𝑺𝑬(𝜷) 




4 )(𝑢diag − 𝑢off)
 
ANC 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 √
1
𝑁
2 (𝑢diag − 𝑢off)
 
CSA 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 √
1
𝑁
2 (𝑢diag − 𝑢off)
 
 
Using the formulae for the 𝑆𝐸(𝛽) from Table 11.5.7 and the values from Table 11.5.6 it is possible 
to calculate theoretical values for the standard error of the model coefficients.  Assuming a sample 
size of 200 (100 per treatment arm), the results of these calculations are presented in Table 
11.5.8.  The table shows that for a multi-follow-up study with four patient assessment time points, 
the 𝑆𝐸(𝛽) is identical for the CSA and ANC analyses across all correlation levels.  By contrast, 
the 𝑆𝐸(𝛽) for the RMA is smaller than that of the CSA and ANC methods across all correlation 
level.  As the 𝑛 is common to the denominator of all 3 calculations the relative difference between 
the analysis strategies will hold true across any sample size. 
Table 11.5.8 Theoretical 𝑆𝐸(𝛽) by analysis strategy – multi-follow-up with 4 patient 
assessments - compound symmetry correlation structure 
Correlation 
Standard Error of the Coefficient (𝑺𝑬(𝜷)) 
RMA ANC CSA 
0 0.063 0.100 0.100 
0.25 0.055 0.087 0.087 
0.5 0.045 0.071 0.071 
0.75 0.032 0.050 0.050 
0.99 0.006 0.010 0.010 
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11.6 Simulations  
11.6.1 Design 
Simulation studies were undertaken to assess the performance of each baseline analysis strategy 
under a variety of scenarios.  From the theoretical calculations presented above, we defined the 
following four objectives: 
1) Compare the theoretical calculations from Table 11.4.8 and Table 11.5.8 to empirical 
results from simulation 
2) Compare the power of each baseline analysis method across number of time points 
where we hypothesise that when there is only 1 follow-up assessment (pre-post) the 
ANC will be more powerful than the RMA or CSA methods.  By contrast when there is 
more than one follow-up assessment (multi-follow-up), the RMA will be more powerful 
than the ANC and CSA methods 
3) As a consequence of mathematical coupling, we hypothesise that in multi-follow-up 
designs, CSA analyses specifying an unstructured covariance matrix will have an 
improved fit as compared with AR specification even when the raw response data has 
an AR correlation structure. 
 
The power of each analysis method depends on the sample size, effect size, its standard error 
(as calculated above), and significance level (fixed at α = 0.05).  Effect size and sample size were 
chosen to give moderate power so that differences between the analysis methods can be readily 
observed (which is not possible if power is very low or very high).   
Table 11.6.1 presents the power calculations using the Overall and Doyle (OD) Method from 
Equation (8.3.5 with the assumption of 100 patients in each treatment group.  The table shows 
that an effect size (Δ) of 0.25 has power of between 46% and 84% across both correlation 
structures when the correlation is less than or equal to 0.5. 
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Table 11.6.1 Estimated power for various number of time points, effect size (Δ) and correlation 
strength and correlation structure assuming a two group comparison with 100 patients in each 
treatment group.   
  OD Method 
Number of 
 assessment  
time points 
(𝒎) 
Δ Autoregressive(1) Compound Symmetry 
Correlation Strength (𝝆𝟎,𝑻)   
0 0.25 0.5 0.75 0 0.25 0.5 0.75 
4 
0.1 0.11 0.13 0.17 0.29 0.11 0.14 0.18 0.32 
0.25 0.46 0.53 0.71 0.94 0.46 0.58 0.75 0.96 
0.5 0.96 0.98 1.00 1.00 0.96 0.99 1.00 1.00 
6 
0.1 0.13 0.13 0.17 0.29 0.13 0.16 0.22 0.39 
0.25 0.55 0.53 0.71 0.94 0.55 0.68 0.84 0.99 
0.5 0.99 0.98 1.00 1.00 0.99 1.00 1.00 1.00 
 
Using the design number 6 data from Chapter 10 (no baseline imbalance, Δ=0.25) we sampled 
100 patients in each study arm under two covariance structures (AR and CS), 5 correlation 
strengths (0, 0.25, 0.50, 0.75 and 0.99) and three different assessment time points (2, 4 and 6).  
For each scenario, 2000 simulated data sets were created, and each was analysed by the RMA, 
ANC and CSA methods.  Each simulated data set was analysed using three different covariance 
structures, AR, CS, and unstructured (UN), regardless of the covariance structure used in the 
simulation.     
11.6.2 Precision, power and fit 
The precision of model coefficients 𝑆𝐸(𝛽) is calculated from the standard deviation of the 𝛽 
coefficient across all 2000 simulations.  The statistical power of each baseline analysis method 
was calculated as the percentage of simulations where the null hypothesis was rejected at a 
significance level of α=0.05.  The fit of each analysis method was assessed using the Akaike 
information criterion (AIC).  
11.6.3 Simulation results 
11.6.3.1 Objective 1: Comparing theoretical values with results of simulation study 
Table 11.6.2 presents the theoretical (from Table 11.4.8) and empirical (calculated from the 
simulation) calculations of the 𝑆𝐸(𝛽) side by side.  For pre-post studies (2 time points), the 
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simulation results confirm the theoretical expectation and show that the 𝑆𝐸(𝛽) for the RMA and 
CSA methods is very similar across all levels of correlation.  At low to intermediate correlation, 
the 𝑆𝐸(𝛽) for the ANC is smaller than the 𝑆𝐸(𝛽) for the RMA and CSA methods, however, the 
estimates converge at higher levels of correlation (𝜌 > 0.75).  




RMA ANC CSA RMA ANC CSA 
0 0.20 0.14 0.20 0.2053 0.1420 0.2058 
0.25 0.17 0.14 0.17 0.1723 0.1352 0.1723 
0.5 0.14 0.12 0.14 0.1414 0.1211 0.1414 
0.75 0.10 0.10 0.10 0.0952 0.0892 0.0952 
0.99 0.02 0.02 0.02 0.0202 0.0201 0.0202 
† Theoretical results were calculated using the methods presented in 11.4.  Empirical results 
are derived from the standard deviation of the 𝜷 across 2000 simulations each using 200 
patients (100 per treatment arm). 
 
For four time points, the theoretical (from Table 11.5.8) and empirical (calculated from the 
simulation) estimates of the 𝑆𝐸(𝛽) are presented in Table 11.6.3.  The simulation results confirm 
the theoretical expectation and show that 𝑆𝐸(𝛽) is lower for the RMA than for the CSA and ANC 
across all levels of correlation.  
Table 11.6.3 Theoretical and empirical standard error of the coefficient (𝑆𝐸(𝛽)) for multi-follow-
up study with four assessment time points and compound symmetry correlation structure†– 
Correlation 
Theoretical Empirical 
RMA ANC CSA RMA ANC CSA 
0 0.063 0.100 0.100 0.057 0.095 0.095 
0.25 0.055 0.086 0.086 0.051 0.083 0.083 
0.5 0.045 0.071 0.071 0.044 0.070 0.070 
0.75 0.032 0.050 0.050 0.035 0.053 0.053 
0.99 0.006 0.010 0.010 0.007 0.011 0.011 
† Theoretical results were calculated using the methods presented in 11.4.  Empirical results 
are derived from the standard deviation of the 𝜷 across 2000 simulations each using 200 
patients (100 per treatment arm) 
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11.6.3.2 Objective 2: comparing power by number of assessment time points 
Figure 11.6.1 the empirical power results for each data correlation structure against correlation 
panelled by the number of assessment time points and data structure.  For the RMA and ANC 
analysis methods the correct specification is used in the analysis (that is the model specified 
AR(1) for the AR(1) data and CS for the CS data).  For the CSA analyses, we used an 
unstructured covariance matrix for all multi-follow-up AR analyses. 
In general, across all three analysis methods (RMA, CSA and ANC), we observe that power:  
1) Increases with higher intra-patient correlation. 
2) Is higher with compound symmetry correlation structure as compared with 
autoregressive-1 correlation structure. 
3) Increases with the number of assessment time points. 
 
These results confirm our hypothesis that the ANC is the most powerful method in pre-post 
studies and that the RMA is the most powerful method in multi-follow-up studies.  The power 
difference between the RMA and ANC/CSA methods is greater with compound symmetry than 
with auto-regressive correlation structure.  With six time points, under auto-regressive correlation 
structure, the power was similar for all analysis methods.     
11.6.3.3 Objective 3: covariance structure assumptions for simulation and analysis model 
To assess the fit of each model, we used the Akaike information criterion (AIC) for each 
simulation, with low AIC values indicating a better model fit.  Figure 11.6.2 displays the distribution 
of AIC values across the replications for the multi-follow-up scenario with m=6 and  𝜌 = 0.5.  The 
lower row of figures indicates that when the correlation structure in the simulation study is 
compound symmetry, using the correct model specification (CS) yields the best model fit.  When 
the data structure is autoregressive (AR) (upper row), correct specification results in the best fit 
for the RMA and ANC methods.  By contrast, for the CSA method, when the data correlation 
structure is AR, a model specification of UN gives improved model fit.
   




Figure 11.6.1 Power for each analysis method, by correlation structure and number of assessment time points. 
For the ANC and CSA analyses, the model specification matched the data structure.  For the CSA we used a correct specification for pre-post analyses and an 
unstructured covariance matrix for the multi-follow-up analyses.  For pre-post studies, the ANC has more power than either the RMA or ANC methods.  For multi-
follow-up studies, RMA is more powerful. 
   




Figure 11.6.2 Density plot of the AIC for m=6 and correlation=0.5. 
Each panel shows the fit of three model specifications for the covariance matrix (AR, CS and UN).  For the CSA method, the UN covariance specification results in 
improved model fit when the data correlation structure is AR.  For the RMA and ANC methods, model specification matching the correlation structure results in the 
best fit (smallest values), although in each case the unstructured method performs well.  
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11.7 Discussion  
This study establishes the distinction between pre-post and multi-follow-up designs as a key factor 
in the choice of analysis for repeated measures clinical trials.  Although the calculation and 
interpretation of the model coefficients from RMA, CSA and ANC have been described previously 
we are the first to examine the differences in the standard error of the coefficients in relation to 
the number of follow-up assessments, level of correlation and correlation structure. 
 Our results suggest 3 important findings: 
1) When there is only a baseline and one follow-up assessment (pre-post) design, the 
ANCOVA (ANC) is the most statistically efficient method in the absence of baseline 
imbalance. 
2) With more assessment time points (multi-follow-up), including the baseline 
measurement in the outcome vector (RMA) offers more power to detect a group x time 
interaction than either the ANC or CSA methods. 
3) For multi-follow-up studies, the use of change scores (CSA) to analyse data that does 
not have compound symmetry correlation structure should specify an unstructured 
covariance matrix in the analysis.  
 
This first finding supports the body of evidence where ANCOVA has been shown to be the 
analysis method of choice for incorporating baseline into the analysis of repeated measures data 
insofar as the analysis of pre-post design data.  Vickers et al. [297], Senn et al. [385] and 
Egbewale et al. [87] all state that the ANCOVA has greater statistical power as compared with 
change scores, or using the baseline measure in the response vector.  This improvement in power 
is commonly attributed to the adjustment in variance for the correlation between pre and post 
scores however we demonstrate that even in the absence of correlation the ANCOVA is more 
powerful than the RMA and CSA.  This demonstrates that the gain in power for the ANC arises 
from differences in the variance but also is a consequence of a difference in the design matrix 
rather than ‘adjustment’.   
If the trial collects more than a single follow-up assessment (multi-follow-up), including the 
baseline measurement in the outcome vector (RMA) is a more powerful technique than either the 
ANC or CSA.  Both the CSA and ANC methods have a different number of predictors in multi-
follow-up studies as compared with pre-post designs and consequently the design matrix for both 
these analysis methods changes when switching from a pre-post design to a multi-follow-up.  We 
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observed that the critical difference between the RMA and CSA/ANC methods in multi-follow-up, 
which drives the disparity in power, is the additional baseline measurement in the response 
vector.  While the specific difference between diagonal and off diagonal elements of the inverse 
covariance matrix is similar between analysis methods within a given correlation structure, the 
inclusion of the baseline in the response vector gives the covariance matrix of the RMA an extra 
row and extra column (corresponding to the extra time point).  The consequence of this is that the 
𝑆𝐸(𝛽) for the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑥 𝑡𝑖𝑚𝑒 coefficient in the RMA will almost always be smaller than the 
𝑆𝐸(𝛽) for the ANC and CSA methods, even when the covariance matrices hold the same values.   
Because CSA uses outcome variables that derive from the subtraction each patient’s baseline 
measurement, it has two distinct statistical challenges: 1) Regression to the mean and 2) 
mathematical coupling.  Regression to the mean renders the CSA baseline analysis method 
statistically inefficient at low correlation for both pre-post and multi-follow-up designs.  By contrast, 
mathematical coupling occurs only in multi-follow-up designs and is not recognisable from its 
effect on power.  This is because statistical software requires user defined covariance matrices 
and misspecification of the covariance structure can result in an under or over estimation of the 
covariance between time points.  Without specifically checking the model fit between covariance 
structures this error would go undetected and has the potential to inflate type-I error.  It is clear 
from our results that when a change score is used for multi-follow-up data that is AR(1) (i.e. data 
that is not CS structure), the resulting covariance matrix will be asymmetrical and therefore an 
unstructured covariance matrix should always yield the best model fit.  This is not to advocate the 
use of unstructured covariance matrices as the default option.  The unstructured covariance 
matrix uses up a large number of degrees of freedom and would decrease power if a ‘structured’ 
covariance matrix would fit the data.   
This work has several important limitations.  Firstly, we fixed the variance to be equal across all 
assessment time points.  This assumption may not be valid as heterogeneity of patient responses 
to treatment will likely become more prevalent over time [339]. Given that the covariance matrix 
is adjusted for the variance at each time the results of our baseline method comparison would still 
be expected to hold true even under simulated conditions of variance heterogeneity, however, 
future work might seek to confirm this.  Similarly, we have assumed equally spaced assessment 
time points.  
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 A second important point is that we assumed that the slope difference between baseline and the 
first post-baseline assessment was similar to the response profile of change over time for the 
post-baseline assessments.  It is conceivable that the immediate/short-term response of patients 
could differ from the long-term response profile.  If the initial response does not match subsequent 
response slope (and the on-treatment response slope is consistent) then the decision to include 
baseline in the outcome vector will result in a bias of the 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ×  𝑡𝑖𝑚𝑒 interaction coefficient.  
Under these conditions, the exclusion of the baseline value by both the ANC or CSA analysis 
methods would be advantageous, regardless of the number of follow-up assessments.  Even if 
the group response slope was similar, it is conceivable that the correlation between on-treatment 
responses might differ from the correlation between baseline and first on treatment assessment.  
In conclusion, ANCOVA should be the analysis of choice for pre-post trials.  The increase in power 
it offers over other baseline analysis methods is particularly marked when the correlation between 
pre- and post- measurements is low.  In the absence of a discrepancy between the baseline and 
first post treatment response, and subsequent follow-up treatment responses, we believe that 
including the baseline in the response vector (RMA) should be the analysis method of choice for 
multi-follow-up studies.  We specifically caution against the use of change scores in multi-follow-
up studies as the correlation structure of the change scores may be altered from the correlation 
structure of the raw data, however, we note that misspecification of the correlation structure is 
potentially a problem for all analysis methods, and advocate that covariance assessment and 
covariance specification in repeated measures analyses become standard items of clinical study 
reports and publications from multi-follow-up studies. 
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Chapter 12. Discussion 
12.1 Personalised medicine 
Personalised medicine is a key goal of modern oncology.  To achieve this vision of patient care 
researchers first need to identify the myriad factors - baseline, genetic and environmental, that 
shape a person's individual response to a particular treatment.  This thesis used a series of 
studies to explore the link between efficacy and safety responses by identifying the factors that 
influence each.  The data used in this thesis represent a unique opportunity to explore clinical and 
germline genetic factors for their association with platinum drug response.  Germline genetic 
variation are associated with the pharmacokinetics of a drug [386, 387] and consequently may 
identify patients with increased risk of developing severe adverse events that could lead to 
treatment discontinuation or disruption.  As both cohorts (lung and ovarian cancer) in this study 
received platinum containing regimens, the original study design envisaged using the cohorts for 
both discovery and replication of any polymorphisms associated with toxicity.  Our work was 
focused on examining the similarities and differences between predictors of efficacy and 
predictors of toxicity, without the objective of replication.  We explored the potential to combine 
both cohorts for identification of genetic and clinical factors that associate with response. In 
Chapter 2 we observed differences between the cohorts with respect to baseline factors (i.e. 
gender, performance status, platinum subtype) that are known to influence the safety profile.  
Additionally, there were inherent differences between each cancer type with respect to the overall 
survival and progression free-survival curves.  We concluded that the differences in baseline 
characteristics, safety profile and efficacy curves between cohorts prohibited the use of aggregate 
data (combining both cohorts) for the discovery of response associated factors.     
In Chapter 3 we introduced a framework for the link between efficacy and toxicity before exploring 
if toxicity responses during treatment predict 2-year efficacy status.  In contrast to previous 
studies, the results of our analysis did not uncover an association between toxicity and efficacy 
responses.  We believe that this may in part be due to the use of colony stimulating factor and 
antiemetic concomitant medications, both of which would confound the reporting of adverse 
events.  Concomitant medication related exclusion criteria are among the most common barriers 
to enrolment in clinical trials.  Since our data were from a treatment centre, rather than a clinical 
   
   
259 
 
trial, no such restrictions existed.  Concomitant medication use in cancer patients is both common 
and varied and therefore it was not collected as part of the original study owing to the time 
commitment required to collect data retrospectively from patient medical files 
Chapter 4 builds upon previous work that has examined baseline factors for their potential to 
predict improved efficacy outcomes and/or risk of experiencing severe adverse events.  Our 
results confirm performance status as a significant independent predictor of PFS and OS efficacy 
endpoints in both lung and ovarian cohorts.  We also observed cohort differences in prognostic 
factors.  Performance status was prognostic of toxicity in the ovarian cohort while age and sex 
were prognostic of toxicity in the lung cohort.  Sex was also an additional independent predictor 
for OS in the lung cohort and renal function was an additional predictor of OS in the ovarian 
cohort.  Smoking status at baseline predicted for PFS in the lung cohort only.  The difference 
between cohorts with respect to significant prognostic factors may reflect baseline differences in 
the cohort patient populations but may also be a reflect of the power differences between cohorts 
as the effective sample size (number of events) was higher in the lung cohort as compared with 
the ovarian cohort. 
Pharmacogenomics have been widely recognised as fundamental steps toward personalised 
medicine.  In Chapter 5 we explored how germline variants are associated with patient response 
in each cohort.  While this study identified two novel variants associated with overall survival in 
the lung cohort (rs17117678 and rs35075952), we noted that the addition of baseline covariates 
did not improve our ability to detect SNP-phenotype associations, as expected in a logistic 
regression analysis framework. 
Lastly, in Chapter 6 we developed a novel graphical method to describe the similarities of 
association results between the different clinical endpoints measured in cancer studies.  Patients 
undergoing platinum chemotherapy typically experience several adverse reactions.  While the 
toxicity phenotypes often co-occur, little is known about genetic correlation between adverse 
events.  Our method characterises the similarities between association results of different 
phenotypes.  If observed, this similarity could represent genetic correlation as a result of 
pleiotropy.  It is hoped that with further development this method could help shed light on the 
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shared genetic basis of efficacy and toxicity phenotypes, and ultimately contribute to the 
understanding of the causal relationships among cancer therapeutic responses. 
12.1.1 Limitations 
Our work has several important limitations that must be discussed; these limitations can be 
broadly categorised into 1) sample size, 2) dosing and 3) factor independence.  We discuss each 
below. 
12.1.1.1 Sample size 
A sample size with sufficient statistical power is important to the success of genetic association 
studies aiming to detect causal factors of human complex disease.  In contrast to clinical 
covariates, genome-wide association studies require much larger sample sizes to achieve an 
adequate statistical power owing to the required alpha correction when testing a large number of 
potentially associated factors (SNPs).  
The required sample size for detecting associations between disease and SNP markers is known 
to be a function of the following: 
1) inheritance model (e.g. additive, dominant, or recessive) 
2) prevalence (of response) 
3) frequency of causal variant 
4) coverage 
5) effect size of the genetic variants (in our case -  odds ratio or hazard ratio) 
 
Genetic association tests for a relationship between the outcome (safety, efficacy, disease) and 
the genotype at a genetic variant.  This is usually performed through a logistic regression, with 
SNP genotype as an explanatory variable, and including ancestry-informative principal 
components to control for population stratification.  A SNP has three genotypes (e.g. AA, AB, BB) 
to be included in the model.   
The genotypes for a SNP can also be grouped into inheritance models, such as dominant, 
recessive, or additive models [388, 389].  It is standard practice for genetic association studies to 
examine allelic models only, an approach that we adopted for our analyses.  Previous work [389, 
390] has indicated the allelic model as the standard analysis approach as it has reasonable power 
to detect both additive and dominant effects.  If however the true underlying model of inheritance 
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was recessive then this assumption would result in underpowered analyses to detect SNP-
phenotype associations [389]. Rather than choosing one model a priori, we might have opted to 
evaluate multiple genetic models.  This would need to have concomitant alpha correction for 
multiple testing across all genetic models thereby reducing our power to detect significant SNP-
phenotype associations.  
Prevalence is the proportion of individuals with the affected phenotype.  Within our study the 
prevalence of adverse events varied by efficacy and toxicity phenotype.  Of the recorded adverse 
event terms, only severe neutropenia was experienced by 10% of patients in both cohorts.  
Consequently to explore the effects of gastrointestinal intestinal upset we mapped adverse event 
terms to MedDRA system organ class (SOC) [391].   As not all SOC groupings are based upon 
aetiology, then an analysis of SOC terms might contain adverse event terms with disparate 
genetic underpinnings that reduce our power to detect SNP-‘SOC’ associations. 
For survival (efficacy) endpoints the 'prevalence' is less applicable, as the survival analysis aims 
to answer the question regarding differences between levels of a prognostic factor in the time to 
affected status.  If all patients achieved affected status by the end of the study period, then the 
effective sample size would match the number of patients. As the partial likelihood function is 
essentially based on the number of events the effective sample size is usually much lower than 
the number of patients within the trial [392]. In the lung cohort, the proportion of patients 
experiencing OS and PFS events was greater than in the ovarian cohort.  Differences in the 
response prevalence between phenotypes (efficacy and safety outcomes) and cohorts, render 
comparison of association results difficult. 
Illumina’s HumanExome array targets around 250,000 SNPs.  The marker SNPs were identified 
from an analysis of over 12,000 whole exome sequenced genomes individuals from diverse 
populations, including European, African, Chinese, and Hispanic individuals, and includes SNPs 
associated with a range of common conditions including type 2 diabetes, cancer, metabolic, and 
psychiatric disorders.  The chip was designed to help researchers in identifying functionally 
relevant associations within exonic regions; and it has proven a useful tool in identifying such 
associations.  However, the human exome is less than 1% of the genome (30 megabases, 
compared to 3.3 gigabases in the whole genome), and therefore this chip is not equivalent to a 
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genome-wide genotyping array where coverage is designed to capture common variation across 
the genome.  Many SNPs on the Illumina HumanExome array have low frequency, and are not 
in linkage disequilibrium with other SNPs on the array.  Our analyses identified two SNPs that 
were significantly associated with overall survival in lung cancer patients receiving platinum-
based chemotherapy, one within the OMA1 and the other within the TACSTD2 gene.  In both 
cases, none of the other tagged SNPs in the region was in strong enough linkage disequilibrium 
to observe supporting association signals for either significant SNP.  Replication studies will be 
essential to determine whether these are true findings or false positive results, but at present, few 
similar studies exist. 
12.1.1.2 Dosing 
The data collected in this study did not include patient specific dosing information or patient body 
size.  The specific quantity of platinum chemotherapy administered to each patient varies by body 
size.  Platinum therapy is dosed according to body surface area (BSA) which is calculated as a 
function of patient height and weight [393, 394].  It has been suggested that BSA-based dosing 
results in therapeutic inconsistencies between patients as it does not account for the patient 
variations in hepatic or renal function, the proportion of muscle and fat tissues, or multiple other 
variables involved with drug processing [395].  These inconsistencies may lead to a variation in 
drug exposure and therefore response. 
As inter-patient variation in the dose intensity by cycle will likely contribute to patient efficacy and 
safety responses, it represents a potential confounding factor when identifying prognostic 
variables.      
Another potentially critical piece of information not contained within the data was patient specific 
records of concomitant medications.  Common side effects of platinum drugs include emesis and 
neutropenia.  When neutropenia is observed in a patient, granulocyte colony stimulating factor 
(G-CSF) may be prescribed to help stimulate white blood cell recovery.  Similarly, severe or 
persistent emesis is often managed through antiemetic medications.  Both of these concomitant 
medications would result in an underreporting of adverse event endpoints and reduce our power 
to identify prognostic factors associated with gastrointestinal and neutropenic outcomes.    
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12.1.1.3 Factor independence 
Associations between cancer prognosis and common but low penetrance genetic polymorphisms 
may not be independent of other known clinical prognostic factors.  In order to clarify the 
independent contribution of germline genetic polymorphisms beyond known clinical prognostic 
factors, it has been suggested that studies exploring clinical outcome associations with germline 
polymorphisms take into account clinical prognostic factors in addition to genetic variation [396]. 
Consequently, within our work, we explored the addition of the prognostic factors age and sex 
when identifying germline variant association with clinical outcomes.  The addition of these 
baseline patient characteristics consistently weakened our SNP-outcome associations, and while 
we concluded that this was a feature of the statistical methods employed it is possible that the 
variants identified are not acting independently of the baseline characteristics.  
Until we are able to assess the genetic contribution of germline variants to baseline features such 
as age of disease onset, performance status and renal function, the independent role of germline 
genetic variations upon patient responses will remain hard to delineate.  
Clarifying this will require large-scale replication studies of germline polymorphisms and drug 
response that extend beyond hypothesis-generating studies that currently dominate medical 
literature. 
12.1.2 Future directions 
Future work on this dataset could revisit the patient records to collect drug dosing information, 
concomitant medications and more detailed body mass information.  This information could be 
used to explore the body mass adjusted association between dose and the exposure-adjusted 
risk of adverse events.  A refined understanding of the interplay between BMI, dose and total 
exposure could then be used to construct an improved model with which to detect SNP-AE 
associations, and could be used to update the analysis in which adverse events were used to 
predict efficacy outcomes.  Once reliable SNP-outcome associations are established for both 
safety and efficacy endpoints, a scoring model, akin to a polygenic risk score, could combine a 
patient’s variant information to provide SNP-informed benefit-risk assessment.  For example, if 
the specific variants carried by an individual predict an above average risk for an adverse event, 
and a below average survival response, then the benefit risk might be considered unfavourable.  
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Balancing the efficacy and safety of prescribed chemotherapy treatments is crucial to optimising 
chemotherapy treatment outcomes.  Individual variability in drug efficacy and safety remain a 
challenge in drug development and clinical practice.  Knowledge of genetic determinants of 
efficacy and safety outcomes promises a potential pathway to achieving the ultimate goal of 
personalised medicine within oncology. 
12.1.3 Conclusions 
Every day, patients are exposed to medications that will have limited or no benefit to them.  
Classical clinical trials harvest a handful of measurements from thousands of people [397]. Such 
trials result in treatment decisions that follow a ‘one size fits all’ approach as clinical trials are 
typically unable to distinguish patient characteristics that interact with response within a given 
treatment arm.  Personalised medicine is essentially the ability to tailor treatments, as well as 
prevention strategies, to the unique characteristics of each person.  When it comes to cancer, 
personalisation can take several different forms.  Advances in our ability to characterise genetic 
changes that occur within tumours has resulted in targeted therapeutics.  Studies exploring the 
role of germline or inherited genetic variation on cancer outcome have identified germline 
polymorphisms associated with differential survival and toxicity.  Lastly, numerous studies have 
identified baseline patient characteristics that can be used to stratify patient response. 
This thesis has examined both patient characteristics and germline genetic factors for their 
association with efficacy and safety responses in patients receiving platinum therapy.  It is hoped 
that these studies will contribute towards identification of the relevant prognostic factors that 
shape patient response to platinum therapy.  Investigation of the potential use of germline genetic 
variation as prognostic and predictive markers is a relatively new area of research.  Advances in 
predicting patient responses based on current, common therapeutic strategies represent a key 
step in the process of bringing personalised medicine to clinical practice 
12.2 Repeated measures clinical trials 
In the recent past, licencing approval of a therapeutic agent within oncology depended primarily 
on the demonstration of improved efficacy outcomes in patients treated with the new agent as 
compared with patients treated with the standard of care.  Increasingly the strategy is evolving to 
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accept a novel compound if it can be demonstrated that there is similar efficacy with reduced 
toxicity.  As a result of the increasing desire to minimise toxicities, adverse events are closely 
scrutinized and patients enrolled in clinical trials are intensively monitored for safety events that 
may relate to treatment.  Consequently, oncology trials ubiquitously collect repeated 
measurements of adverse events during treatment and frequently even after treatment cessation.  
The wealth of safety data generated has led biostatisticians to question if the longitudinal safety 
data can be used to elucidate treatment effects on clinical outcomes such as overall survival or 
progression free survival.  One popular methodological approach to this problem involves the joint 
modelling of survival with longitudinal data.  In this approach, longitudinal mixed models are used 
to incorporate the effects of time-varying covariates in the evaluation of efficacy endpoints [398].  
Outside of oncology, longitudinal values of blood pressure [399, 400] and CD43 cell counts [401-
403] have previously been used in the evaluation of treatment influence upon disease progression 
and survival.  At the onset of this thesis, one of the primary objectives was to use longitudinal 
information of adverse events to inform the survival process.  To prepare for this we undertook a 
review of longitudinal marginal models, the results of which are presented in this thesis and 
summarised below.  Upon examination of the adverse events across the four cycles of therapy, 
we discovered that the changes in CTCAE grade between cycles did not follow linear patterns, 
and therefore it would not be possible to model this data as originally planned.  Our analyses of 
adverse events dichotomised patients based upon the adverse event severity at any time during 
therapy.  Despite not being able to longitudinally model the adverse event data, our early 
examination of longitudinal methods revealed items relevant for the design and analysis of 
repeated measures studies.  Given the prevalence of repeated measures trial designs, we believe 
that this information can contribute to the wider field even if it was not applicable to our data.  
Below we summarise our findings from the work on repeated measures linear regression in 
Chapters 7 to 11.   
                                                     
3  Cluster of differentiation 4; a protein encoded by the CD4 gene which is found on the surface 
of immune cells. 
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12.2.1 Repeated measures linear regression 
The analysis of repeated measures data represents a continuing challenge for clinical trials 
collecting repeated measurements on each subject.  While generalised linear models have 
emerged as the standard for analysing repeated measures data, there are several commonly 
employed strategies for handling the baseline measurement: 
1) Retain it as part of the outcome vector (RMA); 
2) Use the baseline measurement as a covariate in the analysis of the post-baseline 
measurements (ANC); 
3) Subtract the baseline measurement from all the remaining post-baseline measurements 
and then analyse the change scores (CSA). 
 
The relative strengths and weaknesses of each strategy have been extensively covered for pre-
post designs, however, we found very few studies examining each analysis strategy where there 
is more than one follow-up assessment or across alternate correlation structures.  Moreover, 
despite the frequent claim that the ANCOVA is more precise/efficient and therefore powerful in 
pre-post designs, we were not able to readily identify the exact reason for this and sought to 
elucidate.   
In Chapter 7 we review how sample size is estimated for repeated measures experiments.  This 
chapter introduces the idea that in longitudinal studies the natural experimental unit is no longer 
an individual measurement in time, but the vector of patient measurements that give rise to linear 
mean differences between treatment groups across time.  It also introduces the critical concepts 
of a covariance matrix and correlation structure as key features in determining the required 
sample size to achieve 1 − 𝛽 in repeated measures experiments.  Chapter 8 uses the formulae 
from Chapter 7 to present an analytic study exploring how the correlation strength, correlation 
structure, effect size and number of assessment time points influence the sample seize required 
to achieve a given level of power.  This work reveals that for a linear trend with evenly spaced 
assessment time points, there is no gain in power associated with the transition from a pre-post 
design to a design with two follow-up assessments.  This finding has major implications for trial 
design and efficiency of trial resources as it indicates that increasing the sample size may 
represent the best use of trial resources when the frequency of assessment cannot be increased 
beyond three patient assessment time points.  We also confirm the previous finding that increased 
correlation strength reduced the sample size required when the correlation structure is compound 
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symmetry, but that low and intermediate correlation strength require an increased sample size 
when the correlation structure is autoregressive. 
As information regarding intra-patient correlation strength and structure is often unavailable at the 
time of study planning, it is not uncommon for researchers to assume that the correlation between 
baseline and post-intervention measures is zero and calculate a sample size for a simple two-
sample comparison of means.  We show that this practice results in dramatic inflation of the 
required sample size.  Further, we conclude that assuming an autoregressive correlation structure 
with low patient correlation results in adequate power across all correlation strengths and 
structures while significantly reducing the estimated sample size from the estimate produced by 
the comparison of group means at final assessment.   
Chapter 9 reviews two alternate generalised linear model used in repeated measures data 
analysis: the marginal model and the mixed-effects model.  This chapter also presents alternate 
baseline analysis strategies and reviews previous research that has examined alternate 
strategies. Given the frequency of repeated measures trials and the length of time that repeated 
measures analytical methods have been available, it was surprising to find that the statistical 
analysis of change is still mired in controversy over how to best handle the baseline measurement.  
Despite the wealth of literature, we still found an absence of clear guidance regarding the 
implications of alternate baseline analysis strategies upon the estimated model coefficients.  
Therefore, in Chapter 10 we use simulation across a range of hypothetical trial scenarios to 
ascertain how model coefficients relate to specific trial design parameters.   
Our work demonstrates that the interpretation of the model estimates depends on the number of 
assessment time points and, that the choice between analysis methods should depend on 
whether the experiment is a pre-post design or has more than one follow-up measurement.  This 
work is able to describe each model coefficient in relation to the intercepts and slopes of each 
treatment arm, and describes how the interpretation of model estimates changes when 
transitioning from a pre-post to a multi-follow-up design.   
A key finding of this work is that the estimated coefficients for ‘change’ are equal between baseline 
analysis methods for pre-post designs in the absence of baseline imbalance, and equal 
irrespective of baseline imbalance for multi-follow-up trials (more than one follow-up assessment).  
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As power is a function of both the estimated coefficient and the standard error of the coefficient, 
we explore in Chapter 11 the similarities and differences between baseline analysis strategies for 
the calculation of the variance of the estimates.  Through a combination of algebraic solution and 
simulation, we detail how each method differs in the covariance matrix used to estimate variance 
of the estimate, and explore the implications of these differences upon statistical power.  
Specifically, we show that for a pre-post design, the ANCOVA has the greatest power, but when 
there is more than one follow-up measurement, the greatest power is achieved by using the 
baseline measurement as part of the response vector.  Due to mathematical coupling, we show 
that calculation of the change score can result in a non-symmetric covariance structure, and 
therefore advocate the use of an 'unstructured' covariance specification when the analysed data 
has an autoregressive correlation structure.  Lastly, we show how the calculation of the standard 
error of the estimate changes for ANCOVA and change-score methods depending on the number 
of time points, which explains the difference in power between baseline analysis methods when 
moving from a pre-post design to a repeated measures experiment in which there is more than a 
single follow-up measurement. 
12.2.2 Limitations 
Our work has several important limitations that offer the potential for future directions in this line 
of research; these limitations can be broadly categorised into: 
1) covariance structure misspecification 
2) missing data 
3) random effects  
 
12.2.2.1 Covariance structure misspecification 
Misspecification of the correlation structure within a repeated measures analysis refers to 
specifying a correlation structure within the analysis that does not match the correlation structure 
of the data being analysed.  Previous researchers have identified [404] three categories of 
covariance structure misspecification: underspecified, overspecified and general 
misspecification. Underspecified refers to a model specified covariance structure that is simpler 
than the true covariance matrix (i.e. compound symmetry is specified in the model but   the   true   
structure   is   AR(1)).  Overspecification refers to a model specified covariance structure that is 
more complex than the true covariance matrix with the caveat that the true covariance matrix is 
   
   
269 
 
nested within the specified matrix (e.g. ARMA(1) structure chosen but AR(1) is the true structure).  
Lastly, general misspecification occurs when the specified and true covariance matrices are not 
nested (i.e. CS structure chosen but AR(1) is the true structure).  Simulation studies examining 
the consequences of covariance structure misspecification have found either no or modest bias 
in the estimates of fixed effects.  There is evidence that the bias for the estimated standard errors 
of the fixed effects is much stronger [404-406].  These studies identified that both 
underspecification and general misspecification result in inflation of the estimated standard errors 
even in the absence of coefficient bias.  Conversely, overspecification of the covariance structure 
resulted in smaller estimates of coefficient standard errors as compared to the correct 
specification.  These articles did not explore the impact of the frequency of patient assessment or 
compare baseline analysis strategies.  Given the observed differences between each baseline 
analysis method with respect to the covariance matrices, it is reasonable to assume that 
misspecification would result in differential variable inflation/deflation of the standard errors across 
methods. 
12.2.2.2 Missing data 
The work in this thesis assumed that all patients had complete data, a potentially unrealistic 
scenario.  Data missingness is a common feature of repeated measures clinical trials that 
represents a major challenge during the analysis of the longitudinal data.    Missing data can have 
both different patterns and causes, all of which have the potential to bias the estimates and/or 
efficiency of analysis results [407-410].  Future work could systematically examine if missingness 
results in bias and/or loss of power equally between each baseline analysis method across a 
range of alternate types and quantities of missing data.  
12.2.2.3 Random effects 
Chapter 9 introduced both marginal and mixed-effect generalised linear models for the analysis 
of repeated measures data.  A marginal model adjusts for repeated measures through estimation 
of the covariance of residuals. By contrast, mixed models adjust for repeated measures by altering 
the model to include random effect (leaving the residuals alone).  In recent years, two types of 
mixed models have merged as popular choices for repeated measures data. These are: 
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1) The random intercept model, and 
2) The random slope model.   
 
The addition of a random intercept term allows each patient to deviate from the overall mean 
response by a person-specific constant that applies equally over time.  Similarly, the random 
slope model adds a random term that captures how the patient specific slope varies from the 
overall mean slope parameter for the study population.  Mixed models have been shown to 
be robust to missing data and irregularly spaced measurement occasions [411]. As such, they 
are among the most popular methods for the analysis of longitudinal data. As our work did 
not incorporate missing data we chose to explore the alternate baseline analysis strategies 
using marginal models.  Future work would seek to explore if there are similar differences 
between baseline analysis strategies with respect to the 𝐷 covariance matrix of random 
effects as were observed with the 𝑅 covariance matrix of residuals from the marginal model. 
12.2.3 Conclusions 
In summary, repeated measures regression models offer a robust method for the analysis of 
repeated measures.  The ability to model and compare longitudinal response patterns can 
increase statistical power and therefore represent a major strength of this methodology.  Due to 
the greater statistical power, a repeated measures design can use fewer subjects to detect a 
desired effect size and therefore represent an effective use of research resources.  However, 
repeated measures designs require that care be taken to understand the correlation structure 
between repeated measures.  The correlation structure gives rise to the covariance matrix, which 
is a critical component in the calculation of both the parameter estimates and their standard errors.  
While modern software will estimate a study specific covariance matrix, it is still necessary for the 
researcher to define the covariance structure that will be used in the estimation.  We have shown 
that alternate methods for inclusion of the baseline measurement in the analysis of repeated 
measures data have important consequences for the covariance matrix that affect the power of 
each method.  Therefore, we advocate that repeated measures studies should rountinely report 
information regarding the strength and structure of intra-patient correlation between assessment 
time points. 
In summary, this thesis has performed research in two different areas of relevance to personalised 
medicine.  The genetic study of efficacy and safely in cancer chemotherapeutics showed the 
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challenges integral to analysis of clinical cohorts.  Patient heterogeneity is a substantial barrier to 
accruing the large sample sizes that are essential for powerful genetic association studies.  
Differences in cancer site and medication – as well as individual patient characteristics of age, 
and sex – all impact the choice of analyses to be performed.  Our work developed a novel 
exploratory data analysis tool to explore any correlation between genetic associations for efficacy 
and safety.   
Clinical studies and trials often produce longitudinal data with repeated measures on patients or 
study participants.  The second part of this thesis considered in detailed the choice of analytical 
method for this study design.  We showed that care is needed in how to deal with the baseline 
measurement, with the choice of method depending on the number of assessments for each 
patient, and the correlation structure between observations at different time points.  Our work 
adds to the literature in this area by showing that ANCOVA methods are most powerful for pre-
post studies, and we advise that for multi-follow-up studies, using the baseline measurement as 
an outcome variable increases power.  Both these research areas illustrate the importance of 
rigorous statistical analysis in clinical studies.  Personalised medicine will require multi-
disciplinary clinical and research teams, with statisticians having a key role to ensure effective 
studies are performed, that maximise the potential for patient benefit.   
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Appendix A. Association between baseline characteristics and safety outcomes 
Table 12.2.1 Univariate analysis of potential prognostic factors for neutropenia 
Characteristic Ovarian Lung 
 Affected Unaffected OR (95% CI) p-value Affected Unaffected OR (95% CI) p-value 
Age . . 1.012 (0.989-1.036) 0.3151 . . 1.028 (1.005-1.052) 0.0161 
Sex 162 61   . 223 120   . 
     Female 162 61   . 94 53   . 
     Male . .   . 129 67 0.921 (0.589-1.441) 0.7192 
ECOG Performance Status 162 61   . 223 120   . 
     0-1 110 48   . 200 99   . 
     2-3 30 8 0.611 (0.261-1.431) 0.2567 18 14 1.571 (0.751-3.289) 0.2306 
     Missing 22 5   . 5 7   . 
Renal Function 162 61   . 223 120   . 
     0-1 139 48   . 191 96   . 
     2-3 17 11 1.874 (0.820-4.283) 0.1362 26 22 1.684 (0.907-3.125) 0.0988 
    Missing 6 2   . 6 2   . 
Ethnicity 162 61   . 223 120   . 
Caucasian 139 50   . 191 107   . 
Asian 2 1 1.390 (0.123-15.665) 0.9499 2 4 3.570 (0.643-19.814) 0.1179 
Black 12 6 1.390 (0.495-3.901) 0.9114 20 5 0.446 (0.163-1.223) 0.0721 
Other 4 1 0.695 (0.076-6.368) 0.5204 6 2 0.595 (0.118-3.000) 0.3807 
Mixed 1 1 2.778 (0.171-45.253) 0.5218 2 2 1.785 (0.248-12.854) 0.5728 
Missing 4 2   . 2 .   . 
Smoking 162 61   . 223 120   . 
Never 45 19   . 25 16   . 
Ex-smoker 11 3 0.646 (0.162-2.580) 0.6443 67 30 0.700 (0.327-1.498) 0.3822 
Current 25 8 0.758 (0.290-1.979) 0.8351 120 68 0.885 (0.442-1.773) 0.8464 
Unknown 81 31 0.906 (0.460-1.785) 0.6845 11 6 0.852 (0.263-2.763) 0.9997 
         
   




Table 12.2.2 Univariate analysis of potential prognostic factors for gastrointestinal disorder 
Characteristic Ovarian Lung 
 Affected Unaffected OR (95% CI) p-value Affected Unaffected OR (95% CI) p-value 
Age . . 1.020 (0.982-1.059) 0.3138 . . 1.002 (0.972-1.033) 0.8931 
Sex 203 20   . 298 45   . 
     Female 203 20   . 119 28   . 
     Male . .   . 179 17 0.404 (0.212-0.770) 0.0059 
ECOG Performance Status 203 20   . 298 45   . 
     0-1 147 11   . 258 41   . 
     2-3 31 7 3.018 (1.084-8.401) 0.0344 28 4 0.899 (0.300-2.696) 0.8492 
     Missing 25 2   . 12 .   . 
Renal Function 203 20   . 298 45   . 
     0-1 174 13   . 252 35   . 
     2-3 22 6 3.650 (1.259-10.580) 0.0171 39 9 1.662 (0.742-3.722) 0.2172 
    Missing 7 1   . 7 1   . 
Ethnicity 203 20   . 298 45   . 
Caucasian 172 17   . 258 40   . 
Asian 2 1 5.059 (0.436-58.719) 0.9637 6 . <0.001 (<0.001->999.999) 0.9764 
Black 17 1 0.595 (0.075-4.752) 0.9877 21 4 1.229 (0.401-3.765) 0.9526 
Other 4 1 2.529 (0.267-23.932) 0.9714 8 . <0.001 (<0.001->999.999) 0.9732 
Mixed 2 . <0.001 (<0.001->999.999) 0.9762 3 1 2.150 (0.218-21.179) 0.9468 
Missing 6 .   . 2 .   . 
Smoking 203 20   . 298 45   . 
Never 58 6   . 32 9   . 
Ex-smoker 12 2 1.611 (0.289-8.968) 0.4273 86 11 0.455 (0.172-1.200) 0.2775 
Current 31 2 0.624 (0.119-3.276) 0.4397 166 22 0.471 (0.199-1.117) 0.2564 
Unknown 102 10 0.948 (0.328-2.741) 0.9127 14 3 0.762 (0.179-3.247) 0.7151 
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Figure 12.2.1 Manhattan plots of overall survival in the ovarian cohort. 
The association of SNP genotype and overall survival was evaluated using a Cox regression 
models for 29328 SNPs across 223 patients with ovarian cancer treated with platinum therapy.  
Regression included p-values (−log10 p-values; y axis) are plotted against the respective 
chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex results; (C) 
Overlay plot of (A)-(B). 
 
   





Figure 12.2.2 Manhattan plots of progression free survival in the ovarian cohort. 
The association of SNP genotype and progression free survival was evaluated using a Cox 
regression models for 29328 SNPs across 223 patients with ovarian cancer uniformly treated with 
platinum therapy.  Regression included p-values (−log10 p-values; y axis) are plotted against the 
respective chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex 
results; (C) Overlay plot of (A)-(B). 
 
   




Figure 12.2.3 Manhattan plots of progression free survival in the lung cohort. 
The association of SNP genotype and progression free survival was evaluated using a Cox 
regression models for 29328 SNPs across 343 patients with lung cancer treated with platinum 
therapy.  Regression included p-values (−log10 p-values; y axis) are plotted against the 
respective chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex 
results; (C) Overlay plot of (A)-(B). 
 
 
   





Figure 12.2.4 Manhattan plots of neutropenia in the ovarian cohort. 
The association of SNP genotype and neutropenia was evaluated using a logistic regression 
models for 29328 SNPs across 223 patients with ovarian cancer treated with platinum therapy.  
Regression included p-values (−log10 p-values; y axis) are plotted against the respective 
chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex results; (C) 




   





Figure 12.2.5 Manhattan plots of neutropenia in the lung cohort. 
The association of SNP genotype and neutropenia was evaluated using a logistic regression 
models for 29328 SNPs across 343 patients with lung cancer treated with platinum therapy.  
Regression included p-values (−log10 p-values; y axis) are plotted against the respective 
chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex results; (C) 




   





Figure 12.2.6 Manhattan plots of gastrointestinal disorder in the ovarian cohort. 
The association of SNP genotype and gastrointestinal disorder was evaluated using a logistic 
regression models for 29328 SNPs across 223 patients with ovarian cancer treated with platinum 
therapy.  Regression included p-values (−log10 p-values; y axis) are plotted against the 
respective chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) SNP Age Sex 
results; (C) Overlay plot of (A)-(B).
   





Figure 12.2.7 Manhattan plots of gastrointestinal disorder in the lung cohort. 
The association of SNP genotype and gastrointestinal disorder was evaluated using a logistic 
regression models for 29328 SNPs across 343 patients with lung cancer treated with platinum-
therapy containing regimens.  Regression included p-values (−log10 p-values; y axis) are plotted 
against the respective chromosomal position of each SNP (x axis).  (A) SNP Only results; (B) 
SNP Age Sex results; (C) Overlay plot of (A)-(B).
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Appendix C. Quantile-Quantile (Q-Q) plots
 
Figure 12.2.8 Q-Q-plots for overall survival results 
   




Figure 12.2.9 Q-Q-plots for progression free survival results  
   




Figure 12.2.10 Q-Q-plots for neutropenia results
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Appendix D. Power calculations using the sample size estimated by correlation structure misspecification  
Table 12.2.3 Power under misspecification of the correlation structure. 
Power for the Autoregressive(1) columns was calculated from the sample size required to provide 80% power with compound symmetry for the equivalent 
correlation strength and number of assessment time points.  Power for the Compound Symmetry columns was calculated from the sample size required to provide 





Autoregressive(1) Compound Symmetry 
Correlation Strength 
0 0.25 0.5 0.75 0 0.25 0.5 0.75 
2 
0.1 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
0.25 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
0.5 0.80 0.81 0.81 0.81 0.80 0.81 0.81 0.81 
3 
0.1 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
0.25 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.80 
0.5 0.80 0.81 0.81 0.81 0.80 0.81 0.81 0.81 
4 
0.1 0.80 0.76 0.76 0.76 0.80 0.85 0.85 0.85 
0.25 0.80 0.76 0.76 0.76 0.80 0.85 0.85 0.85 
0.5 0.80 0.76 0.77 0.78 0.80 0.85 0.86 0.87 
5 
0.1 0.80 0.71 0.71 0.71 0.80 0.89 0.89 0.89 
0.25 0.80 0.71 0.71 0.71 0.80 0.89 0.89 0.89 
0.5 0.81 0.71 0.72 0.72 0.81 0.90 0.89 0.90 
6 
0.1 0.80 0.66 0.66 0.66 0.80 0.93 0.93 0.93 
0.25 0.80 0.66 0.66 0.66 0.80 0.93 0.93 0.93 
0.5 0.80 0.66 0.67 0.69 0.80 0.93 0.93 0.93 
   




Appendix E. Implementation of each baseline analysis method in 
SAS 
Proc mixed  is a SAS procedure based on mixed model methodology used to analyse 
longitudinal data [343, 412].  The syntax used to fit a linear model with fixed effects only in SAS 
is shown below, followed by a brief description of the primary statements: 
6) proc mixed data=mydata; 
7) class group subjid; 
8) model response = group time group*time / solution; 
9) repeated time / subject = subjid type=AR(1); 
10) run; 
The proc mixed statement calls the MIXED procedure. The class statement specifies which 
variables are classification (i.e. nominal) variables.  The model statement is used to indicate the 
dependent (response) variable and to specify the fixed effects of the model.  Our model includes 
fixed effects of group, time, and the interaction term group, time. 
By specifying the solution option on the model statement we request t-tests and standard 
errors for each fixed effect (output into a table called “Solutionfor Fixed Effects”).   
Proc mixed uses the repeated statement to model within subject variation.  Here the repeated 
statement indicates that each subject (identified through their unique subjid has measurements 
repeated across the variable time.  All subjects are assumed to have the same measurement 
covariance structure specified through the type=AR(1) code.  
From a programming perspective, the difference between each of the three baseline analysis 
strategies is a function of 1) restricting the data to post baseline measurements only for the ANC 
and CSA analyses and 2) changing the model statement to match the scalar models. 
For the RMA analysis, both the pre-post and multi-follow-up analyses use the same code: 
11) proc mixed data=mydata; 
12) class group subjid; 
13) model response = group time group*time / solution; 
14) repeated time / subject = subjid type=AR(1); 
15) run; 
   
   
303 
 
Assuming that mydata is a dataset of pre-post design then the ANC analysis would adapt this 
code as follows: 
16) proc mixed data=mydata(where=(time^=0); 
17) class group subjid; 
18) model response = group baseline/ solution; 
19) repeated time / subject = subjid type=AR(1); 
20) run; 
The (where=(time^=0) restricts the input dataset to post baseline rows only and the model 
statement no longer includes time or its interaction with treatment.  The variable baseline is a 
column containing the baseline response measurement for each patient. 
If instead mydata was a multi-follow-up dataset then the ANC analysis code would take the 
following form: 
 
21) proc mixed data=mydata(where=(time^=0); 
22) class group subjid; 
23) model response = group time group*time baseline/ solution; 
24) repeated time / subject = subjid type=AR(1); 
25) run; 
For the CSA analysis, if mydata is a dataset of pre-post design then we would use the following 
code for analysis: 
26) proc mixed data=mydata(where=(time^=0); 
27) class group subjid; 
28) model Delta_Resp = group / solution; 
29) repeated time / subject = subjid type=AR(1); 
30) run; 
Where Delta_Resp is a change score calculated from response - baseline 
And if mydata is a dataset of multi-follow-up design then the following code would be used for 
CSA analysis: 
31) proc mixed data=mydata(where=(time^=0); 
32) class group subjid; 
33) model Delta_Resp = group time group*time / solution; 
34) repeated time / subject = subjid type=AR(1); 
35) run; 
For each set of model parameters, data were simulated for 10,000 individuals using the simulation 
steps described above.  Each data set was analysed using the SAS code, for each analysis 
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method (RMA, ANC, CSA) and model parameters were extracted and compared across the 
analysis methods.   
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Appendix F. Calculation of the average intra-patient correlation 
 
Given the following example correlation matrix: 
  Time point l 









 0 1 0.63 0.40 0.25 
1 0.63 1 0.63 0.40 
2 0.40 0.63 1 0.63 
3 0.25 0.40 0.63 1 
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Appendix G. Pre-Post Covariance matrix 
 
For a pre-post design, the covariance matrix will be of dimensions 2x2: 
 




] = 𝜎2 [
1 𝜌01
𝜌10 1
] (12.2.1)  
 
Where 𝜌01 = 𝜌01, the correlation between pre and post measurements. 
 














] (12.2.2)  
 











] (12.2.3)  
 











































And we can see that 𝑢11 = 
1
1−𝜌2
 which matches the inverse of the variance reduction associated 
with ANCOVA [381]. 
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The ratio of   
𝑢11
𝑤


















Which matches the inverse of the variance adjustment associated with the use of change scores 
[297]. 
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Appendix H. Pre-post 𝑿𝑻𝑹−𝟏𝑿 
Here we present the steps involved in the calculation of the 𝑆𝐸(𝛽) for a pre-post study.  For the ANC method the inversion of the 𝑋𝑇𝑅−1𝑋 matrix requires that an 
assumption be made about the baseline measurement 𝐸(𝑌0) for both the control and active treatment arms.  This is because the (𝐸(𝑌0))
2 will always be positive even 
when 𝐸(𝑌0) = 0.  In the calculations presented below we have assumed that   𝐸(𝑌0) = 0 for both the control and active treatment groups and therefore 
(𝐸(𝑌0)|𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
2 = 1 and (𝐸(𝑌0)|𝑎𝑐𝑡𝑖𝑣𝑒)
2 = 1 














1 𝑅1 𝑇0 𝑅1𝑇0
1 𝑅1 𝑇1 𝑅1𝑇1
⋮ ⋮ ⋮ ⋮















1 1 ⋯ 1
𝑅𝑖 𝑅𝑖 ⋯ 𝑅𝑁
𝑇0 𝑇1 ⋯ 𝑇𝑚
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Variable CSA ANC RMA 
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We can therefore rewrite the 𝑆𝐸(𝛽) for treatment effect for each analysis method as: 
 
𝑆𝐸(𝛽) for treatment effect 































































Which confirms the equality of the 𝑆𝐸(𝛽) for the RMA and CSA methods in a pre-post design. 
